University of California San Francisco
CURRICULUM VITAE

Name: **Arie Perry, M.D.**

Position: Tenured Professor, Step VI, Ladder Rank Series
Departments of Pathology and Neurological Surgery
UCSF School of Medicine

Director of Neuropathology Division and Neuropathology Fellowship Program

Address: 505 Parnassus Avenue, #M551
San Francisco, CA 94117
Box# 0102

Voice: 415-476-5236
FAX: 415-476-7963
Email: Arie.Perry@ucsf.edu
Website: http://labmed.ucsf.edu/about/faculty/pathology-aperry.html

EDUCATION:

1982-1986	U. Texas, Austin, TX	B.S.	Zoology
1986-1990	U. Texas Southwestern, Dallas, TX	M.D.	
1988 (3 mo)	U. Texas Southwestern, Dallas, TX	Autopsy Externship	Pathology
1990-1994	U. Texas Southwestern, Dallas, TX	AP/CP Resident	Pathology
1994-1995	Mayo Clinic, Rochester, MN	Surgical Pathology Fellow	Pathology
1995-1997	Mayo Clinic, Rochester, MN	Neuropathology Fellow	Pathology
1997-1998	Mayo Clinic, Rochester, MN	Research Fellow	Pathology

LICENSES, CERTIFICATION:

11/90-11/97	Medical Licensure, Texas, J0190
9/17/94-9/98	Medical Licensure, Minnesota, 37481
2/1/98-1/01	Medical Licensure, Missouri, 114289
12/4/09-now	Medical Licensure, California, C 53919
November 1995	ABP Certification, Anatomic Pathology / Clinical Pathology
September 1997	ABP Certification, Neuropathology

PRINCIPAL POSITIONS HELD:

1997-1998	Mayo Clinic Graduate School of Medicine	Instructor	Pathology
1998-2003	Washington U. School of Medicine	Assistant Professor	Pathology
2003-2008	Washington U. School of Medicine	Associate Professor	Pathology
2008-2010	Washington U. School of Medicine	Professor	Pathology
2009-2010	Washington U. School of Medicine	Professor	Neurosurgery
2010-now	University of California, San Francisco	Professor	Pathology
2010-now	University of California, San Francisco	Professor	Neurosurgery

OTHER POSITIONS HELD CONCURRENTLY:

2004-2010	Washington University	Medical Director, AP FISH Lab
2006-2007	Washington University	Chair of Search Committee for Neuropathology Faculty Recruitment
2009-2010	Washington University	Member, Molecular Pathology Curriculum Subcommittee
2009-2010	Washington University	Member, Educational Committee for the Molecular Genetic Pathology Fellowship
2010-now	UCSF Pathology	Director, Neuropathology Division
2010-now	UCSF Pathology	Director, Neuropathology Fellowship Program

HONORS AND AWARDS: *[All inclusive, most recent last]*

1986	**B.S. with Honors** in Zoology, Univ. of Texas
1993	First Place **Resident Award** (poster): Texas Society of Pathologists meeting
1994	First Place **Resident Award** (podium): Texas Society of Pathologists meeting
1994	**Matthew T. Moore Award**, best presentation dealing with clinicopathologic correlations, International Congress of Neuropathology meeting
1995	**Mary Tom Award**, best presentation dealing with clinicopathologic correlations, Canadian Association of Neuropathologists meeting
1995-1997	American Brain Tumor Association **Fellowship Award**
2000-2002	Siteman Cancer Center / Barnes-Jewish Hospital Foundation **Cancer Research Award**
2000-2001	Siteman Cancer Center **Gene Chip Award**
1999	Distinguished Service **Teaching Award**, WUSM (Medical School Class of 2001)
2002	**Lucien J. Rubenstein Award**, best presentation dealing with neuro-oncology, American Association of Neuropathologists meeting
2002	Distinguished Service **Teaching Award**, WUSM (Medical School Class of 2004)
2004	Distinguished Service **Teaching Award**, WUSM (Medical School Class of 2006)
2005	**Professor of the Year Award**, WUSM (Medical School Class of 2007)
2006-now	Listed as one of America's **Top Doctors** and America's Top Doctors for Cancer (Castle Connolly Medical Ltd.)
2007	**Matthew T. Moore Award**, American Association of Neuropathologists (AANP) meeting, CR Miller (presenter), A Perry (senior author)
2007	Distinguished Service **Teaching Award**, WUSM (Medical School Class of 2009)
2008	Elected to **Alpha Omega Alpha** (AOA), WUSM Chapter for recognition of faculty commitment to medical education
2008	**Professor of the Year Award**, WUSM (Medical School Class of 2010)

2009-2010	Appointed **Vice President Elect** of AANP
2009-now	Listed in **Best Doctors** in America, U.S. News and World Reports
2009-now	Listed in America's **Top Pathologists**, Consumers' Research Council of America
2009	Listed in St. Louis Magazine's **Best Doctors**
2009	Distinguished Service **Teaching Award**, WUSM (Medical School Class of 2011)
2010-2011	Appointed **Vice President** of AANP
2012-now	Listed in San Francisco Super Doctors
2012	**Matthew T. Moore Award (honorable mention)**, American Association of Neuropathologists meeting, JJ Phillips (presenter), A Perry (senior author)
2013	Nominated for MS1 Essential Core **Teaching Award**, UCSF (Medical School Class of 2016)
2012-2015	Served as North American Chief Editor for 9th Edition of Greenfield's Neuropathology (main 2 volume reference textbook utilized internationally)
2014	Appointed **Vice President** of International Society of Neuropathology for 2015-2018
2014	Appointed as **Senior Reviewer** for World Health Organization (WHO) 4th edition brain tumor classification scheme update
2015	Appointed **President Elect** of AANP for 2015-2016
2015	Appointed **President** of AANP for 2016-2017
2016-now	Appointed to the **Editorial Advisory Board** (EAB) for the American Registry of Pathology (ARP) Publications / Armed Forces Institute of Pathology (AFIP) Fascicles
2016-now	**Member** of cIMPACT‐NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy
2017-now	**Member** of International Collaboration on Cancer Reporting (ICCR) for the development of a reporting protocol for tumours of the central nervous system (CNS)
2018	Society for Neuro-Oncology in Latin America (SNOLA) **International Imaging and Pathology Recognition Award**
2018-2021	Elected as a **Board of Directors Member** for the United States and Canadian Academy of Pathology (USCAP)

KEYWORDS/AREAS OF INTEREST:

Astrocytoma, brain tumors, biomarkers, cancer cytogenetics, classification, diagnosis, diffuse gliomas, embryonal neoplasms, ependymoma, epilepsy pathology, expression profiling, familial tumor syndromes, fluorescence in situ hybridization (FISH), genomics, germ cell tumors, glioblastoma, glioma, glioneuronal tumors, grading, histiocytic disorders, immunohistochemistry, medulloblastoma, melanocytic tumors, meningioma, molecular diagnostics, neurocytoma, neurofibromatosis types I and II, oligodendroglioma, pediatric neuropathology, peripheral nerve sheath tumors, pituitary/sellar neoplasms, prognosis, rhabdoid tumors, sarcomas, schwannomatosis, solitary fibrous tumor/hemangiopericytoma, tissue microarray, treatment effects, tuberous sclerosis complex (TSC)

CLINICAL ACTIVITIES

CLINICAL ACTIVITIES SUMMARY

With the development of a busy personal consult service, my clinical activities form a prominent portion of my time, even when I'm officially off service. By nature, these consults are often interesting and highly complex cases that often require ancillary studies and a considerable investment of time. They also have great teaching value for our trainees and other colleagues. On average, I spend about 2-4 hours

each day working on these cases. When I am on service, in-house biopsies and autopsies supplement my clinical activities further and typically take up the majority of my working hours. Additionally, administrative duties include serving as the director of the Neuropathology Division, a member of the Brain Tumor Research Center (BTRC) executive committee, and co-director of the BTRC Biospecimen core. Associated responsibilities include organizing the clinical Neuropathology sign-out and call schedules, supervising the training of clinical fellows, implementing ACGME requirements, monitoring divisional manpower and ancillary support requirements, running faculty recruitments, participating in leadership initiatives, and supervising laboratory activities at the BTRC. Being joint appointed in the department of Neurological Surgery, I also work closely with my surgical colleagues to make sure that their daily clinical and residency training needs are adequately met, including high quality pathology services, availability of cutting edge molecular diagnostics, efficient turnaround times, and interdepartmental educational activities.

CLINICAL SERVICES

2010 - present	UCSF Surgical Neuropathology Service	10-12 weeks per year
2010 - present	UCSF Neuropathology Autopsy Service	7-8 weeks per year
2010 - present	UCSF Personal Neuropathology Consult Service	Full time

PROFESSIONAL ORGANIZATIONS

Memberships

1992-now	United States and Canadian Academy of Pathology (USCAP)
1994-now	American Association of Neuropathologists (AANP)
1996-now	Society for Neuro-Oncology (SNO)
1999-2010	Alvin J. Siteman Cancer Center, Cancer Genetics Research Program, Washington University School of Medicine
1999-2007	American Association for Cancer Research (AACR)
2004-2009	Association for Molecular Pathology (AMP)
2004-now	Canadian Association of Neuropathologists (CANP)
2005-now	International Society for Bone and Soft Tissue Pathology (ISBSTP)
2007-now	College of American Pathologists (CAP)
2010-now	California Society of Pathologists (CSP)
2010-now	South Bay Pathology Society (SBPS)
2016-now	Associate Member of UCSF Helen Diller Family Comprehensive Cancer Center, Neurologic Oncology Program

Service to Professional Organizations

2000-2006	SNO	**Member**, Future Sites Committee
2001-02, 2007	American Association of Neuropathologists (AANP)	**Member**, Awards Committee
2002, 2005-10	AANP	**Member**, Program Committee
2002-now	Radiation Therapy Oncology Group (RTOG)	**Member**, Brain Tumor Steering Committee
2003-2004	AANP	**Chair**, Program Committee

2003-2008	National Alliance for Autism Research (NAAR), Autism Tissue Program (ATP)	**Member**, Executive Committee
2004-now	AANP	**Charter Member**, Diagnostic Slide Session
2006-now	SNO	**Abstract Reviewer**
2006-now	USCAP Neuropathology Section	**Abstract Reviewer**
2006	World Health Organization (WHO)	**Participant** in Classification of CNS Tumors Consensus and Editorial Meeting
2009-2015	AANP	**Councilor** to the International Society of Neuropathology
2009-2010	AANP	**Vice President Elect**
2009-2015	RTOG Meningioma Clinical Trial 0539	**Pathology Chair/Central Reviewer**
2009-2012	National Brain Tumor Society (NBTS)	**Member**, Scientific Advisory Council
2010-2011	AANP	**Vice President**
2012 (Aug)	Institute of Neuropathology, Zurich, Switzerland	**External Evaluator** of Institute
2013-2016	USCAP Publications Committee	**Member**
2013-2014	XVIII International Congress of Neuropathology	**Member**, Scientific Committee
2013-2014	XVIII International Congress of Neuropathology	**Co-Organizer**, Meningioma Session
2014-2016	WHO Brain Tumor Classification, 4th ed. update	**Senior Reviewer**
2015-2018	International Society for Neuropathology	**Vice President**
2015-2016	AANP	**President Elect**
2016-2017	AANP	**President**
2018-now	CAP Neuropathology Committee	**Member**
2018-2020	USCAP Board of Directors	**Member**
2018-now	NRG Meningioma Clinical Trial BN003	**Pathology Chair/Central Reviewer**

SERVICE TO PROFESSIONAL PUBLICATIONS:

2007-2014	**Editor-in-chief**, Brain Pathology
2014-now	**Senior Editor**, Brain Pathology
2014-now	**Review Editor**, Pituitary Endocrinology (within Frontiers in Endocrinology)
2016-now	**Editorial Advisory Board** member, American Registry of Pathology (ARP) Publications

Editorial board member

2000-now	Advances in Anatomic Pathology
2004-2017	Journal of Neuro-Oncology
2005-now	Acta Neuropathologica
2005-2018	Human Pathology
2005-now	Journal of Neuropathology and Experimental Neurology
2009-2014	Neurosurgery

Ad hoc journal reviewer

Acta Neurochirurgica
American Journal of Clinical Pathology
American Journal of Medical Genetics
American Journal of Pathology
Ann Surg Oncol
Archives of Pathology and Laboratory Medicine

Cancer
Cancer Research
Clinical Cancer Research
Clinical Neurology & Neurosurgery
Clinical Neuropathology
Frontiers in Bioscience
Genes Chromosomes & Cancer
Histology and Histopathology
International Journal of Cancer
Journal of Clinical Oncology
Journal of Clinical Pathology
Journal of Molecular Diagnostics
Journal of Neurosurgery
Journal of Pathology
Mayo Clinic Proceedings
Neurogenetics
Neurology India
Neuro-Oncology
Neurosurgery
New England Journal of Medicine
Oncogene
Surgical Neurology
World Neurosurgery

INVITED PRESENTATIONS

INTERNATIONAL

1. University of Calgary / Foothills Medical Centre, Department of Pathology, Calgary, Alberta, Canada, February 6, 2003 (invited talk).
2. Canadian Brain Tumor Consortium (CBTC), Investigator's Meeting: Advances in the Management of Glioma, Lake Louise, Alberta, Canada, February 7, 2003 (invited talk).
3. International Society of Neuropathology, Workshop at the XVth International Congress of Neuropathology, Turin, Italy, September 17, 2003 (invited talk).
4. Instituto di Anatomia Patologica, University of Ancona, Ancona, Italy, September 22, 2003 (2 invited talks).
5. USCAP, 93rd annual meeting, Short Course #59, Vancouver, B.C., Canada, April 2004 (faculty presenter).
6. Montreal Neurologic Institute at McGill University, Invited Lecture, Montreal, Quebec, Canada, July 5, 2004 (invited talk).
7. Canadian Association of Pathologists / Association Canadienne des Pathologistes (CAP/ACP), 55th Annual Meeting, Symposium Sponsored by Schering Canada, Montreal, Quebec, Canada, July 6, 2004 (invited talk).
8. German Society for Neuropathology and Neuroanatomy, Molecular Neuropathology Course and 49th Annual Meeting, Cologne, Germany, September 25, 2004 (invited talk).
9. University Medical Center in Nijmegen, Pathology Department, Invited Lecture, Nijmegen, Netherlands, September 27, 2004 (invited talk).
10. Erasmus Medical Center in Rotterdam, Pathology Department, Invited Lecture, Rotterdam, Netherlands, September 30, 2004 (invited talk).

11. Heinrich-Heine-University, Department of Neuropathology, Invited Lecture, Düsseldorf, Germany, October 4, 2004 (invited talk).
12. 2nd Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) and 6th Meeting of the European Association of Neuro-Oncology (EANO), Plenary Symposium on Malignant Glioma, Edinburgh, Scotland, May 6, 2005 (invited talk).
13. British Neuropathological Society, 107th Meeting, Symposium on Brain Tumours in the Future, London, England, January 6, 2006 (invited talk).
14. Brain Tumour Foundation of Canada, 12th Canadian Neuro-Oncology Meeting**,** Winnipeg, Manitoba, Canada, May 27, 2006 (keynote speaker).
15. World Health Organization (WHO) Classification of Tumours of the Nervous System Consensus and Editorial Meeting, Working Subgroup C (schwannoma, meningioma, hematopoietic and germ cell tumors), Heidelberg, Germany, November 17-18, 2006 (led session).
16. 21st European Congress of Pathology, Istanbul, Turkey, September 9, 2007 (2 invited talks).
17. Euro-CNS Brain Tumor Course, Athens, Greece, May 8, 2008 (invited talk).
18. Canadian Association of Pathologists / Association Canadienne des Pathologistes (CAP/ACP), 59th Annual Meeting, "Neuropathology Workshop". Ottawa, Ontario, Canada, July 13, 2008 (faculty presenter).
19. Canadian Association of Pathologists / Association Canadienne des Pathologistes (CAP/ACP), 59th Annual Meeting, Neuropathology Symposium: Ottawa, Ontario, Canada, July 14, 2008 (invited talk).
20. International Academy of Pathology (IAP) 27th Annual Congress, Slide Session SS02, Athens, Greece, October 13, 2008 (chair and lecturer).
21. IAP 27th Annual Congress, Symposium SYM18, Athens, Greece, October 14, 2008 (co-chair and lecturer).
22. IAP 27th Annual Congress, Short Course SC09, Athens, Greece, October 15, 2008 (co-chair and lecturer).
23. QE II Health Sciences Center, Pathology Grand Rounds, Halifax, Nova Scotia, Canada, April 15, 2009 (invited talk).
24. CNS Symposium: Current Trends in the Management of Malignant Gliomas, Tokyo, Japan, May 10, 2009 (invited talk).
25. World Federation of Neuro-Oncology (WFNO) 3rd Quadrennial Meeting / Asian Society for Neuro-Oncology (ASNO) 6th Annual Meeting, Educational Lectures: Treatment of Malignant Brain Tumors, Yokohama, Japan, May 11, 2009 (invited talk).
26. Institute of Biomedical Sciences, Academia Sinica Special Seminar, Taipei, Taiwan, January 4, 2010 (2 invited talks and a slide seminar).
27. Brain 2010 Course, Chinese Society of Neuro-oncology and the Society of Neuroscience of China, Hong Kong, January 8-9, 2010 (2 invited talks).
28. 33rd Annual Meeting of the Spanish Society of Pathology/Sociedad Española de Anatomía Patológica (SEAP), Madrid, Spain, February 5, 2010 (3 invited talks).
29. CNS Symposium: Current Trends in the Management of Malignant Gliomas, Translating Science into Practice Cancun, Mexico, March 6, 2010 (invited talk).
30. 20th Peruvian Congress of Pathology, Lima, Peru, November 18-20, 2010 (4 invited talks).
31. 25th Congress of SEAP, Zaragoza, Spain, May 18-19, 2011 (3 invited talks).
32. University of British Columbia and Vancouver General Hospital, Clarisse L. Dolman Memorial Lecture, Neurosciences Grand Rounds, Vancouver, B.C., Canada, May 25, 2011 (invited talk).
33. 16th Annual Meeting of the Japanese Congress for Brain Tumor Surgery, Yokohama, Japan, September 9-11, 2011 (2 invited talks).
34. Taiwan Neuro-Oncology Society, National Science Council, Abbott Taiwan, and the Tri-Service General Hospital Pathology Department, September 25-30, 2011 (3 invited talks).

35. USCAP 101st Annual Meeting, Neuropathology (AANP) Companion Meeting, Vancouver, BC, Canada, March 17, 2012 (invited talk).
36. USCAP 101st Annual Meeting, Neuropathology Specialty Conference, Vancouver, BC, Canada, March 21, 2012 (case presentation).
37. 10th European Congress of Neuropathology (ECN), Edinburgh, Scotland, June 8, 2012 (invited talk).
38. Cukurova Pathology Society Conference, "A Tribute to Dr. Bernd Scheithauer on the First Anniversary of his Passing", Adana, Turkey, September 21-22, 2012 (2 invited talks).
39. Asian Society for Neuro-Oncology Meeting, Mumbai, India, March 21-24, 2013 (2 invited talks).
40. Canadian Association of Neuropathologists (CANP) 53rd Annual Meeting, Session 4: Nerve & Muscle & other topics, Ottawa, ON, Canada, October 16-19, 2013 (case presentation).
41. 'WHO's Next?' A Colloquium to Guide Next Steps in Brain Tumor Classification and Grading, Haarlem, The Netherlands, May 1-3, 2014 (co-organizer and faculty).
42. Hiroshima University, Alumni Association of the Dept. of Neurosurgery, Hiroshima, Japan, May 21, 2014 (invited talk).
43. 32nd Annual Meeting of the Japan Society of Brain Tumor Pathology, Tokushima, Japan, May 23-24, 2014 (2 invited talks).
44. 20th International Conference on Brain Tumor Research and Therapy (ICBTRT), Lake Tahoe, CA, USA, July 20-23, 2014 (neuropathology chair/moderator and invited talk).
45. XVIIIth International Congress of Neuropathology (ICN), Rio de Janeiro, Brazil, September 14-18, 2014 (symposium organizer and 3 invited talks).
46. 24th National Pathology Congress of the Turkish Pathology Society, Pediatric Brain Tumor Pathology Course, Trabzon, Turkey, November 19-23, 2014 (2 invited talks).
47. Marmara University Institute of Neurological Sciences, Brain Tumor Seminar, Istanbul, Turkey, November 24, 2014 (2 invited talks).
48. 2015 Spanish National Neurosurgery Conference, Pamplona (Navarra), Spain, May 19-22, 2015 (invited talk).
49. XXVII National Congress of the Spanish Society of Pathology (SEAP), Santander, Spain, May 21-23, 2015 (2 invited talks).
50. World Health Organization (WHO) Classification of Tumours of the Nervous System Consensus Meeting, Heidelberg, Germany, June 22-24, 2015 (senior advisor, presenter, and participant).
51. European Low-grade Glioma Network (ELGGN) meeting, Paris, France, June 26, 2015 (invited talk).
52. Sarah Hospitals, Dept. of Pathology Seminar, Brasilia, Brazil, October 27-28, 2015 (2 invited talks).
53. XXX Congress of the Brazilian Society of Pathology (SBP), São Paulo, Brazil, October 29-November 1, 2015 (2 invited talks).
54. Hong Kong International Academy of Pathology (IAP) Silver Jubilee Convention, Kowloon, Hong Kong, November 6-8, 2015 (3 invited talks).
55. 21st International Conference on Brain Tumor Research and Therapy (ICBTRT), Okinawa, Japan, April 10-13, 2016 (invited talk).
56. Brain Tumour Workshop, University of Malaya, Kuala Lumpur, Malaysia, April 17-19, 2016 (8 invited talks and microscope sessions).
57. 20th Pathology Meeting, A.C. Camargo Cancer Center, Salvador and São Paulo, Brazil, June 27-July 2, 2016 (2 invited talks).
58. International Society of Neuropathology Outreach Teaching Workshop, Lima, Peru, August 23-24, 2016 (2 invited talks).
59. XXII International Course of Neurosciences, Lima, Peru, August 25, 2016 (invited talk).
60. 76th Annual Meeting of the Japan Neurosurgical Society, Nagoya, Japan, October 12-14, 2017 (2 invited talks).

61. Hopital Lariboisiere, Neurosurgery/Neuropathology Lecture, Paris, France, November 14, 2017 (invited talk).
62. Sociedade Latino Americana de Neuro-oncologia (SNOLA) 2018 Meeting, Sao Paulo, Brazil, March 15, 2018 (invited talk).
63. USCAP 107th Annual Meeting, Short Course 05: "The nerve of some nerve sheath tumors! A practical approach to common problems in surgical pathology", Vancouver, BC, Canada, March 21, 2018 (faculty).
64. 10th Annual Indian Society of Neuro-oncology (ISNO) Conference, All India Institute of Medical Sciences, New Delhi, India, April 5-8, 2018 (invited talk).
65. 60th Congress of the Mexican Association of Pathologists, Neuropathology Course, Ixtapa, Mexico, April 27 to May 1, 2018 (invited talk).
66. 22nd International Conference on Brain Tumor Research and Therapy, Bergen, Norway, June 22-27, 2018 (invited talk).
67. 3rd Pediatric Latin American Neuro Oncology Symposium (PLANO), Lima, Peru, August 31-September 1, 2018 (2 invited talks).
68. 19th International Congress of Neuropathology (ICN2018) and the 36th Annual Meeting of the Japan Society of Brain Tumor Pathology (BTP2018), Tokyo, Japan, September 23-27, 2018 (2 invited talks).
69. 5th International Symposium of Brain Tumor Pathology (ISBTP2018), Hakone, Kanagawa, Japan, September 28, 2018 (invited talk).
70. XXXII Congress of the International Academy of Pathology, Dead Sea, Jordan, October 14-18, 2018 (3 invited talks).
71. The Israeli Association of Pathologists Annual Meeting, Tel Aviv, Israel, October 22, 2018 (2 invited talks).

NATIONAL

72. North Central Cancer Treatment Group (NCCTG), Pathology Committee Meeting, Rochester, MN, October 30, 1997 (invited talk).
73. NCCTG, Pathology Committee Meeting, Rochester, MN, April 18, 1998 (invited talk).
74. American Society of Clinical Pathologists (ASCP), Teleconference Series, December 4, 1998 (invited talk).
75. University of South Dakota and LCM Pathologists, P.C., Sioux Falls, SD, September 23, 1999 (invited talk).
76. Society for Neuroscience (SFN), 29th Annual Meeting, 1999 Neurobiology of Disease Workshop: Neurobiology of Glia and Glial Brain Tumors, Miami, FL, October 23, 1999 (invited talk).
77. United States and Canadian Academy of Pathology (USCAP), 89th Annual USCAP meeting, Neuropathology Specialty Conference, Panelist, New Orleans, LA, March 29, 2000 (case presentation).
78. University of South Dakota and LCM Pathologists, P.C., Sioux Falls, SD, April 21, 2000 (invited talk).
79. University of Texas M.D. Anderson Cancer Center, Division of Pathology and Laboratory Medicine Grand Rounds, Houston, TX, September 22, 2000 (invited talk).
80. Society for Neuro-Oncology (SNO) Educational Symposium, 2000 Annual Meeting, Chicago, IL, November 9, 2000 (invited talk).
81. USCAP, 90th Annual Meeting, Neuropathology Specialty Conference, Panelist, Atlanta, GA, March 8, 2001 (case presentation).
82. University of South Dakota and LCM Pathologists, P.C., Sioux Falls, SD, July 13, 2001 (invited talk).

83. American Society for Therapeutic Radiology and Oncology (ASTRO), 43rd annual meeting, Faculty Panelist in Controversies in the Management of CNS Germ Cell Tumors Session, San Francisco, CA, November 6, 2001 (invited talk).
84. USCAP, 91st annual meeting, Short Course #59, Chicago, IL, April 2002 (faculty presenter).
85. University of South Dakota and LCM Pathologists, P.C., Sioux Falls, SD, July 19, 2002 (invited talk).
86. SNO, Plenary Session 1, Moderator, San Diego, CA, November 22, 2002 (summary of posters).
87. USCAP, 92nd annual meeting, Short Course #59: Washington, D.C., April 2003 (faculty presenter).
88. Colorado Neurological Institute, Center for Brain and Spinal Tumors, Denver, CO, May 2, 2003 (invited talk).
89. University of South Dakota and LCM Pathologists, P.C., Sioux Falls, SD, July 18, 2003 (invited talk).
90. Aspen Conference on Pediatric Disease, 25th Annual Meeting, the Pathology of Tumors in Children, Institute for Pediatric Medical Education, Snowmass Village at Aspen, CO, August 4-8, 2003 (3 invited talks).
91. University of California in Los Angeles (UCLA), Pathology Grand Rounds, Los Angeles, CA, October 22, 2003 (invited talk).
92. SNO Educational Symposium, 2003 Annual Meeting, Keystone, CO, November 13, 2003 (invited talk).
93. SNO, 2003 Annual Meeting, Keystone, CO, November 15, 2003 (poster summaries).
94. Johns Hopkins University, Pathology Grand Rounds, Baltimore, MD, November 6, 2003 (invited talk).
95. Yale University School of Medicine, Grand Rounds in Surgical Pathology, New Haven, CT, January 8, 2004 (invited talk).
96. Vysis, Inc., Seminar, Downers Grove, IL, April 15, 2004 (invited talk).
97. Stanford University Medical Center, Pathology Grand Rounds, Palo Alto, CA, April 20, 2004 (invited talk).
98. University of California in San Francisco (UCSF), Pathology Lecture, San Francisco, CA, April 21, 2004 (invited talk).
99. Applied Imaging Corporation, San Jose, CA, June 11, 2004 (invited talk).
100. American Association for Neuropathologists (AANP), 80th Annual Meeting, Special Course, Cleveland, OH, June 24, 2004 (invited talk).
101. University of South Dakota and LCM Pathologists, P.C., Sioux Falls, SD, August 20, 2004 (invited talk).
102. SNO Educational Symposium, 2004 Annual Meeting, Toronto, Ontario, Canada, November 18, 2004 (invited talk).
103. U.T. M.D. Anderson Cancer Center, Pathology Grand Rounds, Houston, TX, December 10, 2004 (invited talk).
104. USCAP, 94th annual meeting, Short Course #59, San Antonio, TX March 2005 (faculty presenter).
105. Cleveland Clinic Taussig Cancer Center Research Conference, Cleveland, OH, March 11, 2005 (invited talk).
106. Indiana University School of Medicine, Gregory Derringer Pathology Grand Rounds, Indianapolis, IN, March 16, 2005 (invited talk).
107. Indiana University School of Medicine, Molecular Pathology Seminar, Indianapolis, IN, March 16, 2005 (invited talk).
108. University of Florida College of Medicine, Neurosurgery Grand Rounds, Gainesville, FL, April 4, 2005 (invited talk).

109. University of Florida College of Medicine, Pathology Conference, Gainesville, FL, April 4, 2005 (invited talk).
110. Memorial Sloan-Kettering Cancer Center, Pathology Grand Rounds, New York, NY, May 26, 2005 (invited talk).
111. Diagnostic Pediatric Surgical Pathology Course, University of Chicago, Chicago, IL, July 25, 2005 (invited talk).
112. University of South Dakota and LCM Pathologists, P.C., Sioux Falls, SD, August 19, 2005 (invited talk).
113. College of American Pathologists CAP '05 Meeting, Vysis Inc. Workshop IW101: Chicago, IL, September 12, 2005 (invited talk).
114. University of Oklahoma, Pathology Grand Rounds, Oklahoma City, OK, October 3, 2005 (invited talk).
115. Evanston Hospital, Neuro-Oncology Grand Rounds, Evanston, IL, November 11, 2005 (invited talk).
116. USCAP, 95th Annual Meeting, Short Course #37, Atlanta, GA, February 2006 (faculty presenter).
117. Yale University School of Medicine, Grand Rounds in Surgical Pathology, New Haven, CT, March 16, 2006 (invited talk).
118. Cleveland Clinic Foundation, 3rd Glioblastoma Brain Tumor Summit, Cleveland, OH, May 20, 2006 (invited talk).
119. Ohio State University, Seminar, Columbus, OH, June 22, 2006 (invited talk).
120. Henry Ford Hospital, Neuro-Oncology Grand Rounds, Detroit, MI, July 26, 2006 (invited talk).
121. Aspen Conference on Pediatric Disease, 26th Annual Meeting, the Pathology of Tumors in Children, Institute for Pediatric Medical Education, Snowmass Village at Aspen, CO, August 8, 2006 (3 invited talks).
122. University of Texas Southwestern Anatomic Pathology Seminar, Dallas, TX, September 26, 2006 (invited talk).
123. FISH Consensus Meeting, Mount Sinai Medical Center, New York, NY, October 27, 2006 (invited talk).
124. Children's Memorial Hospital Pathology Grand Rounds, Chicago, IL, February 21, 2007 (invited talk).
125. University of Medicine and Dentistry of New Jersey (UMDNJ) Medical School, Neurology Grand Rounds, Newark, NJ, February 28, 2007 (invited talk).
126. USCAP, 96th Annual Meeting, Short Course #37, San Diego, CA, March 2007 (faculty presenter).
127. University of South Dakota and LCM Pathologists, P.C., Sioux Falls, SD, August 10, 2007 (invited talk).
128. Columbus Children's Hospital, Children's Oncology Group (COG), and OSU Comprehensive Cancer Center sponsored seminar, Pediatric Brain Tumors: Advances in Molecular Biology, Therapies and Outcomes Conference, Columbus, OH, September 7, 2007 (invited talk).
129. 2007 Symposium on Gliomas and Secondary Brain Tumors, New York, NY, September 29, 2007 (invited talk).
130. University of Toronto Grand Rounds, Toronto, Ontario, Canada, October 22, 2007 (invited talk).
131. University of Pennsylvania Department of Pathology and Laboratory Medicine Grand Rounds series, Philadelphia, PA, October 29, 2007 (invited talk).
132. Temple University, Department of Pathology Lecture, Philadelphia, PA, October 30, 2007 (invited talk).
133. Society of Neuro-Oncology (SNO) 12th Annual Scientific Meeting, Sunrise Session on Meningiomas, Dallas, TX November 16, 2007 (invited talk).
134. Memorial Sloan-Kettering Cancer Center, Pathology Grand Rounds, New York, NY, February 7, 2008 (invited talk).

135. Duckworth Pathology Group Full-Day Educational Conference, Methodist-University Hospital, Memphis, TN, February 9, 2008 (gave all-day seminar).
136. USCAP, 97th Annual Meeting, Faculty of Short Course #37, Denver, CO, March 2008 (faculty presenter).
137. USCAP 97th Annual Meeting, AANP Companion Meeting on The Newly Revised WHO Classifications of Tumors of the Nervous System: An Update of New Entities and Recent Progress Denver, CO, March 1, 2008 (invited talk).
138. USCAP 97th Annual Meeting, Special Course: Basic Principles and Practice of Molecular Pathology in Cancer, Denver, CO, March 3, 2008 (invited talk).
139. University of Iowa College of Medicine, Neurosurgery and Neuroradiology Conference, Iowa City, IA, March 26, 2008 (invited talk).
140. University of Iowa College of Medicine, Pathology Grand Rounds, Iowa City, IA, March 27, 2008 (invited talk).
141. 6th Annual Alvord Lecture in Neuropathology at the University of Washington, Seattle, WA, April 23, 2008 (invited talk).
142. Aspen Conference on Pediatric Disease, 27th Annual Meeting, Current Concepts in Pediatric Pathology, Maui, HI, June 15-18, 2008 (3 invited talks).
143. Stanford School of Medicine, Pathology Seminar, Palo Alto, CA, May 28, 2008 (invited talk).
144. Society of Neuro-Oncology (SNO) 13th Annual Scientific Meeting, Education Day, Lake Las Vegas, NV, November 20, 2008 (invited talk).
145. University of California San Francisco (UCSF) Pathology/Neurosurgery Seminar, San Francisco, CA, Jan 8, 2009 (invited talk).
146. American Brain Tumor Association (ABTA), Oligodendroglioma Roundtable Meeting, Chicago, IL, February 20, 2009 (discussant).
147. USCAP, 98th Annual Meeting, Faculty of Short Course #37, Boston, MA, March 2009 (faculty presenter).
148. USCAP 98th Annual Meeting, Special Course: Basic Principles and Practice of Molecular Pathology in Cancer, Boston, MA, March 9, 2009 (invited talk).
149. USCAP 98th Annual Meeting, Neuropathology Specialty Conference: Panelist, Boston, MA, March 9, 2009 (case presentation).
150. 27th Aspen Conference on Pediatric Disease, Snowmass Village, CO, August 3-7, 2009 (3 invited talks).
151. University of South Dakota and LCM Pathologists, P.C., Sioux Falls, SD, August 28, 2009 (invited talk).
152. USCAP 99th Annual Meeting, Special Course: Basic Principles and Practice of Molecular Pathology in Cancer, Washington, D.C., March 22, 2010 (invited talk).
153. Indiana University School of Medicine, Neuropathology Seminar, Indianapolis, IN, April 20, 2010 (invited talk).
154. Visiting Neuropathology Professor Lectureship, Ball Memorial Hospital, Muncie, IN, April 21, 2010 (2 invited talks and a glass slide session).
155. AANP 86th Annual Meeting, Special Course on Hereditary Tumor Syndromes of the Nervous System, Philadelphia, PA, June 10, 2010 (invited talk).
156. University of Pittsburgh School of Medicine, Annual Martinez Memorial Lecture, Pittsburgh, PA, September 29, 2010 (invited talk).
157. University of Nebraska Medical Center, Pathology Grand Rounds, Omaha, NE, December 1, 2010 (invited talk).
158. Educational Symposia (ESI) 32nd Annual Seminar, Pathology Review, Snowmass Village, CO, February 6-11, 2011 (4 invited talks).
159. USCAP 100th Annual Meeting, Special Course: A Practical Guide to Molecular Testing in Cancer, San Antonio, TX, February 28, 2011 (invited talk).

160. USCAP 100th Annual Meeting, Neuropathology Specialty Conference, San Antonio, TX, March 2, 2011 (case presentation).
161. Children's Hospital in Wisconsin, Pathology Seminar, Milwaukee, WI, May 4, 2011 (2 invited talks).
162. Aspen Conference on Pediatric Disease Series, 33rd Conference on Pediatric Disease, Snowmass, CO, August 1-5, 2011 (4 invited talks).
163. American Association of Pathologists' Assistants (AAPA), 37th Annual Continuing Education and Business Conference, San Francisco CA, August 29, 2011 (2 invited talks).
164. Emory University Department of Pathology, Pathology Grand Rounds, November 7, 2011 (invited talk).
165. California Society of Pathologists (CSP), 64th Annual Convention, San Francisco, CA, December 2-3, 2011 (2 invited talks).
166. Washington Neuroradiology Review and Dr. Kenneth M. Earle Memorial Neuropathology Review ("Annual AFIP Review Course"). Bethesda, MD, February 13, 2012 (invited talk).
167. AANP 88th Annual Meeting, Diagnostic Slide Session, Chicago, IL June 23, 2012 (case presentation).
168. University of South Dakota and LCM Pathologists, P.C., Grand Rounds and Slide Session, Sioux Falls, SD, August 31, 2012 (2 invited talks).
169. A. James French Visiting Professorship, University of Michigan Pathology Department, Ann Arbor, MI, September 10, 2012 (invited talk).
170. Washington Neuroradiology Review and Dr. Kenneth M. Earle Memorial Neuropathology Review ("Annual AFIP Review Course"). Bethesda, MD, February 11, 2013 (invited talk).
171. Society for Pediatric Pathology, Short Course on Frozen Section Pathology, Baltimore, MD, March 3, 2013 (faculty).
172. USCAP 102nd Annual Meeting, American Society for Investigative Pathology (ASIP) Companion Meeting, "Interactive Molecular Pathology", Baltimore, MD, March 3, 2013 (faculty).
173. SNO-AANS/CNS Tumor Section, 10th Biennial Satellite Tumor Symposium, Meningioma Session 1, New Orleans, LA, April 27, 2013 (invited talk).
174. USCAP 2013 Diagnostic Pathology Update Course, Anchorage, AK, July 15-16 (4 invited talks).
175. Univ. North Carolina (UNC), Pathology Grand Rounds and Resident Teaching, Chapel Hill, NC, January 7-9, 2014 (2 invited talks).
176. Washington Neuroradiology Review and Dr. Kenneth M. Earle Memorial Neuropathology Review ("Annual AFIP Review Course"). Bethesda, MD, February 10, 2014 (2 invited talks).
177. USCAP 103rd Annual Meeting, AANP Companion Meeting, "Glioblastomas: Present and Future", San Diego, CA, March 1, 2014 (invited talk).
178. USCAP 103rd Annual Meeting, Arthur Purdy Stout Companion Meeting, "Integration of Anatomic and Molecular Pathology: Predictive Markers in Surgical Pathology Practice", San Diego, CA, March 2, 2014 (invited talk).
179. USCAP 103rd Annual Meeting, ASIP Companion Meeting, "Interactive Molecular Pathology", San Diego, CA, March 2, 2014 (invited talk).
180. Society for Pediatric Pathology, Short Course on Frozen Section Pathology, San Diego, CA, March 2, 2014 (faculty).
181. USCAP 103rd Annual Meeting, Neuropathology Specialty Conference, San Diego, CA, March 3, 2014 (case presentation).
182. USCAP 103rd Annual Meeting, Art and Pathology Session: "Let's Talk Music", San Diego, CA, March 5, 2014 (invited talk).
183. Johns Hopkins University, Shelley Lectureship and Pathology Grand Rounds, Baltimore, MD, April 7, 2014 (invited talk).
184. 2014 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, CNS Section on Tumors II: Meningiomas, San Francisco, CA, April 9, 2014 (invited talk).

185. 90th Annual Meeting of the American Association of Neuropathologists (AANP), Presidential Symposium: "State of the Art Brain Tumor Diagnosis", Portland, OR, June 15, 2014 (invited talk).
186. 35th Aspen Conference on Pediatric Disease, Update on Neoplastic and Non-neoplastic Pediatric Diseases, Aspen, CO, August 4-8, 2014 (4 invited talks).
187. Washington Neuroradiology Review and Dr. Kenneth M. Earle Memorial Neuropathology Review ("Annual AFIP Review Course"). Fairfax, VA, February 8, 2015 (2 invited talks).
188. Society for Pediatric Pathology, Short Course on Frozen Section Pathology, Boston, MA, March 22, 2015 (faculty).
189. USCAP 104th Annual Meeting, Special Course: "Molecular Diagnostic and Genomic Applications in Cancer: A Primer for The Pathologist", Boston, MA, March 24, 2015 (invited talk).
190. USCAP 104th Annual Meeting, Neuropathology Specialty Conference: "Biomarker Revolution: Useful New Stains and Assays to Solve Age-old Dilemmas", Boston, MA, March 24, 2015 (moderator).
191. 91st Annual Meeting of the American Association of Neuropathologists (AANP), Special Course: "What Every Neuropathologist Needs to Know", Denver, CO, June 11, 2015 (invited talk).
192. Washington Neuroradiology Review and Dr. Kenneth M. Earle Memorial Neuropathology Review ("Annual AFIP Review Course"). Fairfax, VA, February 1, 2016 (2 invited talks).
193. St. Jude Research Hospital Pathology Seminar, Memphis, TN, March 4, 2016 (invited talk).
194. USCAP 105th Annual Meeting, ASIP Companion Meeting: "The Pathologist and the Development of Targeted Therapies", Seattle, WA, March 13, 2016 (invited talk).
195. USCAP 105th Annual Meeting, Special Course: "Molecular Diagnostic and Genomic Applications in Cancer: A Primer for The Pathologist", Seattle, WA, March 15, 2016 (invited talk).
196. USCAP 105th Annual Meeting, Short Course 05: "The nerve of some nerve sheath tumors! A practical approach to common problems in surgical pathology", Seattle, WA, March 16, 2016 (faculty).
197. USCAP 105th Annual Meeting, Neuropathology Specialty Conference: "The Newly Updated WHO 2016 Blue Book", Seattle, WA, March 16, 2016 (moderator).
198. 36th Aspen Conference on Pediatric Disease, Update on Pediatric Pathology, Aspen, CO, August 4-5, 2016 (4 invited talks).
199. Neuropathology with Special Topics in Ophthalmic Pathology Seminar, Icahn School of Medicine at Mount Sinai, New York, NY, September 16, 2016 (invited talk).
200. MPNST Consensus Conference, National Cancer Institute (NCI), Bethesda, MD, October 5-7, 2016 (pathology discussion panelist).
201. 5th Bernd W. Scheithauer Memorial Lecture, Mayo Clinic Department of Pathology, Rochester, MN, October 11, 2016 (invited talk).
202. 18th Annual Brain Tumor Update and 7th Annual International Symposium on Long-Term Control of Metastases to the Brain and Spine, Las Vegas, NV, October 22-23, 2016 (invited talk).
203. St. Jude Children's Research Hospital, Pathology Grand Rounds, November 4, 2016 (invited talk).
204. 21st Annual Meeting and Education Day, Society for Neuro-Oncology (SNO), Scottsdale, AZ, November 17, 2016 (invited talk).
205. Washington Neuroradiology Review and Dr. Kenneth M. Earle Memorial Neuropathology Review ("Annual AFIP Review Course"), Fairfax, VA, February 7, 2017 (2 invited talks).
206. 38th Annual Pathology Review (sponsored by Educational Symposia): Pulmonary, Neuro and Hepatic Pathology for the General Pathologist, Snowmass Village, CO, February 13-17, 2017 (8 invited talks).

207. Mt. Sinai Hospital in NY, NY, Pathology Residency Video Conference on PathCast Live, February 22, 2017 (1 invited talk).
208. 5th Annual Barrow Neuro-Oncology Symposium, Barrow Neurological Institute, Paradise Valley, AZ, February 25, 2017 (1 invited talk).
209. USCAP 106th Annual Meeting, Special Course: "Molecular Diagnostic and Genomic Applications in Cancer: A Primer for The Pathologist", San Antonio, TX, March 7, 2017 (invited talk).
210. USCAP 106th Annual Meeting, Neuropathology Specialty Conference: "Integrated Diagnosis: Texas Style (Bigger and Better)", San Antonio, TX, March 7, 2017 (moderator).
211. USCAP 106th Annual Meeting, Short Course 05: "The nerve of some nerve sheath tumors! A practical approach to common problems in surgical pathology", San Antonio, TX, March 9, 2017 (faculty).
212. University of California Los Angeles (UCLA) Pathology Grand Rounds, Las Angeles, CA, March 30, 2017 (invited talk).
213. 1st North American Workshop on Neuropathology and Epilepsy Surgery, Cleveland Clinic, Cleveland, OH, April 28, 2017 (invited talk).
214. Brigham and Women's Hospital Surgical Pathology Update series, Boston, MA, May 19, 2017 (invited talk).
215. 93rd Annual Meeting of the American Association of Neuropathologists (AANP), President's Symposium, June 11, 2017 (invited talk).
216. 2017 Sanford Cancer Symposium: Neuro-Oncology, Fargo, ND, October 27, 2017 (invited talk).
217. Pediatric Grand Rounds at Miami Children's Health System/Nicklaus Children's Hospital, Miami, FL, December 15, 2017 (invited talk).
218. Washington Neuroradiology Review and Dr. Kenneth M. Earle Memorial Neuropathology Review ("Annual AFIP Review Course"), Fairfax, VA, January 16-17, 2018 (2 invited talks).
219. Pacific/Hawaii Pathology Conference, Maui, HI, January 22-26, 2018 (4 invited talks).
220. Washington State Society of Pathologists, Spring 2018 Meeting, Seattle, WA, May 5, 2018 (3 invited talks).
221. 37th Aspen Conference on Pediatric Disease, Update on Pediatric Pathology, Aspen, CO, August 9-10, 2018 (4 invited talks).
222. Primary Children's Hospital, Pediatric Grand Rounds, Salt Lake City, UT, November 1, 2018 (invited talk).
223. Primary Children's Hospital, Pathology Department Seminar, Salt Lake City, UT, November 2, 2018 (invited talk).
224. 2018 Society for Neuro-Oncology Annual Scientific Meeting Sunrise session organized by the Asian Society for Neuro-Oncology (ASNO), New Orleans, LA, November 15-18, 2018 (invited talk).
225. Washington Neuroradiology Review and Dr. Kenneth M. Earle Memorial Neuropathology Review ("Annual AFIP Review Course"), Fairfax, VA, February 14-15, 2019 (2 invited talks).

REGIONAL AND OTHER INVITED PRESENTATIONS

226. Alvin J. Siteman Cancer Center Tumor Genetics Seminar Series, St. Louis, MO, April 11, 2000 (invited talk).
227. Washington University School of Medicine (WUSM) Neurology Grand Rounds, St. Louis, MO, April 26, 2000 (invited talk)..
228. WUSM, Master of Science in Clinical Investigation Program-Techniques of Patient Oriented Research Course, St. Louis, MO, October 2, 2000 (invited talk)..
229. WUSM Neurology Grand Rounds, St. Louis, MO, October 18, 2000 (invited talk).

230. Alvin J. Siteman Cancer Center Tumor Genetics Seminar Series, St. Louis, MO, April 3, 2001 (invited talk).
231. WUSM Radiation Oncology Clinical Oncology Lecture Series, St. Louis, MO, August 9, 2002 (invited talk).
232. WUSM Neuro-Oncology Research Group Seminar Series, St. Louis, MO, February 24, 2003 (invited talk).
233. WUSM Neuro-Oncology Research Group Seminar Series, St. Louis, MO, May 17, 2004 (invited talk).
234. WUSM, Neurosurgery Grand Rounds, St. Louis, MO, December 1, 2004 (invited talk).
235. WUSM, Radiation Oncology Clinical Oncology Lecture Series, St. Louis, MO, February 11, 2005 (invited talk).
236. WUSM, Neurology Department Hope Center Research Seminar, St. Louis, MO, March 7, 2005 (invited talk).
237. WUSM, Cancer Biology Course for PhD Students, St. Louis, MO, March 22, 2005 (invited talk).
238. WUSM Neuro-Oncology Research Group Seminar Series, St. Louis, MO, December 12, 2005 (invited talk).
239. WUSM Neurosurgery Grand Rounds, St. Louis, MO, March 22, 2006 (invited talk).
240. Wagih Bari Society of St. Louis Pathologists, St. Louis, MO, April 5, 2006 (invited talk).
241. WUSM Neuro-Oncology Research Group Seminar Series, St. Louis, MO, June 12, 2006 (invited talk).
242. American Brain Tumor Association (ABTA) Sharing Hope Meeting, St. Louis, MO, October 13, 2006 (2 invited talks).
243. WUSM Pathology Grand Rounds, St. Louis, MO, April 3, 2007 (invited talk).
244. WUSM Mini Medical School Course, St. Louis, MO, April 24, 2007 (invited talk).
245. WUSM K12 Multidisciplinary Clinical Research Career Development Seminar Series, St. Louis, MO, June 26, 2007 (invited talk).
246. WUSM Mini Medical School Course, St. Louis, MO, October 9, 2007 (invited talk).
247. WUSM Mini Medical School Course, St. Louis, MO, April 15, 2008 (invited talk).
248. WUSM Mini Medical School Course, St. Louis, MO, October 7, 2008 (invited talk).
249. WUSM Mini Medical School Course, St. Louis, MO, March 24, 2009 (invited talk).
250. WUSM Mini Medical School Course, St. Louis, MO, November 10, 2009 (invited talk).
251. WUSM Mini Medical School Course, St. Louis, MO, April 13, 2010 (invited talk).
252. UCSF Neuropathology Course for Pathology Residents, January 2011 (2 invited talks).
253. UCSF 27th Annual Current Issues in Anatomic Pathology (CIAP) Course, San Francisco, CA, May 27, 2011 (invited talk).
254. UCSF Neurology Grand Rounds, San Francisco, CA, August 10, 2011 (invited talk).
255. UCSF Neurosurgery Resident Research Conference, San Francisco, CA, September 21, 2011 (invited talk).
256. UCSF Neuropathology Course for Pathology Residents, January 2012 (2 invited talks).
257. UCSF 15th Annual CIAP and Cytology Course, San Francisco, CA, May 26, 2012 (invited talk).
258. UCSF Meningioma Patient Educational Series, San Francisco, CA, June 26, 2012 (invited talk).
259. UCSF Controller's Office All-Staff meeting, San Francisco, CA, February 6, 2013 (invited talk).
260. UC Berkeley/UCSF Joint Medical Program, Berkeley, CA, May 1, 2013 (invited talk).
261. UCSF Neurosurgery Grand Rounds, San Francisco, CA, May 9, 2013 (invited talk).
262. California Society of Pathologists (CSP), 66th Annual Convention, San Francisco, CA, December 4-7, 2013 (video tutorial).
263. UCSF Neurosurgery Grand Rounds, San Francisco, CA, May 15, 2014 (invited talk).
264. UCSF Pediatric Brain Tumor Seminar, San Francisco, CA, June 27, 2014 (invited talk).
265. John Muir Neurosciences Institute Weekly Tumor Board and Grand Rounds, Walnut Creek, CA, November 6, 2014 (2 invited talks).

266. California Society of Pathologists (CSP), 67th Annual Convention, San Francisco, CA, December 2-3, 2014 (video tutorial).
267. UCSF 32nd Annual Current Issues in Anatomic Pathology (CIAP) Course, San Francisco, CA, May 28, 2016 (invited talk).
268. UCSF Pathology Grand Rounds, San Francisco, CA, April 20, 2017 (invited talk).
269. UCSF 33rd Annual Current Issues in Anatomic Pathology (CIAP) Course, San Francisco, CA, May 24, 2017 (invited talk).
270. The California Center for Pituitary Disorders at UCSF, Course on Pituitary Disorders: Advances in Diagnosis and Management, San Francisco, CA, October 21, 2017 (invited talk).
271. California Society of Pathologists (CSP), 70th Annual Convention, San Francisco, CA, November 30, 2017 (video tutorial).
272. UCSF 34th Annual Current Issues in Anatomic Pathology (CIAP) Course, San Francisco, CA, May 24, 2018 (invited talk).

CME COURSES ATTENDED

2004	AANP 80th Annual Meeting, Cleveland, OH
	USCAP 93rd Annual Meeting, Vancouver, BC, Canada
	SNO 9th Annual Meeting, Toronto, ON, Canada
2005	AANP 81st Annual Meeting, Arlington, VA
	USCAP 94th Annual Meeting, San Antonio, TX
	CAP '05 Annual Meeting, Chicago, IL
	WFNO 2nd Quadrennial/EANO 6th Annual Meetings, Edinburgh, Scotland
2006	International Congress of Neuropathology 16th Meeting, San Francisco, CA
	USCAP 95th Annual Meeting, Atlanta, GA
	26th Aspen Conference on Pediatric Disease, Aspen, CO
	British Neuropathological Society Winter Meeting, London, U.K.
	American Brain Tumor Association Sharing Hope Meeting, St. Louis, MO
2007	AANP 83rd Annual Meeting, Washington, D.C.
	USCAP 96th Annual Meeting, San Diego, CA
	SNO 12th Annual Meeting, Dallas, TX
	21st European Congress of Pathology, Istanbul, Turkey
	2007 Symposium on Gliomas and Secondary Brain Tumors, New York, NY
2008	AANP 84th Annual Meeting, San Diego, CA
	USCAP 97th Annual Meeting, Denver, CO
	SNO 13th Annual Meeting, Las Vegas, NV
	Euro-CNS Brain Tumor Course, Athens, Greece
	International Association of Pathology 27th Meeting, Athens, Greece
	48th Canadian Association of Pathologists (CANP), Ottawa, ON, Canada
	Aspen Conference on Pediatric Disease, 30th Annual Meeting, Maui, HI
2009	USCAP 98th Annual Meeting, Boston, MA
	SNO 14th Annual Meeting, New Orleans, LA
	Aspen Conference on Pediatric Disease, 31st Annual Meeting, Snowmass, CO
2010	Brain 2010 Course, Hong Kong
	Spanish Society of Pathology, Annual Meeting, Madrid, Spain
	USCAP 99th Annual Meeting, Washington, D.C.
	AANP 86th Annual Meeting, Philadelphia, PA
	International Congress of Neuropathology, 17th Meeting, Salzburg, Austria
2011	Educational Symposia (ESI) 32nd Annual Seminar, Snowmass, CO

	USCAP 100th Annual Meeting, San Antonio, TX
	25th Congress of Spanish Society of Pathology, Annual Meeting, Zaragosa, Spain
	AANP 87th Annual Meeting, Seattle, WA
	Aspen Conference on Pediatric Disease, 33rd Annual Meeting, Snowmass, CO
	Japanese Congress for Brain Tumor Surgery, 16th Annual Meeting, Yokohama, Japan
	SNO 16th Annual Meeting, Orange County, CA
2012	Dr. Kenneth M. Earle Memorial Neuropathology Review, Bethesda, MD
	USCAP 101st Annual Meeting, Vancouver, BC, Canada
	AANP 88th Annual Meeting, Chicago, IL
	SNO 17th Annual Meeting, Washington D.C.
2013	Dr. Kenneth M. Earle Memorial Neuropathology Review, Bethesda, MD
	USCAP 102nd Annual Meeting, Baltimore, MD
	AANS/CNS Tumor Section, 10th Satellite Tumor Symposium, New Orleans, LA
	AANP 89th Annual Meeting, Charleston, SC
	USCAP Diagnostic Pathology Update Course, Anchorage, AK
	53rd Canadian Association of Pathologists (CANP), Ottawa, ON, Canada
	WFNO 4th Quadrennial/SNO 18th Annual Meetings, San Francisco, CA
2014	Dr. Kenneth M. Earle Memorial Neuropathology Review, Bethesda, MD
	USCAP 103rd Annual Meeting, San Diego, CA
	AANP 90th Annual Meeting, Portland, OR
	Aspen Conference on Pediatric Disease, 35th Annual Meeting, Snowmass, CO
2015	Dr. Kenneth M. Earle Memorial Neuropathology Review, Fairfax, VA
	USCAP 104th Annual Meeting, Boston, MA
	AANP 91st Annual Meeting, Denver, CO
2016	Dr. Kenneth M. Earle Memorial Neuropathology Review, Fairfax, VA
	USCAP 105th Annual Meeting, Seattle, WA
	UCSF 32nd Annual Current Issues in Anatomic Pathology, San Francisco, CA
	AANP 92nd Annual Meeting, Baltimore, MD
	Aspen Conference on Pediatric Disease, 36th Annual Meeting, Snowmass, CO
	Mt Sinai: Neuropathology with Special Topics in Ophthalmic Pathology, New York, NY
	18th Annual Brain Tumor Update, Las Vegas, NV
	SNO 21st Annual Meeting, Scottsdale, AZ
	California Tumor Tissue Registry Course on Soft Tissue Pathology, San Francisco, CA
2017	Dr. Kenneth M. Earle Memorial Neuropathology Review, Fairfax, VA
	5th Annual Neuro-Oncology Symposium by the BNI, Phoenix, AZ
	USCAP 106th Annual Meeting, San Antonio, TX
	First North American Workshop on Epilepsy Neuropathology, Cleveland, OH
	33rd Annual Current Issues in Anatomic Pathology, San Francisco, CA
	AANP 93rd Annual Meeting, Garden Grove, CA
	UCSF Course on Pituitary Disorders, San Francisco, CA
2018	Dr. Kenneth M. Earle Memorial Neuropathology Review, Fairfax, VA
	Pathology Education Partners, 2018 Hawaii Pathology Conference, Maui, HI
	Society for Neuro-oncology Latin America 2018 Meeting, Sao Paulo, Brazil
	USCAP 107th Annual Meeting, Vancouver, BC, Canada
	34th Annual Current Issues in Anatomic Pathology 2018, San Francisco, CA

GOVERNMENT and OTHER PROFESSIONAL SERVICE:

2003-2004 Children's Brain Tumor Foundation, Research Programs, **Grant reviewer**

2003	United States Army Medical Research and Material Command (USAMRMC): Neurofibromatosis Research Program (NFRP) FY03 review, **Programmatic reviewer**
2004	USAMRMC: NFRP FY04 Integration Panel, **Member/programmatic reviewer**
2004	Samantha Dickson Research Trust (U.K.), Research Program, **Grant reviewer**
2004-2006	National Brain Tumor Foundation (NBTF), Oligodendroglioma Scientific Advisory Committee, Research Program, **Member/grant reviewer**
2005	Arizona Disease Control Research Commission (ADCRC), **Grant reviewer**
2005	Cancer Research UK, 2005 Research Program, **Grant reviewer**
2006	Univ. Texas M.D. Anderson Brain Tumor Center SPORE Grant, **External advisory board member**
2009-2011	National Brain Tumor Society (NBTS), **Grant Reviewer**
2011	Children's Tumor Foundation, **Grant Reviewer**

UNIVERSITY AND PUBLIC SERVICE

UNIVERSITY SERVICE

DEPARTMENTAL SERVICE:

2006-2007	Chair of Search Committee, Neuropathology Faculty Recruitment, WUSM
2009-2010	Member, Molecular Pathology Curriculum Subcommittee, WUSM
2009-2010	Member, Educational Committee, Molecular Genetic Pathology Fellowship, WUSM
2010-2015	Member, Pathology Executive Committee, UCSF
2010-now	Director of Neuropathology Division and Neuropathology Fellowship Program, UCSF
2010-2012	Chair of Search Committee M-3372, Neuropathology Faculty Recruitment, UCSF
2011-2012	Member of Search Committee M-3485, Neurology Faculty Recruitments, UCSF
2013-2014	Member (ex officio) of Search Committee M-3680, Neurology (Institute of Neurodegenerative Diseases) Faculty Recruitment, UCSF
2014-now	Member of Pathology Appointments, Promotions and Merits Committee (APM), UCSF
2018-now	Member of Pathology Clinical Research Grants Program, UCSF

PUBLIC SERVICE:

2007-2010	Lecturer, Washington U. Mini-Medical School Course (for lay public)
2010-now	Member, UCSF BTRC Executive Committee
2010-now	Co-Director, UCSF BTRC Biospecimen Core

SUMMARY OF SERVICE ACTIVITIES

Beyond the local academic setting, I have been actively involved in service activities for several professional societies, including the American Association for Neuropathology (AANP), the U.S. and Canadian Academy of Pathology (USCAP), the International Society for Neuropathologists (ISN), and the Society for Neuro-Oncology (SNO), serving on or chairing various committees and holding various officer positions (see Professional Organizations). I've also participated in departmental committees and faculty recruitments at Washington University, where I also served as the course director for Neuropathology in the second year medical school curriculum for 8 years. At UCSF, I am heavily involved in Neuropathology faculty recruitments as the director of the division and educational activities as the director of the Neuropathology fellowship program.

Additionally, I serve on the Appointments, Promotions and Merit (APM) committee and actively participate in the Brain Tumor Research Center (BTRC) program at the Helen Diller Cancer Center Building by serving as a member of its Executive Committee and Co-Director of its Biospecimen Core.

TEACHING and MENTORING

FORMAL SCHEDULED CLASSES FOR UCSF MEDICAL STUDENTS:

Qtr	Academic Yr	Course No. & Title	Teaching Contribution	Units	Class Size
	1997-1998	Neuropathology Section, Second Year Mayo Medical School Pathology Course	Lecturer/Laboratory Instructor		120
	1999-2010	Second Year Washington Univ. Medical School "Diseases of the Nervous System" Course	Lecturer/Laboratory Instructor		150
	2000-2008	Second Year Washington Univ. Medical School "Diseases of the Nervous System" Course	Neuropathology Course Director		150
	2011-2013	Brain-Mind and Behavior Course (IDS 104)	Lecturer; 2 lectures		150
	2011-2012	Brain-Mind and Behavior Course (IDS 104)	Discussion Group Leader; 4 two hour sessions	0.5 of 12	12-14
	2013-now	Brain-Mind and Behavior Course (IDS 104)	Discussion Group Leader; 5 two hour sessions	0.5 of 12	12-14

POSTGRADUATE AND OTHER COURSES

See Invited Presentations Section

PREDOCTORAL STUDENTS SUPERVISED OR MENTORED:

	Dates	Name	Program or School	Role	Current Position
1	2003-2004	Eriks Lusis	Medical Student in Doris Duke Foundation Clinical Research Fellowship	Research Mentor	Practicing Neurosurgeon, Kalamazoo, MI
2	2003-2005	R. Stuart Bridge	High school student	Research Mentor	GI/Hepatology Fellow at University of Nebraska, Omaha, NE

POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED:

	Dates	Name	Fellow	Faculty Role	Current Position
1	1998-2000	Leslie Bruch MD	Neuropathology Fellow	Research Supervision and Mentoring	Professor and Vice Chair for Educational Affairs, U. of Iowa, Iowa City, IA
2	1998-	Xiaodan Cai MD,	Neuropathology	Research Supervision	Head of Neuropathology and Autopsy

	2000	PhD	Fellow	and Mentoring	Services, MetroHealth Medical Center
3	2001	Jeffrey Leonard MD	Neurosurgery Resident	Research Supervision	Professor and Chief of Neurosurgery, Nationwide Children's Hospital, Columbus, OH
4	2000-2002	Christine Fuller MD	Neuropathology Fellow	Research Supervision and Mentoring	Professor and Director of Neuropathology, Virginia Commonwealth U, Richmond, VA
5	2002-2003	Kenneth Fallon, MD	Visiting Fellow	Research Supervision	Associate Professor, UAB, Birmingham, AL
6	2002-2004	Pang-hsien Tu, MD, PhD	Neuropathology Fellow	Research Supervision and Mentoring	Assistant Professor, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
7	2002-2004	Veena Rajaram, MD	Neuropathology Fellow	Research Supervision and Mentoring	Associate Professor of Pathology, UT Southwestern U., Dallas, TX
8	2004-2006	C. Ryan Miller, MD, PhD	Neuropathology Fellow	Research Supervision and Mentoring	Associate Professor of Pathology and Laboratory Medicine, U North Carolina, Chapel Hill, NC
9	2005-2006	Christopher Dunham, MD	Molecular NP Fellow	Research Supervision and Mentoring	Clinical Associate Professor of Anatomic Pathology; Neuropathology Residency Program Director, U. British Columbia, Vancouver, Canada
10	2005-2007	Sushama Patil, MD	Neuropathology Fellow	Research Supervision and Mentoring	Surgical and Neuropathology Consultant, Apollo Specialty Hospital, Chennai, India
11	2007-2009	Stephanie Brown Burton, MD	Neuropathology Fellow	Research Supervision and Mentoring	Assistant Professor of Pathology, UT Southwestern, Dallas, TX
12	2007-2008	Amir Behdad, MD	Neurosurgery Resident	Research Supervision and Mentoring	Assistant Professor of Pathology, Northwestern University, Chicago, IL
13	2008-2010	Ashima Agarwal, MD	Neuropathology Fellow	Research Supervision and Mentoring	Practicing Pathologist / Neuropathologist, Mercy Hospital, St. Louis, MO
14	2009-2010	Sonika Dahiya, MD	Neuropathology Fellow	Mentoring	Associate Professor of Pathology, Washington U, St. Louis, MO
15	2010-2012	Michelle Madden, MD	Neuropathology Fellow	Mentoring	Practicing Barrow Neurologic Institute, Phoenix, AZ
16	2011-2012	Aseem Lal, MBBS	Surgical Pathology Fellow	Mentoring	Practicing Pathologist in India
17	2011-2012	Derick Aranda, MD	Post-doctoral Fellow	Mentoring	Senior Clinical Research Associate, Altea Research Institute, Las Vegas, NV
18	2011-2013	Anne Hiniker, MD, PhD	Neuropathology Fellow	Mentoring	Assistant Professor of Pathology, UCSD, San Diego, CA
19	2012 - 2014	Gerald Reis, MD, PhD	Neuropathology Fellow	Mentoring	Practicing Pathologist / Neuropathologist, Memorial Healthcare System, Hollywood, FL
20	2012 - 2014	Melike Pekmezci, MD	Neuropathology Fellow	Mentoring	Assistant Professor of Pathology, UCSF, San Francisco, CA
21	2013 - 2015	Sanda Alexandrescu, MD	Neuropathology Fellow	Mentoring	Assistant Professor of Pathology, Boston Children's Hospital, Boston, MA
22	2013 - 2015	Jennifer Cotter, MD	Neuropathology Fellow	Mentoring	Assistant Professor of Pathology, Children's Hospital of LA, Los Angeles, CA
23	2014 - 2016	Matthew Wood, MD, PhD	Neuropathology Fellow	Mentoring	Assistant Professor of Pathology, OHSU, Portland, OR

24	2014 - 2016	David Solomon, MD, PhD	Neuropathology Fellow	Mentoring	Assistant Professor of Pathology, UCSF, San Francisco, CA
25	2015 - 2017	Chris S. Liverman, MD, PhD	Neuropathology Fellow	Mentoring	Assistant Medical Examiner, Hennepin County Medical Examiner's Office, Minneapolis, MN
25	2015 - 2017	Amber Nolan, MD, PhD	Neuropathology Fellow	Mentoring	Postdoctoral Fellow and Instructor, UCSF
26	2016 - Now	Areli Cuevas-Ocampo, MD	Neuropathology Fellow	Mentoring	Consultant Neuropathologist, Southmead Hospital, Bristol, UK
27	2016 - Now	Giselle Lopez, MD, PhD	Neuropathology Fellow	Mentoring	Assistant Professor of Pathology, Duke University, Raleigh-Durham, NC
28	2017 - Now	Julieann Lee, MD, PhD	Neuropathology Fellow	Mentoring	Neuropathology Fellow, UCSF
29	2017 - Now	Sean Ferris, MD, PhD	Neuropathology Fellow	Mentoring	Neuropathology Fellow, UCSF
30	2018 - Now	Jeffrey Hofmann, MD, PhD	Neuropathology Fellow	Mentoring	Neuropathology Fellow, UCSF
31	2018 - Now	Emily Sloan, MD, PhD	Neuropathology Fellow	Mentoring	Neuropathology Fellow, UCSF

SPONSORED/MENTORED NATIONAL AND INTERNATIONAL VISITORS:

	Dates	Name	Program or Hospital	Current Position
1	Oct - Nov 2003	Cheryl Palmer, MD	Neuropathologist, U. Alabama Birmingham (UAB), AL	Professor/Director of Neuropathology, U. Utah, Salt Lake City, UT
2	July - Oct 2005	Geeta Chako MBBS, MD	Pathologist, Christian Medical College (CMC), Vellore, India	Professor of Neuropathology, CMC, Vellore, India
3	July – Sept 2007; Sept 2009	Sandro Casavilca Zambrano MD	Pathologist, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru	Staff Pathologist, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
4	July 2009 - June 2010	Diego Lin MD	Pathologist, Taipei Veterans General Hospital, Taipei, Taiwan	Staff Pathologist, Taipei Veterans General Hospital, Taipei, Taiwan
5	Oct - Nov 2010	Sriram Venneti MD, PhD	Neuropathology Fellow, U. Pennsylvania, Philadelphia, PA	Postdoctoral Research Associate, Memorial Sloan Kettering Cancer Center, New York, NY
6	Oct - Nov 2010	Jennifer Sehn, MD	Medical Student, Washington U., St. Louis, MO	AP/NP Pathology Resident, Washington U., St. Louis
7	Oct - Nov 2011	David Solomon, MD, PhD	Medical Student, Georgetown U., Washington DC	AP/NP Pathology Resident, UCSF, San Francisco, CA
8	Nov 2011 – April 2012	Eric Richfield, MD, PhD	Neuropathologist, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ	Associate Professor, Pathology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
9	May - June 2012	Yeo (Pony) Yeehui	Medical Student, Tri-Service General Hospital, Taipei, Taiwan	Medical Student, Tri-Service General Hospital, Taipei, Taiwan
10	June - July 2012	María Valentina Díaz, MD	Pathologist, Centro Médico Docente La Trinidad, Caracas, Venezuela	Staff Pathologist, Centro Médico Docente La Trinidad, Caracas, Venezuela
11	July – Dec 2012	Jantima Tanboon, MD	Pathologist, Siriraj Hospital, Mahidol University, Bangkok,	Staff Pathologist, Siriraj Hospital, Mahidol University, Bangkok,

			Thailand	Thailand
12	January 2013-July 2013	Hsin-Yi Huang, MD, PhD	National Taiwan University Hospital, Department of Pathology	Visiting staff, Department of Pathology, National Taiwan University Hospital
13	August 2013	Rawan M Tarawneh, MD	University of Jordan Amman, Jordan	Assistant Professor of Neurology Consultant Neurologist
14	August 2013-January 2014	Wen-Chang Huang, MD	Taipei Medical University-Wan Fang Hospital	Attending physician, Taipei Medical University-Wan Fang Hospital, Department of Pathology
15	August 2013-March 2014	Kathryn Urankar, MD	Consultant, Forensic Pathology, Hamilton Health Sciences	McMaster University and Hamilton Health Sciences in Ontario, Canada
16	September-October 2013	Jesus Adrian Chavez Lopez	Medical Student	Universidad La Salle School of Medicine in Mexico City, Mexico
17	October 2013	Daniel Kerrigan, MD	Pathologist	Pathology Consultants, Eugene Oregon
18	November 2013	Sudha Rao, MD	Pathologist	Kaiser Permanente Redwood City, CA
19	November 2013	Michael Rodriguez BSc(Med)MBBS(Hons I) FRCPA	Neuropathologist	NSW Pathology- South Western Sydney Local Health Districts. Sydney, Australia
20	February 2014-March 2014	Mary Yohana Silva Carmona, MD	Pathology Resident	Donostia Hospital University Hospital in Guipuzcoa, Spain
21	March 2014	María Cabezas Macián, MD	Pathology Resident	Hospital Clinico Universitario in Valenica, Spain
22	July 2014-August 2014	Danijela Kolenc, MD, PhD	Pathologist	University of Zagreb Medical School, Zagreb, Croatia

INFORMAL TEACHING:

1998-now Daily surgical neuropathology sign-out (~3-10 residents/fellows)
1998-now Weekly brain cutting and didactic conferences (~3-10 residents/fellows)

FACULTY MENTORING

Prior to 2010, I did not mentor junior faculty at Washington University. Informally, I am currently mentoring Drs. David Solomon (Assistant Professor) and Marta Pekmezci (Assistant Professor) in the Neuropathology Division at UCSF. Previously, I informally mentored Drs. Han Lee (Assistant Professor), Joanna Phillips (Associate Professor), and Marta Margeta (Associate Professor) in the Division of Neuropathology. Most recently, I've been serving as the formal mentor for Dr. Kwun Wah Wen (Assistant Professor) since 2018.

TEACHING AIDS:

I have contributed to the **Neuropathology Syllabus** for 2nd year medical students at Washington University medical school from 1998-2010. All of my **PowerPoint lectures** have also been made available to the students during this time, along with audio files of "Neuropathology Songs" (see below).

Over the years, I have written and recorded a series of 16 **Neuropathology songs** for medical students in order to provide a novel and refreshing way to learn, when used as a supplement to more conventional approaches. This technique of teaching has since been covered in media reports by the St. Louis Post Dispatch, the Washington University Record, KWMU radio station, National Public Radio's (NPR) Marketplace, the Singer Network, a service of Chorus America, and the Journal of Child Neurology. This approach has been enthusiastically embraced by the medical students at Washington University School of Medicine and UCSF. As word of this practice spread further, I was increasingly asked to include some songs in invited lectures nationally and internationally to well-established medical specialists and even to the lay public in our Mini Medical School Course, both similarly associated with extremely positive feedback. Lastly, I've received requests to share these songs with educators and students from other medical centers, prompting me more recently to record a professional CD version and YouTube video that is more widely available to medical professionals (see Other Creative Activities section).

OTHER:

See visiting professorships and service lectures listed under "Invited Presentations."

TEACHING AWARDS AND NOMINATIONS:

1999	Distinguished Service **Teaching Award**, WUSM (Medical School Class of 2001)
2002	Distinguished Service **Teaching Award**, WUSM (Medical School Class of 2004)
2004	Distinguished Service **Teaching Award**, WUSM (Medical School Class of 2006)
2005	**Professor of the Year Award**, WUSM (Medical School Class of 2007)
2007	Distinguished Service **Teaching Award**, WUSM (Medical School Class of 2009)
2008	Elected to **Alpha Omega Alpha** (AOA), WUSM Chapter for recognition of faculty commitment to medical education
2008	**Professor of the Year Award**, WUSM (Medical School Class of 2010)
2009	Distinguished Service **Teaching Award**, WUSM (Medical School Class of 2011)
2013	Nominated for MS1 Essential Core **Teaching Award**, UCSF (Medical School Class of 2016)

SUMMARY OF TEACHING HOURS:

2009-2010	1,030 total hours of teaching (including preparation) Formal class or course teaching hours at WUSM: 30 Informal teaching hours at WUSM: 650 Mentoring hours: 200 Other CME courses: 200 hours (includes course organization)
2010-now:	Total anticipated hours of teaching: 1080 hours (as above), although at UCSF.

TEACHING NARRATIVE

My teaching duties have been extensive, including medical school teaching at UCSF, Washington University, and Mayo Clinic, as well as numerous educational activities in annual conferences. Medical school teaching has typically involved 1-3 lectures, 4-5 labs/small group sessions, and sometimes, a CPC session. For 8 years, I was also the course director with additional administrative duties, although I stepped down from this position in 2008 due to other time commitments. Informal teaching of our neuropathology fellows, pathology residents, rotating neurology/neurosurgery residents, and other visitors

to our service accounts for a much greater component, averaging 2-3 hours daily in terms of sign-out sessions and formal didactic lectures. As listed in other sections above, I also participate frequently in courses at international, national, and regional meetings, sometimes serving as the course coordinator or chair. In addition to these courses, I receive frequent invitations for lectures and grand rounds presentations at medical centers both within the U.S. and abroad.

RESEARCH AND CREATIVE ACTIVITIES

RESEARCH AWARDS AND GRANTS

CURRENT

1. P50 CA097257 (Berger) 09/18/18 – 08/31/2023
NIH/NCI (Tissue Core Co-Director) $1,570,837
The Brain Tumor SPORE Grant includes 4 translational research projects, a Biospecimen and Pathology Core, an Administrative Core, and a Biostatistics/Clinical Core and represents the efforts of interdisciplinary teams of investigators from the Neuro-Oncology Program of the UCSF Cancer Center to apply their knowledge and expertise to research focused on brain tumors.
5% Effort 0.60 calendar

PENDING

None

PAST

1. ABTA Award (PI) 7/1/95-6/30/97
American Brain Tumor Association $30,000 salary support/yr 1
Detection of potential diagnostic/prognostic markers in brain smears from 100 gliomas using fluorescence in situ hybridization $60,000 direct/yrs 1-2

2. Research Award (PI) 6/1/00-5/31/02
Alvin J. Siteman Cancer Center / BJH Foundation Award $20,000 direct/yr 1
Genetic phenotyping of benign and malignant meningiomas: a FISH analysis of 1p, 14q, 17q (PS6K gene) and 22q (NF2 gene) $40,000 direct/yrs 1-2

3. DAMD 17-98-1-8611 (core director) 2/1/00-9/30/03
Department of Defense (DOD) $27,000 direct/yr 1
Natural History of Plexiform Neurofibromas in NF1 $90,000 direct/yrs 1-3

4. ABTA Award (Sponsor) 7/1/00-6/30/02
ABTA Fellowship Award to Christine Fuller $35,000 salary support/yr 1
Clinical utility of fluorescence in situ hybridization (FISH) in mixed oligoastrocytomas and other diagnostically challenging diffuse gliomas $70,000 direct/yrs 1-2

5. Gene Chip Award (PI) 8/1/2000-2/28/2001
Siteman Cancer Center Gene Chip Award $5,000 direct
Molecular Pathogenesis of Meningioma Development and Progression

6. P01 AG03991-19 (investigator) 7/1/99-6/30/03
NIH/NIA $10,000 direct/yr 1
Healthy Aging and Senile Dementia $40,000 direct/yrs 1-4

7. DAMD 17-01-1A-0717 (core director) 2/6/02-9/30/04
DOD $40,000 direct/yr 1
A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients with Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas $120,00 direct/yrs 1-3

8. DAMD 17-03-1-0445 (investigator) 6/1/03-6/30/07
DOD $35,000 direct/yr 1
Molecular Identification of the Schwannomatosis Locus $140,000 direct/yrs 1-4

9. FY05 Concept Award W81XWH-06-1-0201 (PI) 12/5/05-1/4/07
DOD $65,000 direct total
Genetic Characterization of MPNST by High-Density SNP Array

10. Resident Research Award (sponsor) 11/1/09-10/31/10
College of American Pathologists (CAP) Foundation $2500 direct
Idic(17)(p11.2) Rearrangement in Medulloblastomas; Diagnostic and Prognostic Significance
Awarded to: Gabriel Bien-Willner

11. Resident Research Award (sponsor) 10/11/10-11/12/10
CAP Foundation general elective advanced training grant $2000 direct
Awarded to: Sriram Venneti for visit to UCSF Neuropathology and Molecular Pathology Divisions

12. SARC006 (investigator/central pathology reviewer) 3/1/2006 - 3/31/2013
Sarcoma Alliance for Research through Collaboration $56,000 direct/yr 1
Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated high grade unresectable malignant peripheral nerve sheath tumors $350,000 direct/yrs 1-6
The overall goal of this phase II trial is to determine the clinical response rates of high grade, unresectable, metastatic, or potentially resectable sporadic and NF1 associated MPNST after 4 cycles of neoadjuvant chemotherapy (2 cycles of ifosfamide + doxorubicin 'IA' followed by 2 cycles of ifosfamide + etoposide 'IE').
5% Effort 0.60 calendar

13. Program Project P01 CA118816-04 (Core B Co-Director) 07/2010 - 06/2012
NIH/NCI $1,449,417
Imaging and Tissue Biomarkers in the Treatment of Brain Tumors
The overall goal of this project is to integrate advances in technological development of physiologic neuro-imaging and tissue biomarkers in the management of patients with brain tumors and to translate this knowledge to optimize delivery of novel agents into the brain parenchyma.
Core B: Imaging and Tissue Correlate Core with Imaging and Tissue components
5% Effort 0.60 calendar

14. SPORE in Brain Cancer 5 P50 CA097257-10 07/2010 – Now
NIH/NCI (Tissue Core Co-Director) $126,749/yr
The Tissue Core provides staff and technology dedicated to enhancing sample integrity and usability through use of optimized harvesting procedures; multi-modality preservation and

processing; histopathologic-molecular morphologic characterization; and computerized inventory and web-based request and tracking systems.
5% Effort 0.60 calendar

15. P50 CA097257 (Berger) 09/18/2013 - 08/31/2018
NIH/NCI (Tissue Core Co-Director) $1,456,403
This continuation SPORE proposal includes 5 translational research projects and 4 Cores - Administrative Core, Tissue Bank Core and a Pre-Clinical Animal Core - and represents the efforts of interdisciplinary teams of investigators from the Neuro-Oncology Program of the UCSF Cancer Center to apply their knowledge and expertise to translational research focused on brain tumors.
5% Effort 0.60 calendar

PEER REVIEWED PUBLICATIONS:

1. **Perry A**, Duenzl ML, Ansari MQ. Flow cytometric terminal deoxynucleotidyltransferase analysis. Evaluation of triton-X-100 and methanol permeabilization methods compared with immunofluorescence microscopy. *Arch Pathol Lab Med* 118: 1119-1122, 1994**.**
2. Wiley EL, **Perry A**, Nightingale SD, Lawrence J. Detection of mycobacterium avium-intracellulare complex in bone marrow specimens of patients with acquired immunodeficiency syndrome. *Am J Clin Pathol* 101: 446-451, 1994.
3. **Perry A,** Wiley EL, Albores-Saavedra J. Pagetoid spread of intratubular germ cell neoplasia into rete testis: A morphologic and histochemical study of 100 orchiectomy specimens with invasive germ cell tumors. *Hum Pathol* 25: 235-239, 1994.
4. **Perry A**, Vuitch F. Causes of death in patients with sarcoidosis. *Arch Pathol Lab Med* 119: 167-172, 1995.
5. **Perry A**, Molberg K, Albores-Saavedra J. Physiologic vs. neoplastic C-cell hyperplasia: separation of distinct histologic and biologic entities. *Cancer* 77: 750-756, 1996.
6. **Perry A**, Jenkins RB, Dahl RJ, Moertel CA, Scheithauer BW. Cytogenetic analysis of aggressive meningiomas. Possible diagnostic and prognostic implications. *Cancer* 77: 2567-2573, 1996.
7. Giannini C, Scheithauer BW, Jenkins RB, Erlandson RA, **Perry A**, Borell TJ, Hoda RS, Woodruff JM. Soft-tissue perineurioma. Evidence for an abnormality of chromosome 22, criteria for diagnosis, and review of the literature. *Am J Surg Pathol* 21: 164-173, 1997.
8. **Perry A**, Giannini C, Scheithauer BW, Rojiani AM, Yachnis, AT, Seo IS, Johnson P, Kho J, S Shapiro. Composite pleomorphic xanthoastrocytoma and ganglioglioma: report of four cases and review of the literature. *Am J Surg Pathol* 21: 763-771, 1997.
9. **Perry A**, Tonk V, McIntire D, White C. Interphase cytogenetic (in situ hybridization) analysis of astrocytomas using archival formalin-fixed, paraffin-embedded tissue and light microscopy. *Am J Clin Pathol* 108: 166-174, 1997.
10. **Perry A**, Parisi JE, Kurtin PJ. Metastatic adenocarcinoma to the brain: an immunohistochemical analysis. *Hum Pathol* 28: 938-943, 1997.
11. **Perry A**, Nobori T, Ru N, Anderl K, Borell TJ, Mohapatra G, Feuerstein BG, Jenkins RB, Carson DA. Detection of p16 gene deletions in gliomas: Fluorescence *in situ* hybridization (FISH) versus quantitative PCR. *J Neuropathol Exp Neurol* 56: 999-1008, 1997.
12. **Perry A**, Scheithauer BW, Nascimento AG. The immunophenotype of meningeal hemangiopericytoma: a comparison with fibrous meningioma and solitary fibrous tumor of meninges. *Am J Surg Pathol* 21: 1354-1360, 1997.
13. **Perry A**, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. *Am J Surg Pathol* 21: 1455-1465, 1997.

14. Stafford SL, **Perry A**, Leavitt JA, Garrity JA, Suman VJ, Scheithauer BW, Meyer FB. Anterior visual pathway meningiomas primarily resected between 1978-88. The Mayo Clinic experience. *J Clin Neuro-Ophthalmol* 18: 206-210, 1998.
15. **Perry A**, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. The prognostic role of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas. *Cancer* 82: 2262-2269, 1998.
16. Stafford SL, **Perry A**, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, Shaw EG. Primarily resected meningiomas: Outcome and prognostic factors in 581 Mayo Clinic patients, 1978-1988. *Mayo Clin Proc* 73:936-942, 1998.
17. **Perry A**, Scheithauer BW, Stafford SL, Abell-Aleff PC, Meyer FB. "Rhabdoid" meningioma: an aggressive variant. *Am J Surg Pathol* 22:1482-90, 1998.
18. Couce ME, **Perry A**, Webb P, Scheithauer BW. Fibrous meningioma with tyrosine-rich crystals. *Ultrastructural Pathol* 23:341-5, 1999.
19. **Perry A**, Scheithauer BW, Zaias BW, Minassian HV. Aggressive enterogenous cyst: report of a case with extensive craniospinal spread. *Neurosurgery* 44:401-5, 1999.
20. **Perry A**, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients. *Cancer* 85:2046-56, 1999.
21. Smith JS, Alderete B, Minn Y, Borell TJ, **Perry A**, Mohapatra G, Smith SM, Kimmel D, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins RB. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. *Oncogene* 18:4144-52, 1999.
22. **Perry A**, Jenkins RB, O'Fallon JR, Schaefer PL, Kimmel DW, Mahoney MR, Scheithauer BW, Smith SM, Hill EM, Sebo TJ, Levitt R, Krook J, Tschetter LK, Morton RF, Buckner JC. Clinicopathologic study of similarly treated anaplastic astrocytic tumors: an analysis of DNA content (ploidy), cellular proliferation, and p53 expression. *Cancer* 86:672-83, 1999.
23. Adlakha A, Rao K, Adlakha H, **Perry A**, Crotty TB, Scheithauer BW, Ryu JH. Meningioma metastatic to the lung. *Mayo Clin Proc* 74:1129-33, 1999.
24. **Perry A**, Anderl KA, Borell TJ, Kimmel DW, Wang CH, O'Fallon JR, Feuerstein BG, Scheithauer BW, Jenkins RB. Detection of p16, RB, CDK4, and p53 gene deletion / amplification by fluorescence in situ hybridization (FISH) in 96 gliomas. *Am J Clin Pathol* 112:801-9, 1999.
25. Raffel C, Frederick L, O'Fallon JR, Atherton-Skaff P, **Perry A**, Jenkins RB, James CD. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. *Clin Cancer Res* 5:4085-90, 1999.
26. Halper J, Jung C, **Perry A**, Suliman H, Hill MP, Scheithauer B. Expression of TGFα in meningiomas. *J Neuro-Oncol* 45:127-34, 1999.
27. Smith JS, **Perry A (co-first author)**, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. *J Clin Oncol* 18:636-45, 2000.
28. Gutmann DH, Donahoe J, Brown T, James CD, **Perry A**. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. *Neuropathol Appl Neurobiol* 26:361-7, 2000.
29. Cai D, Mafra M, Schmidt RE, Scheithauer BW, Park TS, **Perry A**. Medulloblastomas with extensive post-therapy neuronal maturation. *J Neurosurg* 93:330-4, 2000.
30. Gutmann DH, Donahoe J, **Perry A**, Lemke L, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningioma. *Hum Mol Genet* 9:1495-1500, 2000.
31. Smith JS, Tachibana I, Lee HK, Qian J, Pohl U, Mohrenweiser HW, Borell TJ, Hosek SM, Soderberg CL, von Deimling A, **Perry A**, Scheithauer BW, Louis DN, Jenkins RB. Mapping of

the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. *Genes Chrom Cancer* 29:16-25, 2000.

32. **Perry A**, Cai DX, Scheithauer BW, Swanson PE, Lohse CM, Newsham IF, Weaver A, Gutmann DH. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: A correlative immunohistochemical study of 175 cases. *J Neuropathol Exp Neurol* 59:872-879, 2000.
33. Cai DX, James CD, Scheithauer BW, Couch FJ, **Perry A**. PS6K amplification characterizes a small subset of anaplastic meningiomas. *Am J Clin Pathol* 115:213-18, 2001.
34. Bruch LA, Hill DA, Cai DX, Levy BK, Dehner LP, **Perry A**. A role for fluorescence in situ hybridization detection of chromosome 22q dosage in distinguishing atypical teratoid/rhabdoid tumors from medulloblastoma/central primitive neuroectodermal tumors. *Hum Pathol* 32:156-62, 2001.
35. Watson MA, **Perry A**, Budhjara V, Hicks C, Shannon WD, Rich KM. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. *Cancer Res* 61:1825-29, 2001.
36. Li J, **Perry A**, James CD, Gutmann DH. Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. *Neurology* 56:885-90, 2001.
37. Leonard J, Cai DX, Rivet D, Kaufman BA, Park TS, Levy BK, **Perry A**. Large cell/anaplastic medulloblastomas and medullomyoblastomas: Clinicopathologic and genetic features. *J Neurosurg* 95:82-88, 2001.
38. **Perry A**, Scheithauer BW, Szczesniak DM, Atkinson JLD, Wald JT, Hammak JE. Combined oligodendroglioma/pleomorphic xanthoastrocytoma: a probable collision tumor. *Neurosurgery* 48:1358-61, 2001.
39. Cai DX, Banerjee R, Scheithauer BW, Lohse CM, Kleinschmidt-DeMasters BK, **Perry A**. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: Diagnostic and prognostic implications. *J Neuropathol Exp Neurol* 60:628-36, 2001.
40. **Perry A**, Roth KA, Banerjee R, Fuller CE, Gutmann DH. *NF1* deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and MPNSTs. *Am J Pathol* 159:57-61, 2001.
41. Gauvain KM, McKinstry RC, Mukherjee P, **Perry A**, Neil JJ, Kaufman BA, Hayashi RJ. Evaluating pediatric brain tumor cellularity with diffusion tensor imaging. *Am J Radiol* 177:449-54, 2001.
42. **Perry A**, Chicoine MR, Filiput E, Miller JP, Cross DT. Clinicopathologic assessment and grading of embolized meningiomas: a correlative study of 64 patients. *Cancer* 92:701-11, 2001.
43. **Perry A**, Giannini C, Raghavan R, Scheithauer BW, Banerjee R, Margraf L, Bowers DC, Lytle RA, Newsham IF, Gutmann DH. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: A clinicopathologic study of 53 cases. *J Neuropathol Exp Neurol* 60:994-1003, 2001.
44. Fuller CE, Pfeifer J, Humphrey P, Bruch LA, Dehner LP, **Perry A**. Chromosome 22q dosage in composite extrarenal rhabdoid tumors: clonal evolution or a phenotypic mimic? *Hum Pathol* 32:1102-1108, 2001.
45. Sinkre P, **Perry A**, Cai D, Raghavan R, Watson M, Wilson K, Rogers BB. Deletion of the NF2 region in both meningioma and juxtaposed meningioangiomatosis: Case report supporting a neoplastic relationship. *Ped Develop Pathol* 4:568-572, 2001.
46. Racette BA, **Perry A**, D'Avossa G, Perlmutter JS. Late-onset neurodegeneration with brain iron accumulation type 1: expanding the clinical spectrum. *Movement Disorders* 16:1148-1152, 2001.
47. **Perry A**. Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. *Adv Anatomic Pathol* 8:183-99, 2001.

48. **Perry A**, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW. A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. *Brain Pathol* 12:183-190, 2002.
49. Gutmann DH, Hedrick NM, Li J, Nagarajan R, **Perry A**, Watson MA. Comparative gene expression profile analysis of neurofibromatosis 1 (NF1)-associated and sporadic pilocytic astrocytomas. *Cancer Res* 62:2085-2091, 2002.
50. Singh PK, Gutmann DH, Fuller CE, Newsham IF, **Perry A**. Differential involvement of protein 4.1 family members, *DAL-1* and *NF2* in intracranial and intraspinal ependymomas. *Mod Pathol* 15:526-531, 2002.
51. Shannon W, Watson M, **Perry A**, Rich K. Mantel statistics to correlate gene expression levels from microarrays with clinical covariates" *Genet Epidemiol* 23:87-96, 2002.
52. Wagner L, Hill A, Fuller C, Pedrosa M, Bhakta M, **Perry A**, Dome JS. Treatment of metastatic rhabdoid tumor of the kidney. *J Pediatr Hematol/Oncol* 24:385-88, 2002.
53. **Perry A**, Kunz SN, Fuller CE, Banerjee R, Marley EF, Liapis H, Watson MA, Gutmann DH. Differential *NF1*, *p16*, and *EGFR* patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. *J Neuropathol Exp Neurol* 61:702-709, 2002.
54. Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt-DeMasters BK, Brown HG, **Perry A**. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. *Am J Pathol* 161:665-72, 2002.
55. Galvin JE, Lee SL, **Perry A**, Havioglu NS, McKeel DW, Morris JC. Familial dementia with Lewy bodies: A clinicopathologic analysis. *Neurology* 59:1079-82, 2002.
56. **Perry A**, Scheithauer BW, Macaulay RJB, Raffel C, Roth KA, Kros JM. Oligodendrogliomas with neurocytic differentiation. A report of four cases with diagnostic and histogenetic implications. *J Neuropathol Exp Neurol* 61:947-55, 2002.
57. Fuller CE, Wang H, Zhang W, Fuller G, **Perry A**. High-throughput molecular profiling of high-grade astrocytomas: the utility of fluorescence *in situ* hybridization on tissue microarrays (TMA-FISH). *J Neuropathol Exp Neurol* 61:1078-84, 2002.
58. Bannykh SI, **Perry A**, Powell HC, Hill A, Hansen LA. Malignant "rhabdoid" meningioma arising in the setting of preexisting ganglioglioma. A diagnosis supported by fluorescence in situ hybridization (FISH). *J Neurosurg* 97:1450-55, 2002.
59. **Perry A.** Medulloblastomas with Favorable vs. Unfavorable Histology. How Many Small Blue Cell Tumor Types are there in the Brain? *Adv Anat Pathol* 9:345-50, 2002.
60. **Perry A**, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. *Front Biosci* 8:a1-9, 2003.
61. Raghavan R, Balani J, **Perry A**, Margraf L, Vono MB, Cai DX, Wyatt RE, Rushing EJ, Bowers DC, Hynan LS, White CL. Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in-situ hybridization. *J Neuropathol Exp Neurol* 62:530-37, 2003.
62. Marden FA, Wippold FJ, II, **Perry A**. Fetal MR Imaging steady-state precession (true FISP) in the prenatal diagnosis of a congenital brain teratoma. *J Computer Assisted Tomography* 27:427-30, 2003.
63. **Perry A.** Pathology of low-grade gliomas. An update of emerging concepts. *Neuro-Oncology* 5:168-78, 2003.
64. MacCollin M, Willet C, Heinrich B, Jacoby LB, Acierno S, **Perry A**, Louis DN. Familial schwannomatosis: Exclusion of the *NF2* locus as the germline event. *Neurology* 60:1968-74, 2003.
65. Nestor SL, **Perry A**, Kurtkaya O, Abell-Aleff P, Rosenblat AM, Burger PC, Scheithauer BW. Melanocytic colonization of a meningothelial meningioma: Histopathologic and ultrastructural findings with immunohistochemical and genetic correlation. *Neurosurgery* 53:211-15, 2003.

66. Robb VA, Li W, Gascard P, **Perry A**, N Mohandas, Gutmann DH: Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogenesis. *Neurobiol Dis* 13:191-202, 2003.
67. Foster WJ, Fuller CE, **Perry A**, Harbour JW. Status of the *NF1* tumor suppressor gene in uveal melanoma. *Arch Ophthalmol* 121:1311-15, 2003.
68. Kaufman D, Heinrich B, Willett C, **Perry A**, Finseth F, Sobel RA, MacCollin M. Somatic instability of the NF2 gene in schwannomatosis. *Arch Neurol* 60:1317-20, 2003.
69. Brat DJ, Seiferheld W, **Perry A**, Hammond EH, Murray KJ, Schulsinger A, Mehta M, Curran W. FISH analysis of genetic markers of prognosis for high-grade astrocytomas using tissue microarrays from RTOG clinical trials. *Int J Radiat Oncol Biol Physics* 57:S135, 2003.
70. Fuller CE, Schmidt RE, Roth KA, Burger PC, Scheithauer BW, Banerjee R, Trinkaus K, Lytle R, **Perry A**. Clinical utility of fluorescence *in situ* hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial / astrocytic features. *J Neuropathol Exp Neurol* 62:1118-28, 2003.
71. Gutmann, DH, James CD, Poyhonen M, Louis DN, Ferner R, Guha A, Hariharan S, Viskochil D, **Perry A**. Molecular analysis of astrocytomas presenting after age ten in individuals with NF1. *Neurology* 61: 1397-1400, 2003.
72. Bajenaru ML, Hernandez MR, **Perry A**, Zhu Y, Parada LF, Garbow JR, Gutmann DH. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. *Cancer Res* 63:8573-77, 2003.
73. Rajaram V, Leuthardt EC, Singh PK, Ojemann JG, Brat DJ, Prayson RA, **Perry A**. 9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases. *Mod Pathol* 17: 9-14, 2004.
74. Su W, Gutmann DH, **Perry A**, Abounader R, Laterra J, Sherman LS. A CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. *Glia* 45:297-306, 2004.
75. Brat DJ, Seiferheld W, **Perry A**, Hammond EH, Murray KJ, Schulsinger A, Mehta M, Curran W. Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using FISH on tissue microarrays from RTOG trials. *Neuro-Oncology* 6: 96-103, 2004.
76. Fallon KB, Palmer CA, Roth KA, Carpenter M, Banerjee R, Forsyth P, **Perry A**. Prognostic value of 1p, 19q, 9p, 10q, and EGFR FISH analyses in recurrent oligodendrogliomas. *J Neuropathol Exp Neurol* 63: 314-22, 2004.
77. Armanios MY, Grossman SA, Yang SC, White B, **Perry A**, Burger PC, Orens JB. Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: Case report and review of the literature. *Neuro-Oncology* 6:259-63, 2004.
78. Horstmann S, **Perry A**, Reifenberger G, Giangaspero F, Huang H, Hara A, Masuoka J, Rainov NG, Bergmann M, Heppner FL, Brandner S, Chimelli L, Montagna N, Davis DG, Markesbery WR, Ellison DW, Weller RO, Taddei GL, Conti R, Del Bigio MR, Gonzalez-Campora R, Radhakrishnan VV, Soylemezoglu F, Uor-Coste E, Qian J, Kleihues P, Ohgaki H. Genetic and expression profiles of cerebellar liponeurocytomas. *Brain Pathol* 14: 281-89, 2004.
79. Watson MA, **Perry A**, Tihan T, Prayson RA, Guha A, Bridge J, Ferner R, Gutmann DH. Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type 1 – associated and sporadic malignant peripheral nerve sheath tumors. *Brain Pathol* 14: 297-303, 2004.
80. Helton KJ, Fouladi M, Boop FA, **Perry A**, Dalton J, Kun L, Fuller C. Medullomyoblastoma: A radiographic and clinicopathologic analysis of 6 cases and review of the literature. *Cancer* 101:1445-54, 2004.
81. Fedi M, Mitchell LA, Kalnins RM, Gutmann DH, **Perry A**, Newton M, Brodtmann A, Berkovic SF. Glioneuronal tumours in neurofibromatosis type 1: MRI-pathological study. *J Clin Neurosci* 11: 745-47, 2004.

82. Surace EI, Lusis E, Murakami Y, Scheithauer BW, **Perry A**, Gutmann DH. Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival. *J Neuropathol Exp Neurol* 63:1015-27, 2004.
83. **Perry A**, Aldape KD, George DH, Burger PC. Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. *Cancer* 101:2318-26, 2004.
84. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, Brat DJ, **Perry A**, Eberhart CG. Notch1 and Notch2 have opposite effects on embryonal brain tumor growth. *Cancer Res* 64: 7787-93, 2004.
85. Fung, K-M, **Perry A**, Payner TD, Shan Y. Rhabdoid glioblastoma in an adult: Report of a case. *Pathology* 36:1-2, 2004.
86. Rajaram V, Brat DJ, **Perry A**. Anaplastic meningioma vs. meningeal hemangiopericytoma: Immunohistochemical and genetic markers. *Hum Pathol* 35:1413-18, 2004.
87. Raisanen J, Biegel JA, Hatanpaa KJ, Judkins A, White CL, **Perry A**. Chromosome 22q deletions in adult atypical teratoid / rhabdoid tumors. *Brain Pathol* 15:23-28, 2005.
88. **Perry A**, Kurtkaya-Yapıcıer O, Scheithauer BW, Robinson R, Prayson RA, Kleinschmidt-DeMasters BK, Stemmer-Rachamimov AO, Gutmann DH. Insights into meningioangiomatosis with and without meningioma: A clinicopathologic and genetic series of 24 cases with review of the literature. *Brain Pathol* 15:55-65, 2005.
89. Bajenaru ML, Garbow JR, **Perry A**, Hernandez MR, Gutmann DH. Natural history of neurofibromatosis 1-associated optic nerve glioma formation in mice. *Ann Neurol* 57:119-27, 2005.
90. Kloub O, **Perry A**, Tu P-H, Lipper M, Lopes MBS. Spindle cell oncocytoma of the adenohypophysis: Report of two recurrent cases. *Am J Surg Pathol* 29:247-53, 2005.
91. Mansur DB, **Perry A**, Rajaram V, Michalski JM, Park TS, Leonard JR, Luchtman-Jones L, Rich KM, Grigsby PW, Lockett MA, Wahab SH, Simpson JR. Post-operative radiation therapy for grade II and III intracranial ependymoma. *Int J Radiat Oncol Biol Phys* 61:387-91, 2005.
92. Dasgupta B, Li W, **Perry A**, Gutmann DH. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. *Cancer Res* 65:236-45, 2005.
93. Covinsky M, Gong S, Rajaram V, **Perry A**, Pfeifer J. EWS-ATF1 fusion transcripts in gastrointestinal tumors previously diagnosed as malignant melanoma. *Hum Pathol* 36:74-81, 2005.
94. **Perry A**, Lusis EA, Gutmann DH. Meningothelial hyperplasia. A detailed clinicopathologic, immunohistochemical, and genetic study of 11 cases. *Brain Pathol* 15:109-15, 2005.
95. Judkins AR, Burger P, Hamilton RL, Kleinschmidt-DeMasters B, **Perry A**, Pomeroy S, Rosenblum MK, Yachnis AT, Zhou H, Rorke LB, Biegel JA. INI1 immunohistochemistry distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. *J Neuropathol Exp Neurol* 64:391-97, 2005.
96. Ashley WW, Jr., Narayan P, Leonard JR, Tu B, **Perry A**, Park TS. Incidental pediatric intraparenchymal xanthogranuloma: Case report and review of literature. *J Neurosurg* (Pediatrics 3) 102:307-10, 2005.
97. Lusis EA, Chicoine MR, **Perry A**. High throughput screening of meningioma biomarkers using a tissue microarray. *J Neuro-Oncol* 73: 219-23, 2005.
98. **Perry A**, Fuller CE, Judkins AR, Dehner LP, Biegel JA. INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. *Mod Pathol* 18;951-58, 2005.
99. Rajaram V, Gutmann DH, Prasad SK, Mansur DB, **Perry A**. Alterations of protein 4.1 family members in ependymomas: A study of 84 cases. *Mod Pathol* 18;991-97, 2005.
100. Lusis EA, Watson MA, Chicoine MR, Lyman M, Roerig P, Reifenberger G, Gutmann DH, **Perry A**. Integrative genomic analysis identifies *NDRG2* as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. *Cancer Res* 65:7121-26, 2005.

101. Siami-Namini K, Shuey-Drake R, Wilson D, Francel P, **Perry A**, Fung K-M. Case of the Month, March 2005: 15-year old female with progressive myelopathy. *Brain Pathol* 15;265-67, 2005.
102. Tu Ph, Giannini C, Judkins AR, Schwalb JM, Burack R, O'Neill BP, Yachnis AT, Burger PC, Scheithauer BW, **Perry A**. Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: A primary low-grade CNS lymphoma that mimics meningioma. *J Clin Oncol* 23:5718-27, 2005.
103. Mawrin C, Schulz S, Hellwig-Patyk A, Kirches E, Roessner A, Lendeckel U, Firsching R, Vorwerk CK, Keilhoff G, Dietzmann K, Grimm K, Lindberg G, Gutmann DH, Scheithauer BW, **Perry A**. Expression and function of somatostatin receptors in peripheral nerve sheath tumors. *J Neuropathol Exp Neurol* 64:1080-88, 2005.
104. Woerner BM, Warrington NM, Kung AL, **Perry A**, Rubin JB. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. *Cancer Res* 65:11392-99, 2005.
105. Fuller CE, **Perry A**. Molecular diagnostics in central nervous system tumors. *Adv Anat Pathol* 12:180-94, 2005.
106. Bridge RS, Rajaram V, Dehner LP, Pfeifer JD, **Perry A**. Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: A comparison of two FISH strategies and RT-PCR in malignant round cell tumors. *Mod Pathol* 19:1-8, 2006.
107. Sharma MK, Watson MA, Lyman M, **Perry A**, Aldape KD, Deák F, Gutmann DH. Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytomas. *Neurology* 66:127-30, 2006.
108. Syed S, Rajaram V, Leonard JR, **Perry A**, Raghavan R. Mixed Glioneuronal Tumors of the Spinal Cord in Two Children. *Acta Neuropathol* 111:53-55, 2006.
109. Kidd EA, Mansur DB, Leonard JR, Michalski JM, Simpson JR, **Perry A**. The efficacy of radiation therapy in the management of grade I astrocytomas. *J Neuro-Oncol* 76:55-58, 2006.
110. Bannykh, SI, Stolt CC, Kim J, **Perry A**, Wegner M. Oligodendroglial-specific transcriptional factor *SOX10* is ubiquitously expressed in human gliomas. *J Neuro-Oncol* 76:115-27, 2006.
111. Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, Mautner V, Upadhyaya M, Muir D, Wallace M, Hagen J, Quelle DE, Watson MA, **Perry A**, Gutmann DH, Ratner N. Large-scale molecular comparison of human Schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. *Cancer Res* 66:2584-91, 2006.
112. **Perry A**, Schmidt, RE. Cancer therapy-associated CNS neuropathology: An update and review of the literature. *Acta Neuropathol* 111:197-212, 2006.
113. Alvarez G, **Perry A**, Tan BR, Wang HL. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. *Mod Pathol* 19:942-49, 2006.
114. Leonard JR, **Perry A**, Rubin JB, King AA, Chicoine MR, Gutmann DH. The role of surgical biopsy in the management of glioma in individuals with neurofibromatosis-1. *Neurology* 76:1509-12, 2006.
115. Miller CR, Dunham CP, Scheithauer BW, **Perry A**. Significance of necrosis in grading of oligodendroglial neoplasms: A clinicopathological and genetic study of newly-diagnosed high-grade gliomas. *J Clin Oncol* 24:5419-26, 2006.
116. Merell R, Nabors LB, **Perry A**, Palmer CA. 1p/19q chromosome deletions in metastatic oligodendroglioma. *Neuro-Oncol* 80:203-207, 2006.
117. Riemenschneider MJ, **Perry, A**, Reifenberger G. Histological classification and molecular genetics of meningiomas. *Lancet Neurol* 5:1045-54, 2006.
118. Yang L, Jackson E, Woerner BM, **Perry A**, Piwnica-Worms D, Rubin JB. Blocking CXCR4-mediated cAMP suppression inhibits brain tumor growth *in vivo*. *Cancer Res* 67:651-658, 2007.

119. Sharma MK, Mansur DB, Reifenberger G, **Perry A**, Leonard JR, Aldape KD, Albin MG, Emnett RJ, Loeser S, Watson MA, Nagarajan R, Gutmann DH. Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. *Cancer Res* 67:890-900, 2007.
120. Ali Z, Ranganathan P, **Perry A**, Gelbart M. Localized striated muscle vasculitis in rheumatoid arthritis. *J Clin Rheumatol* 13:35-37, 2007.
121. Aldape K, Burger P, **Perry A**. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. *Arch Pathol Lab Med* 131:242-51, 2007.
122. Chicoine MR, Zahner M, Won EK, Kalra RR, Kitamura T, **Perry A**, Higashikubo R. The *in vivo* antitumoral effects of lipopolysaccharide against glioblastoma are mediated in part by Toll-like receptor-4. *Neurosurgery* 60:372-81, 2007.
123. Rajaram V, Knezevich S, Bove KE, **Perry A**, Pfeifer JD. DNA sequence of the translocation breakpoints in undifferentiated embryonal sarcoma arising in mesenchymal hamartoma of the liver harboring the t(11;19)(q11;q13.4) translocation. *Genes Chrom Cancer* 46:508-13, 2007.
124. Worley LA, Onken MD, Person E, Robirds D, Branson J, Char DH, **Perry A**, Harbour JW. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. *Clin Cancer Res* 13:1466-71, 2007.
125. Martin DT, Gendron RL, Jarzembowski JA, **Perry A**, Collins MH, Pushpanathan C, Miskiewicz E, Castle VP, Paradis H. Tubedown expression correlates with the differentiation status and aggressiveness of neuroblastic tumors. *Clin Cancer Res* 13:1480-7, 2007.
126. Miller CR, **Perry A**. Glioblastoma: Morphologic and molecular genetic diversity. *Arch Pathol Lab Med* 131:397-406, 2007.
127. Rodriguez FJ, Scheithauer BW, Robbins PD, Burger PC, Hessler RB, **Perry A**, Abell-Aleff PC, Mierau GW. Ependymomas with neuronal differentiation: A morphologic and immunohistochemical spectrum. *Acta Neuropathol* 113:313-24, 2007.
128. Kazmi SAJ, **Perry A**, Pressey JG, Wellons JC, Hammers Y, Palmer CA. Primary Ewing sarcoma of the brain: A case report and literature review. *Diagn Mol Pathol* 16:108-11, 2007.
129. Sanati S, Lu DW, Schmidt E, **Perry A**, Dehner LP, Pfeifer JD. Cytologic diagnosis of Ewing sarcoma/peripheral neuroectodermal tumor with paired prospective molecular genetic analysis. *Cancer* 111:192-99, 2007.
130. Kaplan KJ, **Perry A**. Gliosarcoma with primitive neuroectodermal differentiation. Case report and review of the literature. *J Neuro-Oncol* 83: 313-318, 2007.
131. Brat DJ, Shehata B, Castellano-Sanchez AA, Hawkins C, Yost RB, Greco C, Mazewski C, Janss A, Ohgaki H, **Perry A**. Congenital glioblastoma: A clinicopathologic and genetic analysis. *Brain Pathol* 17:276-81, 2007.
132. Zarovnaya EL, Pallatroni HF, Hug EB, Ball PA, Cromwell LD, Pipas JM, Fadul CE, Meyer LP, Park JP, Biegel JA, **Perry A**, Rhodes CH. Atypical teratoid/rhabdoid tumor of the spine in an adult: Case report and review of the literature. *J Neuro-Oncol* 84:49-55, 2007.
133. Dunham C, Sugo E, Tobias V, Wills E, **Perry A**. Embryonal tumor with abundant neuropil and true rosettes (ETANTR). Report of a case with prominent neurocytic differentiation. *J Neuro-Oncology* 84:91-98, 2007.
134. Chacko G, Chacko AG, Dunham CP, Judkins AR, Biegel JA, **Perry A**. Atypical teratoid / rhabdoid tumor arising in the setting of a pleomorphic xanthoastrocytoma. *J Neuro-Oncol* 84:217-22, 2007.
135. Spinner RJ, Scheithauer BW, **Perry A**, Amrami KK, Emnett R, Gutmann DH. Co-localized cellular schwannoma and plexiform neurofibroma in the absence of neurofibromatosis. *J Neurosurg* 107:435-39, 2007.
136. Warrington NM, Woerner BM, Daniginakatte GC, Dasgupta B, **Perry A**, Gutmann DH, Rubin JB. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in Neurofibromatosis type 1. *Cancer Res* 67:8588-95, 2007.

137. Wagner LM, Garrett JK, Ballard ET, Hill DA, **Perry A**, Biegel JA, Collins MH. Malignant rhabdoid tumor mimicking hepatoblastoma: A case report and literature review. *Ped Develop Pathol* 10:409-15, 2007.
138. Hegedus B, Banerjee D, Yeh TH, Rothermich S, **Perry A**, Rubin JB, Garbow JR, Gutmann DH. Preclinical cancer therapy in a mouse model of Neurofibromatosis-1 optic glioma. *Cancer Res* 68:1520-28, 2008.
139. Rodriguez F**, Perry A**, Gutmann DH, O'Neill BP, Leonard J, Bryant S, Giannini C. Gliomas in patients with neurofibromatosis type 1: A clinicopathologic study of 100 patients. *J Neuropathol Exp Neurol* 67:240-49, 2008.
140. Dunham C, Hussong J, Seiff M, Pfeifer J, **Perry A**. Primary intracerebral angiomatoid fibrous histiocytoma: Report of a case with a t(12;22)(q13;q12) causing type 1 fusion of the EWS and ATF1 genes. *Am J Surg Pathol* 32:478-84, 2008.
141. Zhao XF, Hassan A, **Perry A**, Ning Y, Stass S, Dehner LP. C-myc rearrangements are frequent in aggressive mature B-cell lymphoma with atypical morphology. *Int J Clin Exp Pathol* 1:65-74, 2008.
142. Rodriguez FJ, Scheithauer BW, **Perry A**, Oliveira AM, Jenkins RB, Oviedo A, Mork SJ, Palmer CA, Burger PC. Ependymal tumors with sarcomatous change ("ependymosarcoma"): A clinicopathologic and molecular cytogenetic study. *Am J Surg Pathol* 32:699-709, 2008.
143. Polydorides AD, **Perry A**, Edgar MA. Large cell medulloblastoma with myogenic and melanotic differentiation: A case report with molecular analysis. *J Neuro-Oncol* 88:193-97, 2008.
144. Frei-Jones M, McKinstry R, **Perry A**, Leonard JR, Park TS, Rubin JB. Thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. *J Neurosurg Pediatr* 2:125-29, 2008.
145. Deshmukh H, Yeh TH, Yu J, Sharma MK, **Perry A**, Leonard JR, Watson MA, Gutmann DH, Nagarajan R. High-resolution, dual platform aCGH analysis reveals frequent *HIPK2* amplification and increased expression in pilocytic astrocytomas. *Oncogene* 27:4745-51, 2008.
146. Tepel M, Roerig P, Wolter M, Gutmann DH, **Perry A**, Reifenberger G, Riemenschneider MJ. Frequent promoter hypermethylation and transcriptional down-regulation of the NDRG2 gene at 14q11.2 in primary glioblastomas. *Int J Cancer* 123:2080-86, 2008.
147. Trembath D, Miller CR, **Perry A**. Grey zones in brain tumor classification: Evolving concepts. *Adv Anat Pathol* 15:287-97, 2008.
148. Zhao XF, Hassan A, **Perry A**, Ning Y, Stass SA, Dehner LP. C-myc rearrangements are frequent in aggressive mature B-cell lymphoma with atypical morphology. *Int J Clin Exp Pathol* 1:65-74, 2008.
149. Patil S, **Perry A**, MacCollin M, Dong S, Betensky RA, Yeh TH, Gutmann DH, Stemmer-Rachamimov AO. Immunohistochemical analysis supports a role for INI1/SMARCB1 in hereditary forms of schwannomas, but not in solitary, sporadic schwannomas. *Brain Pathol* 18:517-19, 2008.
150. Goldhoff P, Warrington N, Limbrick DD, Hope A, Woerner BM, Jackson E, Rao M, **Perry A**, Piwnica-Worms D, Rubin JB. Targeted inhibition of phosphodiesterase type 4 promotes brain tumor regression. *Clin Cancer Res* 14:7717-25, 2008.
151. Rodriguez FJ, Giannini C, Asmann YW, Sharma MK, **Perry A**, Tibbetts K, Jenkins RB, Scheithauer BW, Anant S, Jenkins S, Eberhart CG, Sarkaria JN, Gutmann DH. Gene expression profiling of NF1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. *J Neuropathol Exp Neurol* 67:1194-204, 2008.
152. **Perry A**, Miller CR, Gujrati M, Scheithauer BW, Casavilca Zambrano S, Jost SC, Raghavan R, Qian J, Cochran EJ, Huse JT, Holland EC, Burger PC, Rosenblum MK. Malignant gliomas with primitive neuroectodermal tumor-like components: A clinicopathologic and genetic study of 53 cases. *Brain Pathol* 19:81-90, 2009.

153. Filion C, Motoi T, Olshen AB, Lae M, Emnett RJ, Gutmann DH, **Perry A**, Ladanyi M, Labelle Y. The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the *PPARG* nuclear receptor gene: use of tumor expression profiles to guide the search for candidate transcriptional target genes. *J Pathol* 217:83-93, 2009.
154. Shamji MF, Benoit BG, **Perry A**, Jansen GH. Giant cell ependymoma of the thoracic spine: Pathology case report. *Neurosurgery* 64: E566-67, 2009.
155. Lennerz JKM, **Perry A**, Mills JC, Huettner PC, Pfeifer JD. Mucoepidermoid carcinoma of the cervix. Another tumor with the t(11;19)-associated CRTC1-MAML2 gene fusion. *Am J Surg Pathol* 33:835-43, 2009.
156. Tibbetts KM, Emnett RJ, Gao F, **Perry A**, Gutmann DH, Leonard J. Histopathologic predictors of pilocytic astrocytoma event-free survival. *Acta Neuropathol* 117: 657-65, 2009.
157. Chernock RD, **Perry A**, Pfeifer J, Holden JA, Lewis JS, Jr. Receptor tyrosine kinases in sinonasal undifferentiated carcinomas – Evaluation for EGFR, c-kit, and Her2/neu expression. *Head & Neck* 31:919-27, 2009.
158. Ray WZ, Blackburn SL, Casavilca-Zambrano S, Barrionuevo C, Orrego JE, Heinicke H, Dowling JL, **Perry A**. Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: A report of 5 cases and review of the literature. *J Neuro-Oncol* 94:283-92, 2009.
159. Jost SC, Hope A, Kiehl E, **Perry A**, Travers S, Garbow JR. A novel murine model for localized radiation necrosis and its characterization using advanced magnetic resonance imaging. *International Journal of Radiation Oncology, Biology, Physics* 75:527-33, 2009.
160. Hameed O, **Perry A**, Banerjee R, Zhu X, Pfeifer JD. Papillary carcinoma of the breast lacks evidence of RET rearrangements despite morphological similarities to papillary thyroid carcinoma. *Mod Pathol* 22:1236-42, 2009.
161. Darken R, Bogitch R, Leonard J, **Perry A**, McKinstry RC, Gutmann DH, Rubin JB. Brainstem glioma presenting as pruritis in children with Neurofibromatosis-1. *J Pediatr Hematol/Oncol* 31:972-976, 2009.
162. Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah A, Schmidt RE, **Perry A**, Reinwald LT, Carter D, Felton A, Holtzman DM, Mintun MA, Klunk WE, Morris JC. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical cognitive, and cerebrospinal fluid markers of Alzheimer disease. *Arch Neurol* 66:1557-1562, 2009.
163. Lennerz JKM, **Perry A**, Dehner LP, Pfeifer JD, Lind A. CRTC1-rearrangements in primary cutaneous mucoepidermoid carcinoma. *Br J Dermatol* 161:925-29, 2009.
164. Chamberlain WA, Cohen ML, Gyure KA, Kleinschmidt-DeMasters BK, **Perry A**, Powell SZ, Qian J, Staugaitis SM, Prayson RA. Interobserver and intraobserver reproducibility in focal cortical dysplasia (malformations of cortical development). *Epilepsia* 50:2593-98, 2009.
165. Shah MN, Leonard JR, **Perry A**. Rosette forming glioneuronal tumors of the posterior fossa. A case series. *J Neurosurg Pediatr* 5:98-103, 2010.
166. Behdad A, **Perry A**. Central nervous system primitive neuroectodermal tumors: A clinicopathologic and genetic study of 33 cases. *Brain Pathol* 20:441-50, 2010.
167. Mannan AASR, Rifaat AA, Kahvic M, Kapila K, Mallik M, Grover VK, Bharati C, **Perry A**. Proximal-type epithelioid sarcoma in the groin presenting as a diagnostic dilemma. *Pathol Oncol Res* 16:181-88, 2010.
168. Lwu S, Starreveld YP, Branson J, **Perry A**. An anaplastic meningioma arising from an arachnoid cyst. *Neurosurgery* 67:E212-13, 2010.
169. **Perry A**, Burton SB, Fuller GN, Robinson CA, Palmer CA, Resch L, Bigio EH, Gujrati M, Rosenblum MK. Oligodendroglial neoplasms with ganglioglioma-like maturation: A diagnostic pitfall. *Acta Neuropathol* 120: 237-252, 2010.
170. Dorward IG, Luo J, **Perry A**, Gutmann DH, Mansur DB, Rubin JB, Leonard JR. Postoperative imaging surveillance in pediatric pilocytic astrocytomas. *J Neurosurg Pediatr* 6: 346-52, 2010.

171. Mawrin C, **Perry A**. Pathological classification and molecular genetics of meningiomas. *J Neuro-Oncol* 99: 379-391, 2010.
172. Lusis EA, Travers S, Jost SC, **Perry A**. Glioblastomas with giant cell and sarcomatous features in patients with Turcot syndrome type 1: A clinicopathologic study of three cases. *Neurosurgery* 67: 811-817, 2010.
173. Wernicke AG, Dicker AP, Whiton, M, Hyslop T, Hammond EH, **Perry A**, Andrews DW, Kenyon L. Assessment of epidermal growth factor receptor (EGFR) expression in human meningioma. *Radiat Oncol* 5:46(1-7), 2010.
174. Dahiya S, **Perry A**. Pineal tumors: A review of pineal parenchymal tumors and the newly adopted WHO entity papillary tumor of the pineal region. *Adv Anat Pathol* 17:419-27, 2010.
175. Chan O, Chen Z-M, Chung F, Kawachi K, Phan D, Himmelfarb E, Lin F, **Perry A**, Wang H. Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma. *Am J Clin Pathol* 134: 880-885, 2010.
176. Johnson MW, Eberhart CG, **Perry A**, Tihan T, Cohen KJ, Rosenblum MK, Rais-Bahrami S, Goldthwaite P, Burger PC. The spectrum of pilomyxoid astrocytomas: intermediate pilomyxoid tumors. *Am J Surg Pathol* 34: 1783-1791, 2010.
177. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, **Perry A**, Yong W, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. *Acta Neuropathol* 121:381-96, 2011.
178. Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T, Prayson RA, Guha A, Bridge J, Ferner RE, Lindberg GM, Gutmann RJ, Emnett RJ, Salavaggione L, Gutmann DH, Nagarajan R, Watson MA, **Perry A**. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. *Clin Cancer Res* 17:1924-34, 2011.
179. Stuart JE, Lusis EA, Scheck AC, Coons SW, Lal A, **Perry A**, Gutmann DH. Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays. *J Neuropathol Exp Neurol* 70:1-12, 2011.
180. Deshmukh H, Yu J, Shaik J, Macdonald TJ, **Perry A**, Payton JE, Gutmann DH, Watson MA, Nagarajan R. Identification of transcriptional regulatory networks specific to pilocytic astrocytoma. *BMC Med Genomics* 4:57, 2011.
181. Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, Benner A, von Deimling A, Sheurlen W, **Perry A**, Croul S, Kulozik AE, Lichter P, Taylor MD, Pfister SM, Korshunov A. Adult medulloblastoma is comprised of three major molecular variants. *J Clin Oncol* 29: 2717-2723, 2011.
182. Patil S, Scheithauer BW, Strom RG, Mafra M, Chicoine MR, **Perry A**. Malignant meningiomas with epithelial (adenocarcinoma-like) metaplasia: A study of three cases. *Neurosurgery* 69: 884-892, 2011.
183. Han SJ, Clark AJ, Ivan ME, Parsa AT, **Perry A**. Pathology of pineal parenchymal tumors. *Neurosurg Clin North Am* 22: 335-340, 2011.
184. Horbinski C, Kofler J, Yeaney G, Camelo-Piragua S, Venneti S, Louis D, **Perry A**, Murdoch G, Nikiforova M. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. *Brain Pathol* 21: 564-574, 2011.
185. Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, **Perry A**, Yerra R, Schmidt R, Alvarez E, Tyler KL. Rituximab associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. *Arch Neurol* 68:1156-64, 2011.
186. Creach KM, Rubin JB, Leonard JR, Limbrick DD, Smyth MD, Dacey R, Rich KM, Dowling JL, Grubb RL, Linette GP, King AA, Michalski JM, Park TS, **Perry A**, Simpson JR, Mansur DB. Oligodendrogliomas in children. *J Neuro-Oncol* 106: 377-382, 2012.

187. Goldhoff P, Clarke J, Smirnov I, Berger MS, Prados MD, James CD, **Perry A**, Phillips JJ. Clinical stratification of glioblastoma based on alterations in RB1 protein and association with the proneural subtype. *J Neuropathol Exp Neurol* 71:83-89, 2012.
188. Gru AA, Fulling K, **Perry A**. A 39 year-old man with a cerebellar mass and pancytopenia. *Brain Pathol* 22:251-4, 2012.
189. Rodriguez FJ, Folpe AL, Giannini C, **Perry A**. Pathology of peripheral nerve sheath tumors: Diagnostic overview and update on selected diagnostic problems. *Acta Neuropathol* 123: 295-319, 2012.
190. Felicella MM, Hagenkord JM, Kash SF, Powers MP, Berger MS, **Perry A**. Clonal 8q (MYC) amplification detected in a multifocal anaplastic astrocytoma by SNP array karyotyping. *Clin Neuropathol* 31:210-15, 2012.
191. Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau, J, Chesler L, **Perry A**, Phillips JJ, Taylor MD, Weiss WA. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-myc. *Cancer Cell* 21:601-13, 2012.
192. Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, **Perry A**, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch D. Cooperative interactions of $BRAF^{V600E}$ and *CDKN2A* deficiency in pediatric malignant astrocytomas as a basis for rational therapy. *PNAS* 109: 8710-8715, 2012.
193. Bien-Willner GA, Lopez-Terrada D, Bhattacharjee MB, Patel KU, Stankiewicz P, Lupski JR, Pfeifer JD, **Perry A**. Early recurrence in standard risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement. *Neuro-Oncol* 14: 831-40, 2012.
194. Hsieh MS, Ho JTM, Lin LW, Tu PH, **Perry A**, Huang APH. Cerebellar anaplastic pilocytic astrocytoma in a patient of neurofibromatosis type-1: Case report and review of the literature. *Clin Neurol Neurosurg* 114: 1027-1029, 2012.
195. Rodriguez FJ, **Perry A**, Rosenblum MK, Krawitz S, Cohen KJ, Lin D, Mosier S, Lin MT, Eberhart CG, Burger PC. Disseminated oligodendroglial-like leptomeningeal tumor of childhood – A distinctive clinicopathological entity. *Acta Neuropathol* 124: 627-641, 2012.
196. Ellezam B, Theeler BJ, Walbert T, Mammoser A, Horbinski C, Keinschmidt-DeMasters BK, **Perry A**, Puduvalli V, Fuller GN, Bruner JB, Aldape KD. Low rate of R132H *IDH1* mutation in infratentorial and spinal cord grade II and III diffuse gliomas. *Acta Neuropathol* 124: 449-451, 2012.
197. Svajdler M, Rychl B, Gajd M, Pataky F, Frohlichova L, **Perry A**. Gliosarcoma with alveolar rhabdomyosarcoma-like component: Report of a case with a hitherto undescribed sarcomatous component. *Cesk Patol* 48: 210–214, 2012.
198. Barajas RF Jr, **Perry A**, Sughrue M, Aghi M, Cha S. Intracranial subdural osteoma: A rare benign tumor that can be differentiated from other calcified intracranial lesions utilizing MR imaging. *J Neuroradiol* 4:263-6, 2012.
199. Lusis EA, Scheithauer BW, Yachnis AT, Fischer BR, Chicoine MR, Paulus W, **Perry A**. Meningiomas in pregnancy: A clinicopathologic study of 17 cases. *Neurosurgery* 71: 951-961, 2012.
200. Korshunov A, Ryzhova M, Jones DTW, Northcott PA, van Sluis P, Volckmann R, Koster J, Versteeg R, Cowdrey C, **Perry A**, Picard D, Rosenblum M, Giangaspero F, Aronica E, Schüller U, Hasselblatt M, Collins VP, von Deimling A, Lichter P, Huang A, Pfister SM, Kool M. LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). *Acta Neuropathol* 124: 875-881, 2012.
201. Kim YH, Nonoguchi N, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Mariani L, Giangaspero F, Tanaka Y, Nakazato Y, Vital A, Mittelbronn M, **Perry A**, Ohgaki H. Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss. *Brain Pathol* 22: 834-840, 2012.
202. Sarkar K, Way CY, Hiniker A, Brock R, **Perry A**, Verro P. Intracerebral pseudotumors due to a neurologically dominated case of cerebroretinal vasculopathy. *Neurol Clin Pract* 2: 251-254, 2012.

203. Motomura K, Mittelbronn M, Paulus W, Brokinkel, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Nonoguchi N, Pierscianek D, Kim YH, Marian L, Vital A, **Perry A**, Ohgaki H. PDGFRA gain in low-grade diffuse gliomas. *J Neurol Exp Neuropathol* 72:61-66, 2013.
204. Aref D, Moffatt CJ, Agnihotri S, Ramaswamy V, Dubuc AM, Northcott PA, Taylor MD, **Perry A**, Olson JM, Eberhardt CG, Croul SE. Canonical TGF-β pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development. *Brain Pathol* 23:178-191, 2013.
205. Poole Perry LJ, Jakobiec FA, Zakka FR, Reichel E, Herwig MC, **Perry A**, Brat DJ, Grossniklaus HE. Reactive retinal astrocytic tumors (so-called vasoproliferative tumors): Histopathologic, immunohistochemical, and genetic studies of four cases. *Am J Ophthalmol* 155: 593-608 e591, 2013.
206. Allinson, KSJ, Kolias A, Phillippou Y, Bulters DO, Fisher C, **Perry A**, Dean AF. Case of the Month July 2013: A 73-year-old man with a mass at the foramen magnum (Giant Cell-Rich Solitary Fibrous Tumor). *Brain Pathol* 23: 699-702, 2013.
207. Joseph NM, Phillips J, Dahiya S, Madden M, Tihan T, Brat DJ, **Perry A**. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants. *Mod Pathol* 26: 315-326, 2013.
208. Venneti S, Felicella MM, Coyne T, Phillips JJ, Gorovets D, Huse JT, Kofler J, Lu C, Tihan T, Sullivan LM, Santi M, Judkins AR, **Perry A**, Thompson CB. Histone 3 lysine 9 trimethylation (H3K9me3) is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. *J Neuropathol Exp Neurol* 72: 298-306, 2013.
209. Jahangiri A, DeLay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, **Perry A**, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of anti-angiogenic therapy resistance. *Clin Cancer Res* 19:1773-83, 2013.
210. Yeo Y-H, Byrne NP, Counelis GJ, **Perry A**. Adult with cerebellar anaplastic pilocytic astrocytoma associated with BRAF V600E mutation and p16 loss. *Clin Neuropathol* 32: 159-164, 2013.
211. Hiniker A, Hagenkord JM, Powers MP, Aghi MK, Prados MD, **Perry A**. Gliosarcoma arising from an oligodendroglioma (oligosarcoma). *Clin Neuropathol* 32: 165-170, 2013.
212. Jiang T, **Perry A**, Dacey RG Jr., Zipfel GJ, Derdeyn CP. Intracranial atherosclerotic disease associated with moyamoya collateral formation: histopathological findings. *J Neurosurg* 118: 1030-103, 2013.
213. Pekmezci M, **Perry A**. Neuropathology of brain metastases. *Surg Neurol Int* 4:S245-55, 2013.
214. Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, Ligon KL, Horbinski C, Venneti S, Zadeh G, Santi M, Zhou S, Appin CL, Sioletic S, Sullivan LM, Martinez-Lage M, Robinson AE, Mueller S, Marshall R, Haas-Kogan DA, Molinaro AM, **Perry A**. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. *Brain Pathol* 23: 565–573, 2013.
215. Hiniker A, Lee HS, Chang S, Berger M, **Perry A**. Cortical ependymoma with unusual histologic features. *Clin Neuropathol* 32: 318-23, 2013.
216. Tanboon J, Felicella MM, Bilbao J, Mainprize T, **Perry A**. Probable IgG4-related pachymeningitis: a case with transverse sinus obliteration. *Clin Neuropathol* 32: 291-297, 2013.
217. Abedalthagafi M, Phillips J, Kim GE, Mueller S, Haas-Kogen DA, Marshall R, Croul SE, Santi MR, Cheng J, Zhou S, Sullivan LM, Martinez-Lage M, Judkins AR, **Perry A**. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: A multi-institutional study of 214 astrocytomas. *Mod Pathol* 26: 1425-1432, 2013.
218. Reis GF, Bloomer MM, **Perry A**, Phillips JJ, Grenert JP, Karnezis AN, Tihan T. Pilocytic astrocytomas of the optic nerve and their relation to pilocytic astrocytomas elsewhere in the central nervous system. *Mod Pathol* 26: 1279-1287, 2013.

219. Cykowski MD, Allen RA, Kanaly AC, Fung KM, **Perry A**, Marshall R, Stolzenberg ED, Dunn T. The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features. *J Neurooncol* 115: 477-486, 2013.
220. Casavilca S, **Perry A**, Orrego E, Ojeda L, Heredia A, Barrionuevo C, Zaharia M. Reporte de Caso: Oligodendroglioma anaplásico primario de la médula espinal (Primary spinal cord anaplastic oligodendroglioma: case report). *Revista de la Sociedad de Medicina Interna del Perú (Journal of the Society of Internal Medicine of Peru)* 26:136-140, 2013.
221. Dahiya S, Emnett RJ, Haydon DH, Leonard JR, Phillips JJ, **Perry A**, Gutmann DH. *BRAF*-V600E mutation in pediatric and adult glioblastoma. *Neuro-Oncol* 16: 318-319, 2014.
222. Hirbe AC, Pekmezci M, Dahiya S, Apicelli AJ, Van Tine BA, **Perry A**, Gutmann DH. BRAF-V600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. *Neuro-Oncol* 16: 466-467, 2014.
223. Krishnan C, Vogel H, **Perry A**. Atypical teratoid/rhabdoid tumor with gangliogliomatous differentiation. Case report and review of the literature. *Hum Pathol* 45: 185-188, 2014.
224. de Kock L, Sabbaghian N, Plourde F, Srivastava A, Weber E, Soglio DBD, Hamel N, Choi JH, Park SH, Deal CL, Dishop M, Esbenshade A, Kuttesch JF, Jacques TS, **Perry A**, Leichter H, Maeder P, Brundler MA, Warner J, Neal J, Zacharin M, Korbonits M, Cole T, Traunecker H, McLean TW, Rotondo F, Lepage P, Albrecht S, Horvath E, Kovacs K, Priest JR, Foulkes WD. Pituitary blastoma: a pathognomonic feature of germ-line *DICER1* mutations. *Acta Neuropathol* 128: 111-122, 2014.
225. Kool M, Jones DTW, Jager N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, Milde T, Bourdeaut F, Ryzhova M, Sturm D, Pfaff E, Stark S, Hutter S, Seker-Cin H, Johann P, Bender S, Schmidt C, Rausch T, Shih D, Reimand J, Sieber L, Wittmann A, Linke L, Witt H, Weber UD, Zapatka M, Konig R, Beroukhim R, Bergthold G, van Sluis P, Volckmann R, Koster J, Versteeg R, Schmidt S, Wolf S, Lawerenz C, Bartholomae CC, von Kalle C, Unterberg A, Herold-Mende C, Hofer S, Kulozik AE, von Deimling A, Scheurlen W, Felsberg J, Reifenberger G, Hasselblatt M, Crawford JR, Grant GA, Jabado N, **Perry A**, Cowdrey C, Croul S, Zadeh G, Korbel JO, Doz F, Delattre O, Bader GD, McCabe MG, Collins VP, Kieran MW, Cho YJ, Pomeroy SL, Witt O, Brors B, Taylor MD, Schuller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened-inhibition. *Cancer Cell* 25: 393-405, 2014.
226. Lal A, Dahiya S, Gonzales M, Hiniker A, Prayson R, Kleinschmidt-DeMasters BK, **Perry A**. IgG4 overexpression is rare in meningiomas with a prominent inflammatory component: A review of sixteen cases. *Brain Pathol* 24: 352-359, 2014.
227. Pekmezci, M, Vlodavsky E, **Perry A**. Previously unrecognized pattern of central nervous system hemangiopericytoma with pseudoglandular spaces. *Clin Neuropathol* 33: 186-189, 2014.
228. Korshunov A, Sturm D, Ryzhova M, Hovestadt V, Gessi M, Jones DTW, Remke M, Northcott P, **Perry A**, Picard D, Rosenblum M, Antonelli M, Aronica E, Schüller U, Hasselblatt M, Woehrer A, Zheludkova O, Kumirova E, Puget S, Taylor MD, Giangaspero F, Collins VP, von Deimling A, Lichter P, Huang A, Pietsch T, Pfister SM, Kool M. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. *Acta Neuropathol* 128: 279-90, 2014.
229. Spence T, Sin-Chan P, Picard D, Barszczyk M, Hoss K, Lu M, Kim SK, Ra YS, Nakamura H, Fangusaro J, Hwang E, Kiehna E, Toledano H, Wang Y, Shi Q, Johnston D, Michaud J, La Spina M, Buccoliero AM, Adamek D, Camelo-Piragu S, Collins VP, Jones C, Kabbara N, Jurdi N, Varlet P, **Perry A**, Scharnhorst D, Fan X, Muraszko KM, Eberhart C, Ng HK, Gururangan S, Van Meter T, Remke M, Lafay-Cousin L, Chan J, Sirachainan N, Pomeroy S, Clifford SC, Gajjar A, Shago M, Halliday W, Taylor M, Grundy R, Lau CC, Phillips J, Bouffet E, Dirks P, Hawkins CE, Huang A. CNS-PNETs with *C19MC* amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. *Acta Neuropathol* 128: 291-304, 2014.

230. Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, **Perry A**, Zadeh G, Guha A, Croul SE. Analysis of *IDH* mutation, 1p19q deletion, and *PTEN* loss delineates prognosis in low grade diffuse gliomas. Neuro-Oncol 16: 914-923, 2014.
231. de Kock L, Sabbaghian N, Druker H, Weber E, Hamel N, Miller S, Choong CS, Gottardo N, Kees UR, Rednam SP, van Hest L, Jongmans MC, Zacharin M, Soglio DBD, Malkin D, Priest JR, **Perry A**, Albrecht S, Grundy RG, Foulkes WD. Germ-line and somatic *DICER1* mutations in pineoblastoma. *Acta Neuropathol* 128: 583-95, 2014.
232. Louis DN, **Perry A**, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Lopes MB, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P. International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24: 429-35, 2014.
233. Reis GF, **Perry A**. Brain Pathology Case of the Month - May 2014. A 67-Year-Old Man with a Lumbar Spine Lesion (Tophaceous pseudogout). *Brain Pathol* 24: 547–548, 2014.
234. Tanboon J, Pongpaibul A, Chawalparit O, Ananwattanasuk J, Witthiwej T, **Perry A**. A 53-year-old woman with progressive headache (Intracranial tumor-to-tumor metastasis: Metastatic pulmonary adenocarcinoma to a diffuse astrocytoma). *Brain Pathol* 24: 679–680, 2014.
235. Ali S, Joseph NM, **Perry A**, Barajas RF, Jr., Cha S. Apparent diffusion coefficient in glioblastoma with PNET-like components, a GBM variant. *J Neuro-Oncol* 119: 353-360, 2014.
236. Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, **Perry A**, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. A single-institution phase II trial of radiation (RT), temozolomide (TMZ), erlotinib and bevacizumab for initial treatment of glioblastoma. *Neuro-Oncol* 16(7): 984-990, 2014.
237. Chavez JA, Ud Din N, Memon A, **Perry A**. Anaplastic chordoma with loss of INI1 and brachyury expression in a two year old girl. *Clin Neuropathol* 33: 418-420, 2014.
238. Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM, Martinez D, **Perry A**, Lewis PW, Thompson CB, Judkins AR. A sensitive and specific histopathologic prognostic marker for *H3F3A* K27M mutant pediatric glioblastomas. *Acta Neuropathol* 128: 743-53, 2014.
239. Yu JPJ, Wilson DM, Chang EF, Cotter J, **Perry A**, Mahindra A, Glastonbury CM. Isolated intracerebral light chain deposition disease: Novel imaging and pathologic findings. *Clin Imaging* 38: 868-871, 2014.
240. Okimoto RA, **Perry A**, Rubenstein JL. 77-year-old woman with a dural-based mass: Marginal zone B-cell lymphoma (MZBCL)." *Brain Pathol* 25: 111-112, 2015.
241. Chavez JA, Ud Din N, Memon A, **Perry A**. Spinal non-melanotic schwannoma with extensive calcifications. *Clin Neuropathol* 34: 47-49, 2015.
242. Ud Din N, Pekmezci M, Javed G, Horvai AE, Ahmad Z, Faheem M, Navarro AL, López-Terrada D, **Perry A**. Low grade small round cell tumor of the cauda equina with EWSR1-WT1 fusion and indolent clinical course. *Hum Pathol* 46: 153-158, 2015.
243. Pekmezci M, Reuss DE, Hirbe AC, Dahiya S, Gutmann DH, von Deimling A, Horvai AE, **Perry A**. Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. *Mod Pathol* 28, 187–200, 2015.
244. Rodriguez FJ, Schniederjan MJ, Nicolaides T, Tihan T, Burger PC, **Perry A**. High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN). *Acta Neuropathol* 129: 609-610, 2015.
245. Alexandrescu S, Orengo JP, Toossi S, **Perry A**, Treseler P, Hess C, Margeta M. CNS intravascular large cell lymphoma in a patient with autoimmune hemolytic anemia. *Neuropathology* 35: 170-174, 2015.

246. Reis GF, Pekmezci M, Hansen HM, Rice T, Marshall RE, Molinaro AM, Phillips JJ, Vogel H, Wiencke JF, Wrensch MR, Walsh KM, **Perry A**. *CDKN2A* loss is associated with shortened overall survival in lower grade (WHO II-III) astrocytoma. *J Neuropathol Exp Neurol* 74: 442-452, 2015.
247. Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA, Zheludkova O, Milde T, Witt O, Kulozik AE, Reifenberger G, Jabado N, **Perry A**, Lichter P, von Deimling A, Pfister SM, Jones DTW. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. *Acta Neuropathol* 129: 669-678, 2015.
248. Mabray MC, Pekmezci M, Deck MA, **Perry A**, Cha S. Cerebral fat embolism syndrome on susceptibility sensitive imaging: Pathologic correlation in a patient with sickle cell trait. *Neurographics* Volume 5: 124-127, 2015.
249. Wesseling P, van den Bent M, **Perry A**. Oligodendroglioma: pathology, molecular mechanisms and markers. *Acta Neuropathol* 129: 809-827, 2015.
250. Liverman C, Mafra M, Chuang SS, Shivane A, Chakrabarty A, Highley R, Hilton DA, Byrne NP, Wesseling P, **Perry A**. A clinicopathologic study of 11 rosette-forming meningiomas: A rare and potentially confusing pattern. *Acta Neuropathol* 130: 311-313, 2015.
251. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, **Perry A**, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB. Glioma groups based on tumor analysis of 1p/19q, IDH, and the TERT promoter. *NEJM* 372: 2499-508, 2015.
252. Ghoshal N, **Perry A**, McKeel D, Schmidt RE, Carter D, Norton J, Zou WQ, Xiao X, Puoti G, Notari S, Gambetti P, Morris JC, Cairns NJ. Variably protease-sensitive prionopathy in an apparent cognitively normal 93-year-old. Alzheimer Dis Assoc Disord 29: 173-176, 2015.
253. Soroceanu L, Matlaf L, Khan S, Akhavan A, Singer E, Bezrookove V, Decker S, Ghanny S, Hadaczek P, Bengtsson H, Ohlfest J, Luciani-Torres MG, Harkins L, **Perry A**, Guo H, Soteropoulos P, Cobbs CS. Cytomegalovirus immediate early proteins promote stemness properties in glioblastoma. *Cancer Res* 75: 3065-3076, 2015.
254. Cimino PJ, Gonzalez-Cuyer LF, **Perry A**, Dahiya S. Lack of BRAF-V600E mutation in papillary tumor of the pineal region. *Neurosurgery* 77: 621-628, 2015.
255. Hirbe AC, Dahiya S, Miller CA, Li T, Fulton RS, Zhang X, McDonald S, DeSchryver K, Duncavage E, Abel H, Pekmezci M, **Perry A**, Ley T, Gutmann DH. Whole exome sequencing reveals the temporal sequence of genetic changes during malignant transformation and metastasis in a single patient with NF1-associated plexiform neurofibroma. *Clin Cancer Res* 21: 4201-4211, 2015.
256. Menke JR, Raleigh DR, Gown AM, Thomas S, **Perry A**, Tihan T. Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. *Acta Neuropathol* 130: 441-443, 2015.
257. Hansen JM, Larsen VA, Scheie D, **Perry A**, Skjoth-Rasmussen J. Primary intracranial angiomatoid fibrous histiocytoma presenting with anaemia and migraine-like headaches and aura as early clinical features. *Cephalalgia* 35: 1334-1336, 2015.
258. Vaubel RA, Chen SG, Raleigh DR, Link MJ, Chicoine MR, Barani I, Jenkins SM, Aleff PA, Rodriguez FJ, Burger PC, Dahiya S, **Perry A**, Giannini C. Meningiomas with rhabdoid features lacking other histologic features of malignancy: A study of 44 cases and review of the literature. *J Neuropathol Exp Neurol* 75:44-52, 2016.
259. Shows J, Marshall C, **Perry A**, Kleinschmidt-DeMasters BK. Genetics of glioblastomas in rare anatomic locations: Spinal cord and optic nerve. *Brain Pathol* 26:120-23, 2016.
260. Schubert RD, Wood M, Levin MH, **Perry A**, Gelfand JM. The severe side of the IgG4-related hypertrophic pachymeningitis disease spectrum. *Neurol Neuroimmunol Neuroinflamm* 3: e197, 2016.

261. Sturm D, Orr BA, Toprak U, Hovestadt V, Jones DTW, Capper D, Sill M, Buchhalter I, Northcott PA, Picard D, Leis I, Ryzhova M, Kölsche C, Pfaff E, Pajtler K, Brabetz S, Johann PD, Sahm F, Reimand J, Remke M, Phillips J, **Perry A**, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Łastowska M, Scheurlen W, Pietsch T, Hagel C, Gojo J, Berger W, Slavc I, Haberler C, Kramm CM, von Hoff K, Rutkowski S, Herold-Mende C, Frühwald MC, Milde T, Hasselblatt M, Rößler J, Schüller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Schneppenheim R, Zitterbart K, Collins VP, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella Branger D, Wolter M, Schuhmann MU, Shalaby T, Grotzer M, van Meter T, Monoranu C, Felsberg J, Reifenberger G, Koster J, Versteeg R, Volckmann R, van Sluis P, Mikkelsen T, Aldape K, Taylor MD, Moore A, Jones C, Jabado N, Karajannis M, Eils R, Schlesner M, Lichter P, Huang A, von Deimling A, Pfister SM, Ellison DW, Korshunov A, Kool M. New brain tumour entities emerge from molecular classification of CNS PNETs. *Cell* 164:1060-1072, 2016.
262. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, **Perry A**, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. *Neuro-Oncol* 18:557-564, 2016.
263. Rogers CL, **Perry A**, Pugh S, Vogelbaum MA, Brachman D, McMillan W, Jenrette J, Barani I, Shrieve D, Sloan A, Bovi J, Kwok Y, Burri SH, Chao ST, Spalding AC, Anscher MS, Bloom B, Mehta M. Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG trial 0539. *Neuro-Oncol* 18:565-574, 2016.
264. Nauen D, Haley L, Lin MT, **Perry A**, Giannini C, Burger PC, Rodriguez FJ. Molecular analysis of pediatric oligodendrogliomas highlights differences with adult counterparts and other pediatric gliomas. *Brain Pathol* 26: 206-214, 2016.
265. Alexandrescu S, Korshunov A, Lai SH, Dabiri S, Patil S, Li R, Shih CS, Bonnin JM, Baker JA, Du E, Scharnhorst DW, Samuel D, Ellison DW, **Perry A**. Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytomas – same entity or first cousins? *Brain Pathol* 26:215-223, 2016.
266. Louis DN, **Perry A**, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. *Acta Neuropathol* 131:803–820, 2016.
267. Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton J, Tang B, Haupfear K, Punchihewa C, Easton J, Mulder H, Boggs K, Shao Y, Rusch M, Becksfort J, Gupta P, Wang S, Lee R, Brat D, Collins P, Dahiya S, George D, Konomos W, Kurian K, McFadden K, Serafini LN, Nickols H, **Perry A**, Shurtleff S, Gajjar A, Boop F, Klimo P, Mardis E, Wilson R, Baker S, Zhang J, Wu G, Downing J, Tatevossian R, Ellison DW. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. *Acta Neuropathol* 131:833–845, 2016.
268. Röhrich M, Koelsche C, Schrimpf D, Capper D, Sahm F, Kratz A, Reuss J, Hovestadt V, Jones DTW, Bewerunge-Hudler M, Becker A, Weis J, Mawrin C, Mittelbronn M, **Perry A**, Mautner VF, Mechtersheimer G, Hartmann C, Okuducu AF, Arp M, Seiz-Rosenhagen M, Hänggi D, Heim S, Paulus W, Schittenhelm J, Ahmadi R, Herold-Mende C, Unterberg A, Pfister SM, von Deimling A, Reuss D. Methylation based classification of benign and malignant peripheral nerve sheath tumors. *Acta Neuropathol* 131:877–887.
269. Hasselblatt M, Thomas C, Hovestadt V, Schrimpf D, Johann P, Bens S, Oyen F, Peetz-Dienhart S, Crede Y, Wefers A, Vogel H, Riemenschneider MJ, Antonelli M, Giangaspero F, Bernardo MC, Giannini C, Ud Din N, **Perry A**, Keyvani K, van Landeghem F, Sumerauer D, Hauser P, Capper D, Korshunov A, Jones DTW, Pfister SM, Schneppenheim R, Siebert R, Frühwald M, Kool M. Poorly differentiated chordoma with SMARCB1/INI1 loss: A distinct molecular entity with dismal prognosis. *Acta Neuropathol* 132: 149-151, 2016.

270. Ferris S, Goode B, Kline CN, Samuel D, Gupta N, Bollen A, **Perry A**, Mueller S, Solomon DA. IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10 years of age. *Acta Neuropathol* 132:153–155, 2016.
271. Gospodarev V, Câmara J, Chakravarthy V, **Perry A**, Wood M, Dietz R, Wang J, De Los Reyes K, Raghavan R. Treatment of IgG4-related pachymeningitis in a patient with steroid intolerance: The role of early use of Rituximab. *J Neuroimmunol* 299: 62–65, 2016.
272. Duncan VE, Nabors LB, Warren PP, Conry RM, Willey CD, **Perry A**, Riley KO, Hackney JR. Primary sellar rhabdomyosarcoma arising in association with a pituitary adenoma. *Int J Surg Pathol* 24: 753-756, 2016.
273. Winkler EA, Birk H, Safaee M, Yue JK, Burke JF, Viner J, Pekmezci M, **Perry A**, Aghi MK, Berger MS, McDermott MW. Surgical resection of fourth ventricular ependymomas - Case series and technical nuances. *J Neuro-Oncol* 130: 341-349, 2016.
274. Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, **Perry A**. Diffuse midline gliomas with histone H3-K27M mutation: A series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. *Brain Pathol* 26:569-80, 2016.
275. Han SJ, Reis G, Kohanbash G, Srivastav S, Magill ST, Molinaro AM, McDermott MW, Theodosopoulos PV, Aghi MK, Berger MS, Butowski NA, Barani I, Phillips JJ, **Perry A**, Okada H. Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. *J Neuro-Oncology* 130:543-552, 2016.
276. Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Bastian BC, Jin L, Bastian BC, Bollen AW, **Perry A**, Nicolaides T, Solomon DA, Shieh JTC. Activating NF1-BRAF and ATG7-RAF1 fusions in anaplastic pleomorphic xanthoastrocytoma without BRAF p.V600E mutation. *Acta Neuropathol* 132:757-760, 2016.
277. Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, **Perry A**, Uppaluri R, Ferguson C, Schmidt RE, Dahiya S, Ansstas G, Mardis ER, Dunn GP. Immunogenomics of hypermutated glioblastoma: A patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. *Cancer Discov* 6:1230-1236, 2016.
278. Olar A, Lapadat R, Davidson CJ, Stein TD, Dahiya S, **Perry A**, Gheorge G. Central nervous system involvement by myeloid sarcoma: A report of 12 cases and review of the literature. *Clin Neuropathol* 35:314-325, 2016.
279. Schwetye KE, Joseph NM, Al-Kateb H, Rich K, Schmidt RE, **Perry A**, Gutmann DH, Dahiya S. Gliosarcomas lack $BRAF^{V600E}$ mutations, but a subset exhibit β-catenin nuclear localization. *Neuropathology* 36:448-455, 2016.
280. Alshareef MA, Almadidy Z, Baker T, **Perry A**, Welsh CT, Vandergrift WA. Intracranial angiomatoid fibrous histiocytoma: A case report and literature review. *World Neurosurg* 96:403-409, 2016.
281. Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, **Perry A**, Bell RJ, Phillips JJ, Costello JF, Ronen SM, Pieper RO. Mutant IDH expression drives TERT promoter reactivation as part of the cellular transformation process. *Cancer Res* 76:6680-89, 2016.
282. **Perry A**, Chan JW, Cotter JA, Bracha A. Intraorbital neuromuscular choristoma adjacent to the optic nerve. *Hum Pathol Case Reports* 7:1-3, 2017.
283. Cuevas-Ocampo AK, Bollen AW, Goode B, Dai SC, **Perry A**, McDermott M, Solomon DA. Genetic confirmation that ependymoma can arise as part of multiple endocrine neoplasia type 1 (MEN1) syndrome. *Acta Neuropathol* 133:661-63, 2017.
284. Kline CN, Joseph NM, Grenert JP, van Ziffle J, Talevich E, Onodera C, Aboian M, Cha S, Raleigh DR, Braunstein S, Torkildson J, Samuel D, Bloomer M, de Alba Campomanes A, Banerjee A, Butowski N, Raffel C, Tihan T, Bollen AW, Phillips JJ, Korn M, Yeh I, Bastian BC, Gupta N, Mueller S, **Perry A**, Nicolaides T, Solomon DA. Targeted next-generation sequencing of pediatric

brain tumor patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. *Neuro-Oncology* 19:699-709, 2017.

285. Wahl M, Phillips JJ, Molinaro AM, Lin Y, **Perry A**, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM. Chemotherapy for adult low grade gliomas: Clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. *Neuro-Oncol* 19:242-251, 2017.
286. Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon D, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, Batchelor T, Ligon KL, Ligon AH, Meyerson M, Dunn IF, Beroukhim R, Louis DN, **Perry A**, Carter SL, Giannini C, Curry Jr. WT, Cahill DP, Barker FG II, Brastianos PK, Santagata S. Germline and somatic *BAP1* mutations in high-grade rhabdoid meningiomas. *Neuro-Oncology* 19:535-545, 2017.
287. Hirbe AC, Kaushal M, Sharma M, Dahiya S, Pekmezci M, **Perry A**, Gutmann DH. Clinical genomic profiling identifies TYK2 mutation and overexpression in Neurofibromatosis type 1 (NF1) malignant peripheral nerve sheath tumors (MPNSTs). *Cancer* 123:1194-1201, 2017.
288. Neill E, Luks T, Dayal M, Phillips JJ, **Perry A**, Jalbert LE, Cha S, Molinaro A, Chang S, Nelson S. Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. *J Neuro-Oncol* 132:171-179, 2017.
289. Lopez G, Bush NAO, Berger MS, **Perry A**, Solomon DA. Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma. *Acta Neuropathol Com* 15:38, 2017.
290. Dahlin LB, Scherman P, Besjakov J, Lindberg E, Solomon DA, Horvai AE, **Perry A**. Intraneural glomus tumor of "uncertain malignant potential" and with BRAF mutation in the median nerve – an unusual case. *Clin Neuropathol* 36:164-70, 2017.
291. Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen HM, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, **Perry A**, Giannini C, Tihan T, Berger MS, Wiemels JL, Bracci PM, Eckel-Passow JE, Lachance DH, Clarke J, Taylor JW, Luks T, Wiencke JK, Jenkins RB, Wrensch MR. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. *Acta Neuropathol* 133:1001-1016, 2017.
292. Rutkowski MJ, Birk HS, Wood MD, **Perry A**, Nicolaides T, Ames CP, Gupta N. Metastatic clival chordoma: a case report of multiple extraneural metastases following surgical resection and proton beam radiotherapy in a 5-year old boy. *J Neurosurg Pediatr* 19:531-537, 2017.
293. Ferris SP, Hofmann JW, Solomon DA, **Perry A**. Characterization of gliomas: From morphology to molecules. *Virchows Archiv* 471:257–269, 2017.
294. Chan E, Bollen AW, Sirohi D, van Ziffle J, Grenert JP, Kline CN, Tihan T, **Perry A**, Gupta N, Solomon DA. Angiocentric glioma with MYB-QKI fusion located in the brainstem, rather than cerebral cortex. *Acta Neuropathol* 134: 671–73, 2017.
295. Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Poussaint TY, Fangusaro J, Phillips J, **Perry A**, Turner D, Prados M, Packer RJ, Qaddoumi I, Gururangan S, Pollack I, Goldman S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M. A phase 1 trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low grade glioma: A Pediatric Brain Tumor Consortium (PBTC) study. *Neurooncology* 19:1135-1144, 2017.
296. Chan AK, Han SJ, Choy W, Beleford D, Aghi MK, Berger MS, Shieh JT, Bollen AW, **Perry A**, Phillips JJ, Butowski N, Solomon DA. Familial melanoma-astrocytoma syndrome: Synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history. *Clin Neuropathol* 36:213-221, 2017.
297. Barajas RF, Villanueva-Meyer J, **Perry A**, Berger M, Cha S. Biologically aggressive regions within glioblastoma identified by spin-lock contrast T1 relaxation in the rotating frame (T1<rho>) MR Imaging. *Radiol Case Reports* 12:827-32, 2017.
298. Higham C, Steinberg SM, Dombi E, **Perry A**, Helman LJ, Schuetze SM, Ludwig JA, Staddon A, Milhem MM, Rushing D, Jones RL, Livingston M, Goldman S, Moertel C, Wagner L, Janhofer D, Annunziata CM, Reinke D, Long L, Viskochil D, Baker L, Widemann BC. SARC006: Phase II trial

of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapy-naïve malignant peripheral nerve sheath tumors. *Sarcoma* 8685638, 2017.

299. Mercado JJ, Markert JM, Meador W, Chapman P, **Perry A**, Hackney JR. Primary CNS non-amyloidogenic light chain deposition disease: Case report and brief review. *Int J Surg Pathol* 25:755-60, 2017.
300. Pekmezci M, Cuevas-Ocampo AK, **Perry A**, Horvai AE. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. *Mod Pathol* 30:1710-19, 2017.
301. Lopez G, Oberheim Bush NA, Phillips J, Bouffard JP, Moshel Y, Jaeckle K, Kleinschmidt-DeMasters BK, Rosenblum M, **Perry A**, Solomon DA. Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression. *Acta Neuropathol* 134:961-3, 2017.
302. Sorge C, Li R, Singh S, Reddy AT, Solomon DA, **Perry A**, Friedman GK. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. *Pediatric Blood and Cancer* 64: e26708, 2017.
303. Miettinen MM, Antonescu CR, Fletcher CD, Kim A, Lazar AJ, Quezado MM, Reilly KM, Stemmer-Rachamamimov A, Stewart D, Viskochil D, Widemann B, **Perry A**. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in neurofibromatosis 1 patients – A consensus overview. *Hum Pathol* 67:1-10, 2017.
304. Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Mara MA, Cairncross JG, **Perry A**, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Phillips JJ, Luchman HA, Costello JF. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant *IDH1*. *PNAS* 114:10743-10748, 2017.
305. Lee JC, Pekmezci M, Lavezo JL, Vogel H, Katznelson L, Fraenkel M, Harsh G, Dulai M, **Perry A**, Tihan T. Utility of Pit-1 immunostaining in distinguishing pituitary adenomas of primitive differentiation from null cell adenomas. *Endocr Pathol* 28:287-292, 2017.
306. Iorgulescu JB, Van Ziffle J, Stevers M, Grenert JP, Bastian BC, Chavez L, Stichel D, Buchhalter I, Samuel D, Nicolaides T, Banerjee A, Mueller S, Gupta N, Tihan T, Bollen AW, Northcott PA, Kool M, Pfister S, Korshunov A, **Perry A**, Solomon DA. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. *Acta Neuropathol* 135:635-638, 2018.
307. Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, Reis GF, Magill ST, Zhang J, Feng FY, Nicolaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, **Perry A**, Raleigh DR. Comprehensive Molecular profiling identifies FOXM1 as a key transcription factor for meningioma proliferation. *Cell Rep* 22:3672-3683, 2018.
308. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss D, Kratz A, Wefers AK, Huang K, Pajtler K, Schweizer L, Stichel D, Olar A, Engel N, Lindenberg K, Harter P, Braczynski A, Coras R, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez F, Acker T, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Frank S, Serrano J, Kannan K, Tsirigos A, Bruck W, Hofer S, Brehmer S, Seitz-Rosenhagen M, Hans V, Rozsnoki S, Hansford J, Kohlhof P, Kristensen B, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Holsken A, Muhleisen A, Mueller W, Pohl U, Prinz M, Zapatka M, Gottardo N, Monoranu CM, **Perry A**, Jones C, Jacques T, Radlwimmer B, Gessi M, Pietsch T, Reifenberger G, Wesseling P, Weller M, Collins VP, Blumcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott P, Paulus W, Gajjar A, Robinson G, Taylor M, Ryzhova M, Hanggi D, Platten M, Unterberg A, Wick W, Karajannis M, Mittelbronn M, Hartmann C, Aldape K, Schuller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison D, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM. DNA methylation-based classification of human central nervous system tumors. *Nature* 555:469-474, 2018.

309. Johann PD, Bens S, Oyen F, Wagener R, Giannini C, **Perry A**, Raisanen JM, Reis GF, Nobusawa S, Arita K, Felsberg J, Reifenberger G, Agaimy A, Buslei R, Capper D, Pfister SM, Schneppenheim R, Siebert R, Fruhwald MC, Paulus W, Kool M, Hasselblatt M. Sellar region atypical teratoid/rhabdoid tumors (ATRT) in adults display molecular profiles of the ATRT-MYC subgroup. *Am J Surg Pathol* 42(4):506-511, 2018.
310. Pekmezci M, Stevers M, Phillips JJ, Van Ziffle J, Bastian BC, Tsankova N, Kleinschmidt-DeMasters BK, Rosenblum MK, Tihan T, **Perry A**, Solomon DA. Multinodular and vacuolating neuronal tumor of the cerebrum is a clonal neoplasm defined by genetic alterations that activate the MAP kinase signaling pathway. *Acta Neuropathol* 135:485-488, 2018.
311. Wood MD, Tihan T, **Perry A**, Chacko G, Turner C, Pu C, Payne C, Yu A, Bannykh S, Solomon DA. Multimodal molecular analysis of astroblastoma enables reclassification of most cases into a more specific diagnostic entity. *Brain Pathol* 28:192-202, 2018.
312. Wu A, Garcia MA, Magill ST, Chen W, Vasudevan HN, **Perry A**, Theodosopoulos PV, McDermott MW, Braunstein SE, Raleigh DR. Presenting symptoms and prognostic factors for symptomatic outcomes following resection of meningioma. *World Neurosurg* 111:e149-e159, 2018.
313. Goode B, Mondal G, Hyun M, Ruiz DG, Lin YH, van Ziffle J, Joseph N, Onodera C, Talevich E, Grenert J, Hewedi I, Snuderl M, Brat DJ, Kleinschmidt-DeMasters B, Rodriguez F, Louis D, Yong W, Lopes M, Rosenblum M, Butowski N, Tihan T, Bollen A, Phillips J, Wiita A, Yeh I, Jacobson M, Bastian B, **Perry A**, Solomon D. A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle. *Nat Commun* 9:810, 2018.
314. Luks TL, McKnight TR, Jalbert LE, Williams A, Neill E, Lobo KA, Persson A, **Perry A**, Phillips J, Molinaro A, Chang SM, Nelson SJ. Relationship of in vivo MR parameters to histopathological and molecular characteristics of newly-diagnosed, non-enhancing lower-grade gliomas. *Trans Oncol* 11:941-49, 2018.
315. Solomon DA, Korshunov A, Sill M, Jones DTW, Kool M, Pfister SM, Fan X, Bannykh S, Danielpour M, Li R, Cham E, Cooney T, Sun P, Oberheim Bush NA, McDermott M, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Villanueva-Meyer JE, Pekmezci M, Bollen AW, **Perry A**. Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNET-like methylation profile. *Acta Neuropathol* 136:339–343, 2018.
316. Rogers L, Zhang P, Vogelbaum MA, **Perry A**, Ashby L, Modi J, Alleman AM, Galvin J, Brachman D, Jenrette JM, DeGroot J, Bovi JA, Werner-Wasik M, Knisely JPS, Mehta MP. Intermediate-risk meningioma: Initial outcomes from NRG Oncology RTOG-0539. *J Neurosurg* 129:35-47, 2018.
317. Chen WC, Hara J, Magill ST, Wu A, Aghi AK, Theodosopoulos PV, **Perry A**, McDermott MW, Sneed PK, Raleigh DR, Braunstein SE. Salvage therapy outcomes for atypical meningioma. *J Neuro-Oncol* 138:425-33, 2018.
318. Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, Grund KB, Brugieres L, Jones DTW, Pajtler KW, Morissy S, Kool M, Sturm D, Chavez L, Ernst A, Brabetz S, Hain M, Zichner T, Saguara-Wang M, Weischenfeldt J, Rausch T, Mardin BR, Zhou X, Baciu C, Lawerenz C, Chan J, Varlet P, Guerrini-Rousseau L, Fults DW, Grajkowska W, Hauser P, Jabado N, Ra YS, Zitterbart K, Shringarpure SS, De la Vega FM, Bustamante CD, Ng HK, **Perry A**, MacDonald TJ, Hernaiz-Driever P, Bendel AE, Bowers D, McCowage G, Chintagumpala MM, Cohn R, Hassall T, Fleischhack G, Eggen T, Wesenberg F, Feychting M, Lannering B, Schüz J, Andersen TV, Röösli M, Kuehni CE, Grotzer M, Kjaerheim K, Monoranu CM, Archer TC, Duke E, Pomeroy SL, Shelagh R, Frank S, Sumerauer D, Scheurlen W, Ryzhova MV, Milde T, Kratz CP, Samuel D, Zhang J, Solomon DA, Marra M, Eils R, Bartram CR, von Hoff K, Rutkowski S, Ramaswamy V, Korshunov A, Gilbertson R, Taylor MD, Lichter P, Malkin D, Gajjar A, Korbel JO, Pfister SM. Spectrum and prevalence of genetic predisposition in medulloblastoma: A retrospective genetic study and prospective validation in a clinical trial cohort. *Lancet Oncol* 19:S1470-2045, 2018. PMID 29753700.

319. Pekmezci M, Villanueva-Meyer J, Goode B, Van Ziffle J, Onodera C, Grenert JP, Bastian B, Chamyan G, Maher O, Khatib Z, Kleinschmidt-DeMasters B, Samuel D, Mueller S, Banerjee A, Clarke J, Cooney T, Torkildson J, Gupta N, Theodosopoulus P, Chang E, Berger M, Bollen A, **Perry A**, Tihan T, Solomon DA. The genetic landscape of ganglioglioma. *Acta Neuropathol Commun* 6:47, 2018.
320. Lapointe S, **Perry A**, Butowski N. Primary brain tumours in adults. *Lancet* 392:432-46, 2018.
321. Peterson MS, Waddell JK, Ebbert TL, **Perry A**, Berg LC. Malignant peripheral nerve sheath tumor within the spinal canal with apparent drop metastases. *Hum Pathol Case Reports* 14:88-91, 2018.
322. Lee J, Putnam A, Cheshier S, Banerjee A, Raffel C, Van Ziffle J, Onodera C, Grenert JP, Bastian B, **Perry A**, Solomon DA. Oligodendrogliomas, IDH-mutant and 1p/19q-codeleted, arising during teenage years often lack TERT promoter mutation that is typical of their adult counterparts. *Acta Neuropathol Commun* 6:95, 2018.
323. Iorgulescu JB, Ferris S, Agarwal A, Casavilca Zambrano S, Hill DA, Schmidt R, **Perry A**. Non-meningothelial meningeal tumours with meningioangiomatosis-like pattern of spread. *Neuropathol Appl Neurobiol* 44:743-46, 2018.
324. Korshunov A, Chavez L, Sharma T, Ryzhova M, Schrimpf D, Stichel D, Capper D, Sturm D, Kool M, Habel A, Kleinschmidt-DeMasters BK, Rosenblum M, Absalyamova O, Golanov A, Lichter P, Pfister SM, Jones DTW, **Perry A**, von Deimling A. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. *Brain Pathol* 28:656-62, 2018.
325. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters B, **Perry A**, Reifenberger G, Stupp R, von Deimling A, Weller M. cIMPACT-NOW Update 3: Grading of IDH-wildtype diffuse astrocytic gliomas. *Acta Neuropathol* 136:805-10, 2018.
326. Gennatas ED, Wu A, Braunstein SE, Morin O, Chen WC, Magill ST, Gopinath C, Villaneueva-Meyer JE, **Perry A**, McDermott MW, Solberg TD, Valdes G, Raleigh DR. Preoperative and postoperative prediction of long-term meningioma outcomes. *PLOS One* 13:e0204161, 2018.
327. Phillips JJ, Gong H, Chen K, Joseph NM, van Ziffle J, Bastian BC, Grenert JP, Kline CN, Mueller S, Banerjee A, Nicolaides T, Gupta N, Berger MS, Lee HS, Pekmezci M, Tihan T, Bollen AW, **Perry A**, Shieh JTC, Solomon DA. The genomic landscape of anaplastic pleomorphic xanthoastrocytoma. *Brain Pathol* 29:85-96, 2019.
328. Lee JC, Sharifai N, Dahiya S, Kleinschmidt-DeMasters BK, Rosenblum MK, Reis GF, Samuel D, Siongco AM, Santi M, Storm PB, Ferris SP, Bollen AW, Pekmezci M, Solomon DA, Tihan T, **Perry A**. Clinicopathologic features of anaplastic myxopapillary ependymomas. *Brain Pathol* 29:75-84, 2019.
329. Fritchie K, Jensch K, Moskalev EA, Caron A, Jenkins S, Link M, Brown PD, Rodriguez FJ, Guajardo A, Brat D, Velázquez Vega JE, **Perry A**, Wu A, Raleigh DR, Santagata S, Louis DN, Brastianos PK, Kaplan A, Alexander BM, Rossi S, Ferrarese F, Haller F, Giannini C. The impact of histopathology and NAB2-STAT6 fusion subtype in classification and grading of meningeal solitary fibrous tumor/hemangiopericytoma. *Acta Neuropathol* 137:307-319, 2019.
330. Chen WC, Magill ST, Wu A, Vasudevan HN, Morin O, Aghi MK, Theodosopoulos PV, **Perry A**, McDermott MW, Sneed PK, Braunstein SE, Raleigh DR. Histopathological features predict local control of atypical meningioma after surgery and adjuvant radiotherapy. *J Neurosurg* (in press).
331. Lopez GY, **Perry A**, Harding B, Li M, Santi M. CDKN2A/B loss is associated with anaplastic transformation in a case of NTRK2 fusion-positive pilocytic astrocytoma. *Neuropathol Appl Neurobiol* (in press).
332. Lopez GY, Van Ziffle J, Onodera C, Grenert JP, Yeh I, Bastian BC, Clarke J, Oberheim Bush NA, Taylor J, Chang S, Butowski N, Banerjee A, Mueller S, Kline C, Torkildson J, Samuel D, Siongco A, Raffel C, Gupta N, Kunwar S, Mummaneni P, Aghi M, Theodosopoulos P, Berger M, Phillips J, Pekmezci M, Tihan T, Bollen AW, **Perry A**, Solomon DA. The genetic landscape of gliomas arising after therapeutic radiation. *Acta Neuropathol* (in press).

333. Iorgulescu JB, Torre M, Harary M, Smith TR, Aizer A, Reardon DA, Barnholtz-Sloan J, **Perry A**. The misclassification of diffuse gliomas: rates and outcomes. *Clin Cancer Res* (in press).
334. Lee JC, Villanueva-Meyer JE, Ferris SP, Sloan EA, Hofmann JW, Hattab EM, Williams BJ, Guo H, Torkildson J, Florez A, Van Ziffle J, Onodera C, Grenert JP, Cho SJ, Horvai AE, Jones DTW, Pfister SM, Koelsche C, von Deimling A, Korshunov A, **Perry A**, Solomon DA. Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. *Acta Neuropathol* (in press).
335. Torre M, Meredith DM, Dubuc A, Solomon DA, **Perry A**, Vasudevaraja V, Serrano J, Snuderl M, Ligon KL, Alexandrescu S. Recurrent EP300-BCOR fusions in pediatric gliomas with distinct clinicopathologic features. *J Neuropathol Exp Neurol* (in press).

NON-PEER REVIEWED PUBLICATIONS AND OTHER CREATIVE ACTIVITIES:

336. **Perry A**, Hernandez JA. Double heterozygous hemoglobin E/Beta thalassemia**.** ASCP Check Path Case QAH 92-4, J162; 1992.
337. **Perry A**, Scheithauer BW. Malignant transformation of meningioma: an example with rhabdoid morphology with a discussion of meningioma grading. *Pathol Case Rev* 3:296-300, 1998.
338. **Perry A**. Book review of "Practical differential diagnosis in surgical neuropathology by Prayson and Cohen". *Am J Surg Pathol* 25:554-55, 2001.
339. Fuller CE, **Perry A**. Pathology of low and intermediate grade gliomas. *Sem Radiat Oncol* 11:95-102, 2001.
340. Fuller CE, **Perry A**. Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. *Brain Pathol* 12:67-86, 2002.
341. **Perry A**, Scheithauer BW. Chapter 10: Neuropathology. In: Chang YW, Bostwick DG (ed.) *Essentials of anatomic pathology. A practical guide with emphasis on differential diagnosis and diagnostic criteria*. Totowa, NJ: Humana Press, 2002.
342. **Perry A**, Leonard JR, Roth KA, Gutmann DH. Brain Tumor Genetics. In: Batjer HH, Loftus CM (ed.) *Textbook of Neurological Surgery*. Philadelphia: Lipincott Williams and Wilkins, 2002.
343. **Perry A**, Dehner LP. Meningeal tumors of childhood and infancy. An update and literature review. *Brain Pathol* 13:386-408, 2003.
344. McDonald JM, Colman H, **Perry A**, Aldape K. Ch. 2: Molecular and clinical aspects of 1p-19q loss in oligodendroglioma. In: Zhang W, Fuller G (ed.) *Genomic and Molecular Neuro-Oncology*. Jones and Bartlett, Boston, MA, 2004.
345. **Perry A**, Heffner RR, Louis DN. Ch. 58B: Pathology and molecular genetics of nervous system tumors. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J (ed.) *Neurology in clinical practice. 4th ed.* Butterworth-Heinemann, Boston, MA 2004.
346. **Perry A**. Unmasking the secrets of meningioma. A slow but rewarding journey. *Surg Neurol* 61:171-73, 2004.
347. Gutmann DH, **Perry A**, Rangwala R, Sherman LS. Chapter 11: Peripheral Nervous System Tumors. In: *Mouse Models of Cancer*. Wiley Press, New Jersey, 2004.
348. **Perry A**. News in Brief. Metastatic oligodendroglioma: A mini-epidemic? *Adv Anat Pathol* 11:325, 2004.
349. Miller CR, **Perry A**. News in Brief. Immunohistochemical differentiation of hemangioblastoma from metastatic clear cell renal carcinoma: An update. *Adv Anat Pathol* 11:325-26, 2004.
350. Miller CR, **Perry A**. News in Brief. CD34 and MAP-2 Immunohistochemistry in the differential diagnosis of epilepsy-associated glioneuronal tumors. *Adv Anat Pathol* 11:326-27, 2004.
351. **Perry A**, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. *J Neuro-Oncol* 70:183-202, 2004.

352. **Perry A**. Commentary on: "A non-NF2 case of schwannomas of vestibular and trigeminal nerves with different genetic alterations of NF2 gene: Case Report" by Kambe A et al. *Surg Neurol* 63:62-65, 2005.
353. **Perry A**. Molecular diagnostics in gliomas. *CAP-ACP Newsletter* (Canadian Association of Pathologists-Association Canadienne des Pathologistes) 48:13-15, 2005.
354. Rogers L, Jensen R, **Perry A**. Chasing your dural tail (letter to editor). *Int J Rad Oncol Biol Phys* 62:616-18, 2005.
355. **Perry A**. Ch. 9: Glial and Glioneuronal Tumors. In: Prayson RA (ed.) *Neuropathology. A Volume in the Series: Foundations in Diagnostic Pathology*. Churchill Livingstone/Elsevier Science, Philadelphia, PA 2005.
356. Roth KA, **Perry A**. Ch. 36: Cell and Tissue Imaging of Gene Dosage and Expression. In: Schuster D, Powers W (ed.) *Translational and Experimental Clinical Research*. Lippincott Williams and Wilkins, Philadelphia, PA 2005.
357. **Perry A**, Scheithauer BW. Chapter 8: Neuropathology. In: Cheng YW, Bostwick DG (ed.) *Essentials of anatomic pathology (2nd edition)*. Totowa, NJ: Humana Press, 2006.
358. **Perry A.** Chapter 4: Fluorescence *in situ* Hybridization. In: Pfeifer J (ed.) *Molecular Genetic Testing in Surgical Pathology*. Lippincott Williams & Wilkins, Philadelphia, PA 2006.
359. Tu PH, Fuller C, **Perry A.** Chapter 14: Molecular diagnostics of CNS tumors and neurodegenerative diseases. In: Pfeifer J (ed.) *Molecular Genetic Testing in Surgical Pathology*. Lippincott Williams & Wilkins, Philadelphia, PA 2006.
360. **Perry A**, Scheithauer BW. Classification and grading of pituitary tumors. Observations of two working neuropathologists. *Acta Neuropathol* 111:68-70, 2006.
361. Wippold FJ, **Perry A**. Neuropathology for the neuroradiologist: Rosettes and pseudorosettes. *Am J Neuroradiol* 27:488-92, 2006.
362. Wippold FJ, Lennerz J**, Perry A**. Neuropathology for the neuroradiologist: Rosenthal fibers. *Am J Neuroradiol* 27:958-61, 2006.
363. **Perry A**. News in Brief. Lhermitte-Duclos disease: A nearly pathognomonic component of Cowden disease. *Adv Anat Pathol* 13:197-98, 2006.
364. **Perry A**. News in Brief. Familial posterior fossa brain tumor syndrome of infancy. *Adv Anat Pathol* 13:198-99, 2006.
365. **Perry A**. Chapter 34: Meningiomas. In: McLendon R, Rosenblum M, Bigner DD (ed.) *Russell & Rubinstein's Pathology of Tumors of the Nervous System. 7th ed.* Hodder Arnold (Publisher), London, England 2006.
366. **Perry A**. Chapter 35: Solitary fibrous tumors. In: McLendon R, Rosenblum M, Bigner DD (ed.) *Russell & Rubinstein's Pathology of Tumors of the Nervous System. 7th ed.* Hodder Arnold (Publisher), London, England 2006.
367. **Perry A**. Chapter 36: Primary meningeal sarcoma. In: McLendon R, Rosenblum M, Bigner DD (ed.) *Russell & Rubinstein's Pathology of Tumors of the Nervous System. 7th ed.* Hodder Arnold (Publisher), London, England 2006.
368. Gutmann DH, **Perry A**. Chapter 58: Neurofibromatosis type 1. In: McLendon R, Rosenblum M, Bigner DD (ed.) *Russell & Rubinstein's Pathology of Tumors of the Nervous System. 7th ed.* Hodder Arnold (Publisher), London, England 2006.
369. Wippold FJ, Lammle M, Anatelli F, Lennerz J**, Perry A**. Neuropathology for the neuroradiologist: Palisades and pseudopalisades. *Am J Neuroradiol* 27:2037-41, 2006.
370. Wippold FJ, Lennerz J**, Perry A**. Neuropathology for the neuroradiologist: Fluorescence *in situ* hybridization. *Am J Neuroradiol* 28:406-10, 2007.
371. Dear Reader: Greetings and journal update from the incoming editor. *Brain Pathol* 17(1), 2007.
372. **Perry A**, Louis DN, Scheithauer BW, Budka H, Von Deimling A. Ch. 10.1: Meningiomas. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (ed.) *WHO classification of tumours of the central nervous system. 4th ed*. Lyon: IARC; 164-172, 2007.

373. Paulus W, Scheithauer BW, **Perry A**. Ch. 10.2: Mesenchymal, non-meningothelial tumours. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (ed.) *WHO classification of tumours of the central nervous system. 4th ed*. Lyon: IARC; 173-177, 2007.
374. Brat DJ, **Perry A**. Ch. 10.3: Melanocytic lesions. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (ed.) *WHO classification of tumours of the central nervous system. 4th ed*. Lyon: IARC; 181-183, 2007.
375. Paulus W, **Perry A**. Ch. 11.2: Histiocytic tumours. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (ed.) *WHO classification of tumours of the central nervous system. 4th ed*. Lyon: IARC; 193-196, 2007.
376. Von Deimling A, **Perry A**. Ch. 13.1: Neurofibromatosis type 1. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (ed.) *WHO classification of tumours of the central nervous system. 4th ed*. Lyon: IARC; 206-209, 2007.
377. **Perry A**. Dear Reader. *Brain Pathol* 17(3), 2007.
378. Wippold, FJ II, Lubner M, Perrin RJ, Lammle M, **Perry A**. Neuropathology for the neuroradiologist: Antoni A and Antoni B tissue patterns. *Am J Neuroradiol* 28:1633-38, 2007.
379. **Perry A**. Dear Reader: Brain Pathology impact factor on the rise. *Brain Pathol* 17(4), 2007.
380. Louis DN**, Perry A**, Heffner RR. Chapter 56B: Cancer and the nervous system: Pathology and molecular genetics. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J (ed.) *Neurology in clinical practice. 5th ed.* Butterworth-Heinemann-Elsevier, Philadelphia, PA, 2008.
381. **Perry A**. Dear Reader: Singing the praises of Brain Pathology. *Brain Pathol* 18(1), 2008.
382. **Perry A**. Commentary on: "Lipomatous meningioma: Report of 2 cases and review of the literature" by Colnat-Coulbois S et al. *Surg Neurol* 69:398-402, 2008.
383. Ellison D, **Perry A**, Rosenblum, Asa S, Reid R, Louis D. Ch. 24: Tumours: Non-neuroepithelial tumours and secondary effects. In: Love S, Louis DN, Ellison DW (ed.) *Greenfield's Neuropathology, 8th ed.* Hodder-Arnold, London, UK 2008.
384. Patil S, **Perry A**. Ch. 27: Pituitary Gland. In: Humphrey PA, Pfeifer JD, Dehner LP (ed.) *The Washington Manual of Surgical Pathology, 1st ed.* Lippincott Williams & Wilkins, Philadelphia, PA 2008.
385. Patil S, **Perry A**. Ch. 41: Central nervous system: Brain, spinal cord, and meninges. In: Humphrey PA, Pfeifer JD, Dehner LP (ed.) *The Washington Manual of Surgical Pathology, 1st ed.* Lippincott Williams & Wilkins, Philadelphia, PA 2008.
386. Hassan A, **Perry A**. Ch. 58: Fluorescence in situ hybridization. In: Humphrey PA, Pfeifer JD, Dehner LP (ed.) *The Washington Manual of Surgical Pathology, 1st ed.* Lippincott Williams & Wilkins, Philadelphia, PA 2008.
387. **Perry A**. Dear Reader: A GBM by any other name? *Brain Pathol* 18(3): i-iii, 2008.
388. Link MJ, **Perry A**. Ch. 11: Meningioma Tumorigenesis: An Overview of Etiologic Factors. In: JH Lee (ed.) *Meningiomas*. Springer-Verlag, London, England 2008.
389. Rogers L, Shrieve D, **Perry A**. Intracranial meningioma: Fractionated radiation therapy perspective. In: Chin, Regine (ed.) *Principles and Practice of Stereotactic Radiosurgery*. Springer-Verlag, London, England 2008.
390. **Perry A**. Dear Reader: "New blood" in the editorial board. *Brain Pathol* 19(1): i-ii, 2009.
391. **Perry A**. Dear Reader: Married to Brain Pathology? *Brain Pathol* 19(2): iii, 2009.
392. **Perry A**. Dear Reader: Growing pains and the Brain Pathology stimulus package. *Brain Pathol* 19(3): iii, 2009.
393. **Perry A**. Dear Reader: The new Brain Pathology. *Brain Pathol* 19(4): 2009.
394. **Perry A**. Dear Reader: The juggler with half the balls on the ground. *Brain Pathol* 20(1): i, 2010.
395. **Perry A**. Dear Reader: Newborn twins of neuropathology education. *Brain Pathol* 20(2): i, 2010.
396. **Perry A**, Brat DJ (textbook editors). *Practical Surgical Neuropathology*. Elsevier/Churchill Livingstone, Philadelphia, PA 2010.

397. **Perry A**, Brat DJ. Neuropathology patterns and introduction. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology*. Elsevier/Churchill Livingstone, Philadelphia, PA 2010.
398. Brat DJ, **Perry A**. Ch. 1: Astrocytic and oligodendroglial tumors. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology*. Elsevier/Churchill Livingstone, Philadelphia, PA 2010.
399. Yachnis AT, **Perry A**. Ch. 9: Embryonal (primitive) neoplasms of the central nervous system. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology*. Elsevier/Churchill Livingstone, Philadelphia, PA 2010.
400. **Perry A**. Ch. 10: Meningiomas. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology*. Elsevier/Churchill Livingstone, Philadelphia, PA 2010.
401. Fuller GN, **Perry A**. Ch. 13: Epithelial, neuroendocrine, and metastatic lesions. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology*. Elsevier/Churchill Livingstone, Philadelphia, PA 2010.
402. Paulus W, **Perry A**. Ch. 14: Lymphomas and histiocytic tumors. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology*. Elsevier/Churchill Livingstone, Philadelphia, PA 2010.
403. **Perry A**. Ch. 19: Therapy-associated neuropathology. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology*. Elsevier/Churchill Livingstone, Philadelphia, PA 2010.
404. **Perry A**. Ch. 20: Familial tumor syndromes. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology*. Elsevier/Churchill Livingstone, Philadelphia, PA 2010.
405. Decker DA, **Perry A**, Yachnis AT. Ch. 24: Vascular and ischemic disorders. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology*. Elsevier/Churchill Livingstone, Philadelphia, PA 2010.
406. **Perry A**. Dear Reader: Job hunting at the Neuropathology Blog? *Brain Pathol* 20(4): i, 2010.
407. **Perry A**. Dear Reader: Neuropathology, the next generation. *Brain Pathol* 20(6): iii, 2010.
408. Dunham C, **Perry A**. Chapter 10: The nervous system. In: Stocker JT, Dehner LP, Husain AN (ed.) *Pediatric Pathology, 3rd ed.* Lippincott Williams & Wilkins, Philadelphia, PA, 2011.
409. **Perry A**. Molecular diagnostics in neuro-oncology. Introduction. *Brain Pathol* 21: 55-56, 2011.
410. Horbinski C, Miller CR, **Perry A**. Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. *Brain Pathol* 21:57-73, 2011.
411. **Perry A**. Dear Reader: Does there always need to be brain pathology in Brain Pathology? *Brain Pathol* 21(2): i, 2011.
412. Hattab EM, Hagen MC, Scheithauer BW**, Perry A**. Chapter 14: Neuropathology. In: Cheng YW, Bostwick DG (ed.) *Essentials of anatomic pathology (3rd edition).* Springer-Verlag, New York, NY, 2011.
413. **Perry A**. Dear Reader: Formula for success = 3A + 4C + F. *Brain Pathol* 21(4): iii-iv, 2011.
414. **Perry A**. Dear Reader: Experiencing Japanese utopia. *Brain Pathol* 21(6): i, 2011.
415. Perrin RJ, Patil S, **Perry A**. Ch. 27: Pituitary gland. In: Humphrey PA, Pfeifer JD, Dehner LP (ed.) *The Washington Manual of Surgical Pathology, 2nd ed.* Lippincott Williams & Wilkins, Philadelphia, PA 2012.
416. Perrin RJ, Patil S, **Perry A**. Ch. 41: Central nervous system: Brain, spinal cord, and meninges. In: Humphrey PA, Pfeifer JD, Dehner LP (ed.) *The Washington Manual of Surgical Pathology, 2nd ed.* Lippincott Williams & Wilkins, Philadelphia, PA 2012.
417. **Perry A**. Bernd W. Scheithauer, MD (1946-2011): mentor, friend, and prodigy. *Arch Pathol Lab Med* 136: 350-351, 2012.
418. **Perry A**. Dear Reader: A new senior editor. *Brain Pathol* 22(3): i, 2012.
419. **Perry A**. Dear Reader: Lessons from the Berlioz Requiem. *Brain Pathol* 22(5): i, 2012.
420. Antonescu CR, **Perry A**, Woodruff JM. Ch. 11-1: Schwannoma (including variants). In: Fletcher CD, Bridge JA, Hogendoorn PCW, Mertens F (ed.) *WHO classification of tumours of soft tissue and bone*. 4th ed. IARC, Lyon, France 2013.
421. **Perry A**. Ch. 11-7: Ectopic meningioma/meningothelial hamartoma. In: Fletcher CD, Bridge JA, Hogendoorn PCW, Mertens F (ed.) *WHO classification of tumours of soft tissue and bone*. 4th ed. IARC, Lyon, France 2013.

422. **Perry A**. Ch. 11-9: Benign Triton tumor. In: Fletcher CD, Bridge JA, Hogendoorn PCW, Mertens F (ed.) *WHO classification of tumours of soft tissue and bone*. 4th ed. IARC, Lyon, France 2013.
423. **Perry A**. Dear Reader: Announcing free color: another great reason to publish in Brain Pathology. *Brain Pathol* 23(1): i, 2013.
424. **Perry A**. Dear Reader: Gratitude for a job well done! *Brain Pathol* 23(2): i, 2013.
425. **Perry A**. Dear Reader: Practicing neuropathology under great adversity. *Brain Pathol* 23(4): i, 2013.
426. **Perry A**. Dear Reader: "A blustery wind of change." Brain Pathol 24(3): i-ii, 2014.
427. Pekmezci M, **Perry A**. Genetic markers in adult high-grade gliomas. *Sem Radiat Oncol* 24:235-239, 2014.
428. **Perry A**. Dear Reader: "Changing of the guard; Reflections of an 'outgoing' editor." Brain Pathol 24(6): i-ii, 2014.
429. Barani IJ, **Perry A**, Rogers L. Ch. 22: Meningioma-viewpoint: Fractionated radiotherapy. In: Chin LS, Regine WF (ed.), *Principles and Practice of Stereotactic Radiosurgery, 2nd Edition*, Springer Publishing: New York, NY 2015.
430. Love S, Ironside J, Budka H, **Perry A** (editors). *Greenfield's Neuropathology*, 9th Edition. CRC Press, Taylor & Francis Group, LLC, London, UK 2015.
431. **Perry A**, Louis DN. Ch. 26: Introduction to tumours. In: Love S, Ironside J, Budka H, **Perry A** (ed.) *Greenfield's Neuropathology*, 9th Edition. CRC Press, Taylor & Francis Group, Boca Raton, FL 2015.
432. **Perry A**, Reid R. Ch. 35: Tumours of the peripheral nerves. In: Love S, Ironside J, Budka H, **Perry A** (ed.) *Greenfield's Neuropathology*, 9th Edition. CRC Press, Taylor & Francis Group, Boca Raton, FL 2015.
433. **Perry A**. Ch. 36: Tumours of the meninges. In: Love S, Ironside J, Budka H, **Perry A** (ed.) *Greenfield's Neuropathology*, 9th Edition. CRC Press, Taylor & Francis Group, Boca Raton, FL 2015.
434. **Perry A**. Ch. 39: Melanocytic tumours and hemangioblastoma. In: Love S, Ironside J, Budka H, **Perry A** (ed.) *Greenfield's Neuropathology*, 9th Edition. CRC Press, Taylor & Francis Group, Boca Raton, FL 2015.
435. **Perry A**. Ch. 42: Cysts and tumour-like conditions. In: Love S, Ironside J, Budka H, **Perry A** (ed.) *Greenfield's Neuropathology*, 9th Edition. CRC Press, Taylor & Francis Group, Boca Raton, FL 2015.
436. **Perry A**. Ch. 44: Hereditary tumours. In: Love S, Ironside J, Budka H, **Perry A** (ed.) *Greenfield's Neuropathology*, 9th Edition. CRC Press, Taylor & Francis Group, Boca Raton, FL 2015.
437. **Perry A**. Ch. 46: CNS reactions to anti-neoplastic therapies. In: Love S, Ironside J, Budka H, **Perry A** (ed.) *Greenfield's Neuropathology*, 9th Edition. CRC Press, Taylor & Francis Group, Boca Raton, FL 2015.
438. Pekmezci M, **Perry A**. Practical molecular pathological diagnosis of infiltrating gliomas. *Surg Pathol Clin* 8: 49-61, 2015.
439. Martin SE, Hattab EM, **Perry A**. Chapter 14: Neuropathology. In: Chang YW, Bostwick DG (ed.) *Essentials of anatomic pathology (4th edition).* Springer-Verlag, New York, NY, 2016.
440. **Perry A**, Wesseling P. Chapter 5: Histologic classification of gliomas. In: Berger M, Weller M (ed.) *Handbook of Clinical Neurology Vol. 134 (3rd series) Gliomas*. Elsevier, Philadelphia, PA 2016.
441. Dunham C, **Perry A**. Chapter 10: The nervous system. In: Husain AN, Stocker JT, Dehner LP (ed.) *Pediatric Pathology, 4th ed*. Wolters Kluwer, Philadelphia, PA, 2016.
442. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, **Perry A**, Reifenberger G, von Deimling A (ed.): *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
443. Louis DN, Suva ML, Burger PC, **Perry A**, Kleihues P, Aldape KD, Brat DJ, Beirnat W, Bigner DD, Nakazato Y, Plate KH, Giangaspero F, Ohgaki H, Cavenee WK, Wick W, Barnholtz-Sloan J, Rosenblum MK, Hegi M, Stupp R, Hawkins C, Verhaak RGW, Ellison DW, von Deimling A. Glioblastoma, IDH-wildtype. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.

444. Reifenberger G, Rodriguez F, Burger PC, **Perry A**, Capper D. Diffuse leptomeningeal glioneuronal tumour. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
445. Antonescu CR, Louis DN, Hunter S, **Perry A**, Reuss DE, Stemmer-Rachamimov AO. Schwannoma. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
446. **Perry A**, von Deimling A, Louis DN, Hunter S, Reuss DE, Antonescu CR. Neurofibroma. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
447. Antonescu CR, **Perry A**, Reuss DE. Perineurioma. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
448. Antonescu CR, Stemmer-Rachamimov AO, **Perry A**. Hybrid nerve sheath tumours. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
449. Reuss DE, Louis DN, Hunter S, **Perry A**, Hirose T, Antonescu CR. Malignant peripheral nerve sheath tumour. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
450. **Perry A**, Louis DN, Budka H, von Deimling A, Sahm F, Rushing EJ, Mawrin C, Claus EB, Loeffler J, Sadetzki S. Meningioma. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
451. **Perry A**, Louis DN, Budka H, von Deimling A, Sahm F, Mawrin C, Rushing EJ. Meningioma variants. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
452. Antonescu CR, Paulus W, **Perry A**, Rushing EJ, Hainfellner JA, Bouvier C, Figarella-Branger D, von Deimling A, Wesseling P. Mesenchymal, non-meningothelial tumours. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
453. Antonescu CR, Paulus W, **Perry A**, Rushing EJ, Hainfellner JA, Bouvier C, Figarella-Branger D, von Deimling A, Wesseling P. Other mesenchymal tumours. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
454. Brat DJ, **Perry A**, Wesseling P, Bastian BC. Melanocytic tumours. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
455. Paulus W, **Perry A**, Sahm F. Histiocytic tumours. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
456. Reuss DE, von Deimling A, **Perry A**. Neurofibromatosis type 1. In: Louis DN, et al. (ed.) *WHO classification of tumours of the central nervous system* (Revised 4th edition). IARC: Lyon 2016.
457. **Perry A**. WHO's arrived in 2016! An updated weather forecast for integrated brain tumor diagnosis. Brain Tumor Pathol 33: 157-160, 2016.
458. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, **Perry A**, Reifenberger G, Figarella‐Branger D, Wesseling P, Batchelor TT, J Cairncross JG, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A. Announcing cIMPACT‐NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. *Acta Neuropathol* 133:1-3, 2017.
459. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, **Perry A**, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Gregory Cairncross J, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A. cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. *Brain Pathol* 27: 851-52, 2017.
460. **Perry A**, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.

461. Brat DJ, **Perry A**. Ch. 1: Neuropathology Patterns and Introduction. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
462. Brat DJ, **Perry A**. Ch. 6: Astrocytic and Oligodendroglial Tumors. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
463. Brat DJ, **Perry A**. Ch. 7: Nondiffuse Astrocytoma Variants. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
464. Brat DJ, **Perry A**. Ch. 9: Other Glial Neoplasms. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
465. Brat DJ, **Perry A**. Ch. 10: Neuronal and Glioneuronal Neoplasms. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
466. Yachnis AT, **Perry A**. Ch. 12: Embryonal Neoplasms of the Central Nervous System. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
467. **Perry A**. Ch. 13: Meningiomas. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
468. Rodriguez FJ, Giannini C, Spinner RJ, **Perry A**. Ch. 15: Tumors of Peripheral Nerve. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
469. Fuller GN, Ballester LY, **Perry A**. Ch. 16: Epithelial, Neuroendocrine, and Metastatic Lesions. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
470. Paulus W, **Perry A**. Ch. 17: Lymphomas and Histiocytic Tumors. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
471. Brat DJ, **Perry A**. Ch. 19: Melanocytic Neoplasms of the Central Nervous System. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
472. **Perry A**. Ch. 21: Therapy-Associated Neuropathology. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
473. Solomon DA, **Perry A**. Ch. 22: Familial Tumor Syndromes. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
474. Decker DA, **Perry A**, Yachnis AT. Ch. 26: Vascular and Ischemic Disorders. In: Perry A, Brat DJ (ed.) *Practical Surgical Neuropathology, 2nd Edition*. Elsevier/Churchill Livingstone, Philadelphia, PA 2018.
475. Louis DN, Brandner S, Brat D, Ellison D, Giangaspero F, Hattab E, Hawkins C, Kleinschmidt-DeMasters B, Komori T, McLean C, Paulus W, **Perry A**, Reifenberger G, Weller M, Wesseling P, Rous B. *Tumours of the Central Nervous System (CNS) Reporting Guide, 1st Edition.* International Collaboration on Cancer Reporting; Sydney, Australia 2018. ISBN: 978-1-925687-26-2.
476. Suppiah S, Nassiri F, Bi WL, Dunn IF, Hanemann CO, Horbinski CM, Hashizume R, James CD, Mawrin C, Noushmehr H, **Perry A**, Sahm F, Sloan A, Von Deimling A, Wen PY, Aldape K, Zadeh G, and the International Consortium on Meningiomas. Molecular and translational advances in meningiomas. *Neuro-Oncol* 21(S1):i4-17, 2019.
477. Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR, and the International Consortium on Meningiomas (including Perry A). Advances in Multidisciplinary therapy for meningiomas. *Neuro-Oncol* 21(S1):i18-31, 2019.

478. Nassiri F, Price B, Shehab A, Au K, Cusimano MD, Jenkinson MD, Jungk C, Mansouri A, Santarius T, Suppiah S, Teng KX, Toor GS, Zadeh G, Walbert T, Drummond KJ, and the International Consortium on Meningiomas (including **Perry A**). Life after surgical resection of a meningioma: A prospective cross-sectional study evaluating health-related quality of life. *Neuro-Oncol* 21(S1):i32-43, 2019.
479. Huang RY, Bi WL, Griffith B, Kaufmann TJ, la Fougere C, Schmidt NO, Tonn JC, Vogelbaum MA, Wen PY, Aldape K, Nassiri F, Zadeh G, Dunn IF, and the International Consortium on Meningiomas (including **Perry A**). Imaging and diagnostic advances for intracranial meningiomas. *Neuro-Oncol* 21(S1):i44-61, 2019.
480. Asa SL, **Perry A**. Tumors of the Pituitary Gland. AFIP Atlas of Tumor Pathology, Series 5, ARP Press, Washington DC (in press).

MANUSCRIPTS IN REVIEW

481. Dahlin LB, Scherman P, Besjakov J, Lindberg E, Solomon DA, Horvai AE, **Perry A**. Intraneural glomus tumor of uncertain malignant potential in the median nerve – an unusual case. *J Neurosurg*.
482. Oberheim Bush NA, Tihan T, Aghi M, Van Ziffle J, **Perry A**, Solomon DA. Diffuse midline glioma with H3F3A G34R mutation, rather than K27M mutation: a grading and prognostic dilemma. *Acta Neuropathol Comm*.
483. Halfpenny A, Ferris SP, Grafe M, Woltjer R, Selden N, Nazemi K, **Perry A**, Solomon DA, Gultekin SH, Moore S, Olson S, Lawce H, Lucas L, Corless CL, Wood M. An unusual case of recurrent epilepsy associated rosette-forming glioneuronal tumor with anaplastic transformation in the absence of therapy. *Acta Neuropathol*.

OTHER CREATIVE ACTIVITIES

Media Coverage on Music in Education

1. Medical Ditties are Hits with WU students. Story by Kavita Kumar, the St. Louis Post Dispatch, 1/23/06.
2. The Singing Neuropathology Professor. Story by Beth Miller, the Washington University Record (http://record.wustl.edu/news/page/normal/6792.html), 3/24/06.
3. The Singing Brain Doctor. Story by Tom Weber, KWMU Radio Station, 11/12/07 (winner of the Edward R. Murrow regional award for best use of sound).
4. Day in the Work Life: The Singing Doctor. Story by National Public Radio's (NPR) Marketplace. (http://www.marketplace.org/topics/life/day-work-life-singing-doctor), 5/30/08.
5. The Singing Pathologist. Story by Kelsey Menehan, the Singer Network, a service of Chorus America (https://www.chorusamerica.org/singers/singing-pathologist), 10/1/08.
6. Washington University medical student YouTube video "WUMS Geico Celebrity 1" by Roua Azmeh (http://www.youtube.com/watch?v=taRLpIzYunQ), 3/2/09.
7. Reviewed by Roger Brumback for *J Child Neurol* 26: 924, 2011.
8. Doctor's lyrics help medical students' recall. Story by Nanette Asimov, the San Francisco Chronicle (http://www.sfgate.com/default/article/Doc-s-songs-help-medical-students-recall-4142658.php), 12/23/12.
9. Singing professor offers musical lectures for medical students. Story by Jason Bardi, UCSF Pulse, (http://www.ucsf.edu/news/2012/12/13337/singing-professor-offers-musical-lectures-medical-students), 12/28/12.

10. Monocle Weekly Radio Show (Monocle 24 podcasts), episode 184. Audio interview on use of music in neuropathology education with Tom Hall of Monocle Magazine, London, UK, (http://stage.monocle.com/radio/shows/the-monocle-weekly/184), 1/13/13.
11. KCBS Radio Show, Singing Professor. Story by Jeff Bell, 1/13/13.

Published Recordings

1. Neuropathology Songs CD: This educational resource represents an audio compact disc or downloadable mp3 files with 16 neuropathology songs released in May, 2010. It is available through www.neuropathsongs.com, www.apple.com/itunes, www.amazon.com, www.cdbaby.com, and other vendors.
2. YouTube Recording of "Brain Tumor Rhapsody" at https://www.youtube.com/watch?v=FfP4HTuu6Vs. A cappella rendition by the group Musaic, covering brain tumor biomarkers utilized in the WHO 2016 classification scheme and set to the music of Bohemian Rhapsody by Queen. Published on Oct 12, 2015.

ABSTRACTS (over past 5 years):

1. *Abedalthagafi M, Phillips J, Ellison D, Judkins A, Mueller S, Marshall R, Haas-Kogan D,* ***Perry A****. Altered telomeres with loss of ATRX protein are frequently seen in high-grade pediatric gliomas. Mod Pathol 26 (supplement 2):413A (#1722), 2013.*
2. *Aref D, Moffatt CJ, Agnihotri S, Dubuc A, Taylor MD,* ***Perry A****, Eberhardt C, Croul S. Canonical TGF-beta pathway activity is a predictor of SHH-driven medulloblastoma survival. Mod Pathol 26 (supplement 2):414A (#1723), 2013.*
3. *Sabha N, Knobbe CB, Al Omar S, von Deimling A, Mak T,* ***Perry A****, Zadeh G, Guha A, Croul SE. Analysis of IDH mutation, 1p19q deletion, and PTEN loss in low grade diffuse gliomas. Mod Pathol 26 (supplement 2):418A (#1742), 2013.*
4. *Clarke J, Molinaro A, Phillips J, Butowski N, Chang S,* ***Perry A****, Costello J, DeSilva A, Rabbitt J, Prados M. Final results of a single-institution phase II trial of radiation (RT), temozolomide (TMZ), erlotinib and bevacizumab for initial treatment of glioblastoma (GBM). Neuro-Oncol 15:iii76 (#MR-006), 2013.*
5. *Dahiya S, Emnett R, Phillips J, Haydon D, Leonard J,* ***Perry A****, Gutmann D. BRAF-V600E mutation in pediatric and adult glioblastomas. Neuro-Oncol 15:iii157 (#PA-007), 2013.*
6. ***Perry A****, Pugh S, Rogers CL, Brachman D, McMillan W, Jenrette J, Barani I, Shrieve D, Sloan A, Mehta M. Pathology concordance levels for meningioma classification and grading in RTOG trial 0539. Neuro-Oncol 15:iii161 (#PA-023), 2013.*
7. *Robison N, Dhall G, Brown R, Cloughesy T, Davidson TB, Krieger M, Berger M, Wong K,* ***Perry A****, Gilles F, Finlay JL. Glioblastoma multiforme with primitive neuroectodermal-like components (GBM-PNET): clinical course and management of three pediatric cases. Neuro-Oncol 15:iii168 (#PC-016), 2013.*
8. *Hashizume R, Ihara Y, Ozawa T, Parsa A, Clarke J, Butowski N, Prados M,* ***Perry A****, McDermott M, James D. NF2 + CDKN2A deficiency is a common and actionable genotype of tumorigenic meningiomas. Neuro-Oncol 15:iii236 (#TM-007), 2013.*
9. *Menke JR, Gown AM, Thomas S,* ***Perry A****, Tihan T. Reliability of somatostatin receptor 2a as a marker of meningioma: An immunohistochemical study. Mod Pathol 27 (supplement 2):439A (#1801), 2014.*
10. *Pekmezci M, Horvai A,* ***Perry A****. Differential immunohistochemical profiles of malignant peripheral nerve sheath tumors and cellular schwannomas. Mod Pathol 27 (supplement 2):441A (#1809), 2014.*

11. *Pekmezci M, Horvai A, **Perry A**. Patterns of INI1 expression in malignant peripheral nerve sheath tumor, cellular schwannoma and synovial sarcoma. Mod Pathol 27 (supplement 2):441A (#1810), 2014.*
12. *Reis G, Pekmezci M, Hansen H, Marshall R, Rice T, Phillips J, Wiencke J, Wrensch M, Walsh K, **Perry A**. Loss of CDKN2A/p16 is associated with shortened overall survival in grade II and III gliomas. J Neuropathol Exp Neurol 73:586 (#4), 2014.*
13. *Pekmezci M, Reis G, Hansen H, Rice T, Zheng S, Wiencke J, **Perry A**, Wrensch M, Walsh K. TERT promoter mutation is associated with older age at diagnosis, independent of glioma grade, histology and IDH1/2 status. J Neuropathol Exp Neurol 73:586 (#7), 2014.*
14. *Cimino P, Corbo J, **Perry A**, Dahiya S. Lack of BRAF-V600E Mutation in papillary tumor of the pineal region (PTPR). J Neuropathol Exp Neurol 73:606 (#79), 2014.*
15. *Wood M, **Perry A**. Mesial temporal sclerosis with dysplastic dentate fascia neurons: A case report. J Neuropathol Exp Neurol 73:623 (#144), 2014.*
16. *Liverman C, Tihan T, Pekmezci M, Santi-Vicini M, Martinez D, **Perry A**. Transcription factors as potential diagnostic immunostains for glial neoplasms. Mod Pathol 28 (supplement 2):432A (#1725), 2015.*
17. *Pekmezci M, Tihan T, Marshall R, **Perry A**, Walsh K. Telomere maintenance mechanisms in ependymal tumors. Mod Pathol 28 (supplement 2):435A (#1741), 2015.*
18. *Vaubel R, Chen S, Raleigh D, Link M, Chicoine M, Barani I, Dahiya S, **Perry A**, Giannini C. Meningiomas with focal rhabdoid features lacking other histologic features of malignancy: a study of 37 cases. J Neuropathol Exp Neurol 74:591 (#14), 2015.*
19. *Borys E, Wood M, **Perry A**. Radiation-associated sarcoma of the sella after radiotherapy for pituitary adenoma arising adjacent to residual/recurrent adenoma. J Neuropathol Exp Neurol 74:610 (#81), 2015.*
20. *Solomon D, Wood M, Tihan T, Bollen A, Gupta N, Phillips J, **Perry A**. Malignant gliomas with histone H3-K27M mutation: The spectrum of morphologic variation and associated genetic alterations. J Neuropathol Exp Neurol 74:621 (#120), 2015.*
21. *Nauen D, Haley L, Lin MT, **Perry A**, Giannini C, Burger P, Rodriguez F. Molecular Cytogenetic Analysis of Pediatric Oligodendrogliomas. J Neuropathol Exp Neurol 74:621 (#121), 2015.*
22. *Alexandrescu S, Korshunov A, Hui LS, Dabiri S, Shih CS, Li R, Du E, **Perry A**. Epithelioid Glioblastomas and Transformed Pleomorphic Xanthoastrocytomas– How Related are They? J Neuropathol Exp Neurol 74:621 (#122), 2015.*
23. *Orr B, Allen S, Wen J, Dalton J, Mobley B, Schniederjan M, Santi M, Dahiya S, Buccoliero A, **Perry A**, Robinson G, Gajjar A, Ellison D. Molecular Subgroups of CNS-PNET Show Distinct Morphologies and Molecular Characteristics. J Neuropathol Exp Neurol 74:622 (#124), 2015.*
24. *Dietz R, Wood M, Chakravarthy V, De Los-Reyes K, **Perry A**, Raghavan R. IgG4-Associated Meningeal Disease. J Neuropathol Exp Neurol 74:622 (#155), 2015.*
25. *Lee, J, Pekmezci M, **Perry A**, Tihan T. Utility of PIT-1 immunostaining in distinguishing pituitary adenomas of primitive differentiation from null cell adenomas. Mod Pathol 29 (supplement 2):432A (#1713), 2016.*
26. *Lopez G, Blevins LS, **Perry A**. SSTR2a status and response to somatostatin analogues for acromegaly. Mod Pathol 29 (supplement 2):433A (#1715), 2016.*
27. *Pekmezci M, Walsh KM, Molinaro A, Decker P, Hansen HM, Sicotto H, Rice T, Kollmeyer T, McCoy L, Sarkar G, Caron AA, **Perry A**, Giannini C, Tihan T, Berger MS, Wiemels J, Eckel-Passow J, Lachance D, Wiencke J, Jenkins RB, Wrensch M. Utility of PIT-1 immunostaining in distinguishing pituitary adenomas of primitive differentiation from null cell adenomas. Mod Pathol 29 (supplement 2):432A (#1713), 2016.*
28. *Orr B, Sturm D, Toprak U, Hovestadt V, Jones D, Capper D, Northcott P, Allen S, Phillips J, **Perry A**, Mobley B, Schniederjan M, Santi M, Buccoliero A, Dahiya S, Snuderl M, Gajjar A, Aldape K, von Deimling A, Pfister S, Ellison D, Korshunov A, Kool M. Histopathologic*

correlates of newly defined brain tumor entities identified through molecular classification. J Neuropathol Exp Neurol 75:574 (#26), 2016.

29. *Solomon D, Kline C, Nicolaides T, Mueller S, Banerjee A, Torkildson J, Samuel D, Aboian M, Cha S, Gupta N, Raffel C, de Alba Campomanes A, Joseph N, Grenert J, van Ziffle J, Yeh I, Bastian B, Tihan T, Bollen A, Phillips J,* ***Perry A****. Tumor and germline sequencing of pediatric brain tumor patients at first diagnosis: the UCSF experience. J Neuropathol Exp Neurol 75:591 (#90), 2016.*
30. *Ellison D, Orisme W, Wen J, Dalton J, Tang B, Haupfear K, Gupta K, Brat D, Dahiya S, Nickols H,* ***Perry A****, Tatevossian R. Genetic alterations in uncommon low-grade neuroepithelial tumors – frequent BRAF, FGFR1, and MYB/MYBL1 mutations align with morphology. J Neuropathol Exp Neurol 75:592 (#93), 2016.*
31. *Cuevas-Ocampo A, Raleigh D, Wu A, Tomlin B, Menke J, Reis G,* ***Perry A****, Tihan T, Pekmezci M. Loss of H3K27me3 loss is a poor prognostic factor for meningioma. Mod Pathol 30 (supplement 2):430A (#1727), 2017.*
32. *Solomon D, Goode B, Hyun MD, Joseph NM, Van Ziffle J, Butowski N, Brat DJ, Kleinschmidt-DeMasters B, Rodriguez F, Louis DN, Yong W, Lopes B, Rosenblum M, Tihan T, Bollen A,* ***Perry A****. A recurrent kinase domain mutation p.D463H in PRKCA defines chordoid glioma of the third ventricle. Mod Pathol 30 (supplement 2):437A (#1753), 2017.*
33. *Wood M,* ***Perry A****, Korshunov A, Chacko G, Pu C, Payne C, Bannykh S, Turner C, Tihan T, Solomon D. Genetic features of astroblastoma by targeted next-generation sequencing: Lack of unifying alterations across eight cases. J Neuropathol Exp Neurol 76:498 (#27), 2017.*
34. *Cuevas-Ocampo AK, Bollen AW, Goode B, Pajtler K, Chavez L, Sharma T, Dai SC, McDermott M,* ***Perry A****, Korshunov A, Solomon D. Ependymoma can arise as part of Multiple Endocrine Neoplasia Type 1 (MEN1) syndrome: Molecular confirmation. J Neuropathol Exp Neurol 76:506 (#61), 2017.*
35. *Mercado-Acosta J, Fallon K, Hackney J,* ***Perry A****. Anaplastic diffuse leptomeningeal glioneuronal tumor, two cases. J Neuropathol Exp Neurol 76:510 (#76), 2017.*
36. *Lopez G,* ***Perry A****, Li M, Harding B, Santi M. Anaplastic transformation in a pilocytic astrocytoma. J Neuropathol Exp Neurol 76:511 (#81), 2017.*
37. *Ferris S, Phillips J, Bollen A, Tihan T,* ***Perry A****, Solomon D. Clinicopathologic features of the new entity CNS high-grade neuroepithelial tumor with BCOR alteration. J Neuropathol Exp Neurol 76:513 (#86), 2017.*
38. *Lee J, Talevich E, Onodera C, Van Ziffle J, Joseph N, Yeh I, Bastian B, Siongco A, Greco C, Phillips J, Bollen A, Tihan T,* ***Perry A****, Solomon D. Genomic analysis of choroid plexus tumors reveals TERT alterations in atypical papillomas and recurrent chromosomal gains. J Neuropathol Exp Neurol 76:542 (#204), 2017.*
39. *Fritchie K, Jenkins SM, Rodriguez F, Guajardo A,* ***Perry A****, Wu A, Santagata A, Kaplan AB, Rossi S, Link M, Brown P, Jensch K, Haller F, Brastianos P, Louis D, Alexander B, Raleigh D, Velázquez Vega J, Ferrarese F, Brat D, Giannini C. Grading considerations for meningeal solitary fibrous tumor/hemangiopericytoma. Mod Pathol 31 (supplement 2):657A (#1818), 2018.*
40. *Lee J, Sharifai N, Dahiya S, Kleinschmidt-DeMasters B, Rosenblum M, Reis G, Solomon D, Tihan T,* ***Perry A****. Clinicopathologic features of anaplastic myxopapillary ependymomas. Mod Pathol 31 (supplement 2):660A (#1829), 2018.*
41. *Lopez G, Bollen A, Tihan T,* ***Perry A****, Solomon D. The genetic landscape of gliomas arising after therapeutic radiation for childhood cancer. Mod Pathol 31 (supplement 2):661A (#1832), 2018.*
42. *Phillips J, Gong H, Chen K, Joseph N, Van Ziffle J, Bastian B, Nicolaides T, Tihan T, Bollen A,* ***Perry A****, Shieh J, Solomon D. The genomic landscape of anaplastic pleomorphic xanthoastrocytoma. J Neuropathol Exp Neurol 77:486 (#26), 2018.*
43. *Pekmezci M, Villaneuva-Meyer J, Goode B, Van Ziffle J, Grenert J, Bastian B, DeMasters BK, Samuel D, Mueller S, Banerjee A, Clarke J, Cooney T, Torkildson J, Gupta N, Theodosopoulos P,*

*Chang E, Berger M, Bollen A, **Perry A**, Tihan T, Solomon D. The genomic landscape of ganglioglioma. J Neuropathol Exp Neurol 77:487 (#30), 2018.*

44. *Pekmezci M, Stevers M, Phillips J, Van Ziffle J, Bastian B, Tsankova N, DeMasters BK, Rosenblum M, Tihan T, **Perry A**, Solomon D. Multinodular and vacuolating neuronal tumor of the cerebrum is defined by genetic alterations activating the MAP kinase signaling pathway. J Neuropathol Exp Neurol 77:487 (#31), 2018.*
45. *Iorgulescu B, Van Ziffle J, Stevers M, Grenert J, Bastian B, Chavez L, Stichel D, Buchhalter I, Samuel D, Nicolaides T, Banerjee A, Mueller S, Gupta N, Tihan T, Bollen A, Northcott P, Kool M, Pfister S, Korshunov A, **Perry A**, Solomon D. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. J Neuropathol Exp Neurol 77:487-88 (#32), 2018.*
46. *Halfpenny A, Ferris S, Grafe M, Woltjer R, Selden N, Nazemi K, **Perry A**, Solomon D, Moore S, Lawce H, Lucas L, Corless C, Wood M. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. J Neuropathol Exp Neurol 77:493 (#54), 2018.*
47. *Velázquez Vega J, Schniederjan M, Perry A, Solomon D. CNS high-grade neuroepithelial tumor with BCOR alteration: Heterogeneous histologic features expand the morphologic spectrum. J Neuropathol Exp Neurol 77:519 (#157), 2018.*

RESEARCH PROGRAM (SEPARATE SUMMARY)

Please include a list of five significant recent publications with a description of your role/contribution to each study (one page max). In addition, a one page description of your current research interests/program is <u>required</u> for Ladder Rank, In Residence, Clinical X, and Adjunct faculty. Clinical Faculty should include this description as appropriate.

1. **Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, Perry A. Diffuse midline gliomas with histone H3-K27M mutation: A series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol 26:569-80, 2016.**

   This represents the first publication that elucidates the wide histopathologic spectrum that may be encountered in one of the new diagnostic entities in the WHO 2016 CNS tumor classification scheme, the mostly pediatric brain tumor "diffuse midline glioma, H3 K27M-mutant". I served as the mentor and senior author of this study, with the data from this study contributing to the new WHO characterization of this now integrated morphologic and molecular diagnosis.
2. **Rodriguez FJ, Schniederjan MJ, Nicolaides T, Tihan T, Burger PC, Perry A. High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN). Acta Neuropathol 129: 609-610, 2015.**

   This is the most comprehensive clinicopathologic and molecular study to date on a rare but diagnostically challenging type of pediatric brain tumor that was most recently codified into the WHO 2016 CNS tumor classification scheme as the "disseminated leptomeningeal glioneuronal tumor". Ours was the first study to show the combination of BRAF fusion with chromosome 1p deletion as a unique molecular signature of this tumor type. This data has been incorporated into the new WHO 2016 blue book. I served as mentor, collaborator, and senior author on this study.
3. **Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C,**

Hawkins C, Kleihues P, Korshunov A, Kros JM, Lopes MB, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P. International Society of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24: 429-35, 2014.

This represents the first published international guidelines for how to incorporate molecular pathology into the diagnosis of the most common adult and pediatric brain tumors. Along with Drs. David Louis and Pieter Wesseling, I was a co-organizer of the international consensus meeting in Haarlem, the Netherlands that led to these guidelines and served as a precursor to upcoming updates of the World Health Organization (WHO) brain tumor classification scheme. This paper has been cited 126 times in 2 years.

4. **Perry A, Brat DJ (textbook editors). *Practical Surgical Neuropathology*. Elsevier/Churchill Livingstone, Philadelphia, PA 2010.**

   This major textbook on surgical neuropathology is novel in its patterns-based approach to diagnostics and is part of an organ based series based on a similar approach published by Drs. Kevin Leslie and Mark Wick entitled Practical Pulmonary Pathology. These same authors, along with the publisher Elsevier, approached me several years ago to be the primary editor of this textbook based on my reputation as an expert in this field. I subsequently recruited my colleague, Daniel Brat as a co-editor, along with roughly 15 additional colleagues as chapter authors. Along with Dr. Brat, I was primarily responsible for the outline and format of the book, providing detailed guidance to all the authors. I also authored or co-authored 9 of the 25 chapters and edited all of them, along with Dan. Additionally, I supplemented high-quality images from my personal files on nearly all the chapters in order to enhance the visual appeal throughout the entire text. Over 2500 copies have been sold worldwide to date.

5. **Smith JS, Perry A (co-first author), Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-45, 2000.**

   I served as co-first author on this study, along with Justin Smith, being actively involved in all aspects of planning, experimentation, interpretation, and writing. This was one of the first papers to demonstrate that the signature 1p/19q codeletion pattern was specifically associated with patient survival in oligodendrogliomas, including low-grade examples, but not in astrocytic tumors. This paper has been cited 737 times.

Summary of Research Interests

As a diagnostic neuropathologist with a focus on CNS tumors, I am primarily involved in translational research with the primary goal of developing new diagnostic and prognostic markers, which can be utilized in the clinical management of brain tumor patients. In order to achieve this goal, my lab has applied immunohistochemical, molecular cytogenetic, and genomic screening techniques primarily towards the study of gliomas, meningiomas, and primitive pediatric malignancies. I have been particularly interested in improved classification and grading schemes as well as the identification of molecular genetic markers associated with tumorigenesis, malignant progression, and/or biologic behavior. I collaborate with a number of clinical and scientific researchers both within and outside UCSF and it is our hope that the markers we identify will improve patient management and lead to the development of novel therapeutic approaches.